id	sid	tid	token	lemma	pos
dpc-4737	1	1	dermatology	dermatology	NOUN
dpc-4737	1	2	:	:	PUNCT
dpc-4737	1	3	practical	practical	ADJ
dpc-4737	1	4	and	and	CCONJ
dpc-4737	1	5	conceptual	conceptual	ADJ
dpc-4737	1	6	original	original	ADJ
dpc-4737	1	7	article	article	NOUN
dpc-4737	1	8	|	|	ADV
dpc-4737	1	9	dermatol	dermatol	ADJ
dpc-4737	1	10	pract	pract	NOUN
dpc-4737	1	11	concept	concept	NOUN
dpc-4737	1	12	.	.	PUNCT
dpc-4737	2	1	2025;15(1):4737	2025;15(1):4737	NUM
dpc-4737	2	2	1	1	NUM
dpc-4737	2	3	propranolol	propranolol	NOUN
dpc-4737	2	4	:	:	PUNCT
dpc-4737	2	5	a	a	DET
dpc-4737	2	6	promising	promising	ADJ
dpc-4737	2	7	therapeutic	therapeutic	ADJ
dpc-4737	2	8	avenue	avenue	NOUN
dpc-4737	2	9	for	for	ADP
dpc-4737	2	10	classic	classic	ADJ
dpc-4737	2	11	kaposi	kaposi	PROPN
dpc-4737	2	12	sarcoma	sarcoma	PROPN
dpc-4737	2	13	rasha	rasha	PROPN
dpc-4737	2	14	mahmoud	mahmoud	PROPN
dpc-4737	2	15	genedy1	genedy1	PROPN
dpc-4737	2	16	,	,	PUNCT
dpc-4737	2	17	marwa	marwa	PROPN
dpc-4737	2	18	owais1	owais1	PROPN
dpc-4737	2	19	,	,	PUNCT
dpc-4737	2	20	naglaa	naglaa	PROPN
dpc-4737	2	21	mohamed	mohamed	PROPN
dpc-4737	2	22	el	el	PROPN
dpc-4737	2	23	sayed1	sayed1	PROPN
dpc-4737	2	24	1	1	NUM
dpc-4737	2	25	dermatology	dermatology	NOUN
dpc-4737	2	26	,	,	PUNCT
dpc-4737	2	27	venereology	venereology	NOUN
dpc-4737	2	28	,	,	PUNCT
dpc-4737	2	29	and	and	CCONJ
dpc-4737	2	30	andrology	andrology	PROPN
dpc-4737	2	31	department	department	NOUN
dpc-4737	2	32	,	,	PUNCT
dpc-4737	2	33	faculty	faculty	NOUN
dpc-4737	2	34	of	of	ADP
dpc-4737	2	35	medicine	medicine	NOUN
dpc-4737	2	36	,	,	PUNCT
dpc-4737	2	37	alexandria	alexandria	PROPN
dpc-4737	2	38	university	university	PROPN
dpc-4737	2	39	,	,	PUNCT
dpc-4737	2	40	alexandria	alexandria	PROPN
dpc-4737	2	41	,	,	PUNCT
dpc-4737	2	42	egypt	egypt	PROPN
dpc-4737	2	43	key	key	ADJ
dpc-4737	2	44	words	word	NOUN
dpc-4737	2	45	:	:	PUNCT
dpc-4737	2	46	hemangioma	hemangioma	NOUN
dpc-4737	2	47	,	,	PUNCT
dpc-4737	2	48	kaposi	kaposi	PROPN
dpc-4737	2	49	sarcoma	sarcoma	PROPN
dpc-4737	2	50	,	,	PUNCT
dpc-4737	2	51	lymphedema	lymphedema	NOUN
dpc-4737	2	52	,	,	PUNCT
dpc-4737	2	53	propranolol	propranolol	NOUN
dpc-4737	2	54	citation	citation	NOUN
dpc-4737	2	55	:	:	PUNCT
dpc-4737	2	56	genedy	genedy	PROPN
dpc-4737	2	57	rm	rm	PROPN
dpc-4737	2	58	,	,	PUNCT
dpc-4737	2	59	owais	owais	PROPN
dpc-4737	2	60	m	m	PROPN
dpc-4737	2	61	,	,	PUNCT
dpc-4737	2	62	el	el	PROPN
dpc-4737	2	63	sayed	sayed	PROPN
dpc-4737	2	64	nm	nm	PROPN
dpc-4737	2	65	.	.	PUNCT
dpc-4737	2	66	propranolol	propranolol	PROPN
dpc-4737	2	67	:	:	PUNCT
dpc-4737	2	68	a	a	DET
dpc-4737	2	69	promising	promising	ADJ
dpc-4737	2	70	therapeutic	therapeutic	ADJ
dpc-4737	2	71	avenue	avenue	NOUN
dpc-4737	2	72	for	for	ADP
dpc-4737	2	73	classic	classic	ADJ
dpc-4737	2	74	kaposi	kaposi	PROPN
dpc-4737	2	75	sarcoma	sarcoma	NOUN
dpc-4737	2	76	.	.	PUNCT
dpc-4737	3	1	dermatol	dermatol	NOUN
dpc-4737	3	2	pract	pract	PROPN
dpc-4737	3	3	concept	concept	NOUN
dpc-4737	3	4	.	.	PUNCT
dpc-4737	4	1	2025;15(1):4737	2025;15(1):4737	NUM
dpc-4737	4	2	.	.	PUNCT
dpc-4737	4	3	doi	doi	NOUN
dpc-4737	4	4	:	:	PUNCT
dpc-4737	4	5	https://doi.org/10.5826/dpc.1501a4737	https://doi.org/10.5826/dpc.1501a4737	PROPN
dpc-4737	4	6	accepted	accept	VERB
dpc-4737	4	7	:	:	PUNCT
dpc-4737	4	8	october	october	PROPN
dpc-4737	4	9	8	8	NUM
dpc-4737	4	10	,	,	PUNCT
dpc-4737	4	11	2024	2024	NUM
dpc-4737	4	12	;	;	PUNCT
dpc-4737	4	13	published	publish	VERB
dpc-4737	4	14	:	:	PUNCT
dpc-4737	5	1	january	january	PROPN
dpc-4737	5	2	2025	2025	NUM
dpc-4737	5	3	copyright	copyright	NOUN
dpc-4737	5	4	:	:	PUNCT
dpc-4737	5	5	©	©	PROPN
dpc-4737	5	6	2024	2024	NUM
dpc-4737	5	7	genedy	genedy	NOUN
dpc-4737	5	8	et	et	PROPN
dpc-4737	5	9	al	al	PROPN
dpc-4737	5	10	.	.	PUNCT
dpc-4737	6	1	this	this	PRON
dpc-4737	6	2	is	be	AUX
dpc-4737	6	3	an	an	DET
dpc-4737	6	4	open	open	ADJ
dpc-4737	6	5	-	-	PUNCT
dpc-4737	6	6	access	access	NOUN
dpc-4737	6	7	article	article	NOUN
dpc-4737	6	8	distributed	distribute	VERB
dpc-4737	6	9	under	under	ADP
dpc-4737	6	10	the	the	DET
dpc-4737	6	11	terms	term	NOUN
dpc-4737	6	12	of	of	ADP
dpc-4737	6	13	the	the	DET
dpc-4737	6	14	creative	creative	ADJ
dpc-4737	6	15	commons	common	NOUN
dpc-4737	6	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4737	6	17	license	license	NOUN
dpc-4737	6	18	(	(	PUNCT
dpc-4737	6	19	by	by	ADP
dpc-4737	6	20	-	-	PUNCT
dpc-4737	6	21	nc-4.0	nc-4.0	NOUN
dpc-4737	6	22	)	)	PUNCT
dpc-4737	6	23	,	,	PUNCT
dpc-4737	6	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4737	6	25	,	,	PUNCT
dpc-4737	6	26	which	which	PRON
dpc-4737	6	27	permits	permit	VERB
dpc-4737	6	28	unrestricted	unrestricted	ADJ
dpc-4737	6	29	noncommercial	noncommercial	ADJ
dpc-4737	6	30	use	use	NOUN
dpc-4737	6	31	,	,	PUNCT
dpc-4737	6	32	distribution	distribution	NOUN
dpc-4737	6	33	,	,	PUNCT
dpc-4737	6	34	and	and	CCONJ
dpc-4737	6	35	reproduction	reproduction	NOUN
dpc-4737	6	36	in	in	ADP
dpc-4737	6	37	any	any	DET
dpc-4737	6	38	medium	medium	NOUN
dpc-4737	6	39	,	,	PUNCT
dpc-4737	6	40	provided	provide	VERB
dpc-4737	6	41	the	the	DET
dpc-4737	6	42	original	original	ADJ
dpc-4737	6	43	authors	author	NOUN
dpc-4737	6	44	and	and	CCONJ
dpc-4737	6	45	source	source	NOUN
dpc-4737	6	46	are	be	AUX
dpc-4737	6	47	credited	credit	VERB
dpc-4737	6	48	.	.	PUNCT
dpc-4737	7	1	funding	funding	NOUN
dpc-4737	7	2	:	:	PUNCT
dpc-4737	7	3	none	none	NOUN
dpc-4737	7	4	.	.	PUNCT
dpc-4737	8	1	competing	compete	VERB
dpc-4737	8	2	interests	interest	NOUN
dpc-4737	8	3	:	:	PUNCT
dpc-4737	8	4	none	none	NOUN
dpc-4737	8	5	.	.	PUNCT
dpc-4737	9	1	authorship	authorship	NOUN
dpc-4737	9	2	:	:	PUNCT
dpc-4737	9	3	all	all	DET
dpc-4737	9	4	authors	author	NOUN
dpc-4737	9	5	have	have	AUX
dpc-4737	9	6	contributed	contribute	VERB
dpc-4737	9	7	significantly	significantly	ADV
dpc-4737	9	8	to	to	ADP
dpc-4737	9	9	this	this	DET
dpc-4737	9	10	publication	publication	NOUN
dpc-4737	9	11	.	.	PUNCT
dpc-4737	10	1	corresponding	correspond	VERB
dpc-4737	10	2	author	author	NOUN
dpc-4737	10	3	:	:	PUNCT
dpc-4737	10	4	naglaa	naglaa	PROPN
dpc-4737	10	5	mohamed	mohamed	PROPN
dpc-4737	10	6	el	el	PROPN
dpc-4737	10	7	sayed	say	VERB
dpc-4737	10	8	,	,	PUNCT
dpc-4737	10	9	dermatology	dermatology	NOUN
dpc-4737	10	10	,	,	PUNCT
dpc-4737	10	11	venereology	venereology	NOUN
dpc-4737	10	12	,	,	PUNCT
dpc-4737	10	13	and	and	CCONJ
dpc-4737	10	14	andrology	andrology	PROPN
dpc-4737	10	15	department	department	NOUN
dpc-4737	10	16	,	,	PUNCT
dpc-4737	10	17	faculty	faculty	NOUN
dpc-4737	10	18	of	of	ADP
dpc-4737	10	19	medicine	medicine	NOUN
dpc-4737	10	20	,	,	PUNCT
dpc-4737	10	21	alexandria	alexandria	PROPN
dpc-4737	10	22	university	university	PROPN
dpc-4737	10	23	,	,	PUNCT
dpc-4737	10	24	al	al	PROPN
dpc-4737	10	25	khartoum	khartoum	PROPN
dpc-4737	10	26	square	square	PROPN
dpc-4737	10	27	,	,	PUNCT
dpc-4737	10	28	alexandria	alexandria	PROPN
dpc-4737	10	29	,	,	PUNCT
dpc-4737	10	30	egypt	egypt	PROPN
dpc-4737	10	31	.	.	PUNCT
dpc-4737	11	1	e	e	X
dpc-4737	11	2	-	-	NOUN
dpc-4737	11	3	mail	mail	NOUN
dpc-4737	11	4	:	:	PUNCT
dpc-4737	11	5	naglaasayed66@outlook.com	naglaasayed66@outlook.com	X
dpc-4737	11	6	introduction	introduction	NOUN
dpc-4737	11	7	:	:	PUNCT
dpc-4737	11	8	kaposi	kaposi	PROPN
dpc-4737	11	9	sarcoma	sarcoma	PROPN
dpc-4737	11	10	(	(	PUNCT
dpc-4737	11	11	ks	ks	NOUN
dpc-4737	11	12	)	)	PUNCT
dpc-4737	11	13	is	be	AUX
dpc-4737	11	14	a	a	DET
dpc-4737	11	15	low	low	ADJ
dpc-4737	11	16	grade	grade	NOUN
dpc-4737	11	17	angio	angio	NOUN
dpc-4737	11	18	-	-	ADJ
dpc-4737	11	19	proliferative	proliferative	ADJ
dpc-4737	11	20	tumor	tumor	NOUN
dpc-4737	11	21	of	of	ADP
dpc-4737	11	22	endothelial	endothelial	ADJ
dpc-4737	11	23	origin	origin	NOUN
dpc-4737	11	24	.	.	PUNCT
dpc-4737	12	1	human	human	ADJ
dpc-4737	12	2	herpesvirus	herpesvirus	NOUN
dpc-4737	12	3	8	8	NUM
dpc-4737	12	4	(	(	PUNCT
dpc-4737	12	5	hhv8	hhv8	PROPN
dpc-4737	12	6	)	)	PUNCT
dpc-4737	12	7	plays	play	VERB
dpc-4737	12	8	a	a	DET
dpc-4737	12	9	major	major	ADJ
dpc-4737	12	10	role	role	NOUN
dpc-4737	12	11	in	in	ADP
dpc-4737	12	12	the	the	DET
dpc-4737	12	13	pathogenesis	pathogenesis	NOUN
dpc-4737	12	14	of	of	ADP
dpc-4737	12	15	ks	ks	PROPN
dpc-4737	12	16	.	.	PROPN
dpc-4737	12	17	classic	classic	ADJ
dpc-4737	12	18	kaposi	kaposi	PROPN
dpc-4737	12	19	sarcoma	sarcoma	NOUN
dpc-4737	12	20	is	be	AUX
dpc-4737	12	21	commonly	commonly	ADV
dpc-4737	12	22	seen	see	VERB
dpc-4737	12	23	among	among	ADP
dpc-4737	12	24	elderly	elderly	ADJ
dpc-4737	12	25	of	of	ADP
dpc-4737	12	26	mediterranean	mediterranean	PROPN
dpc-4737	12	27	origin	origin	NOUN
dpc-4737	12	28	.	.	PUNCT
dpc-4737	13	1	it	it	PRON
dpc-4737	13	2	is	be	AUX
dpc-4737	13	3	usually	usually	ADV
dpc-4737	13	4	slowly	slowly	ADV
dpc-4737	13	5	progressive	progressive	ADJ
dpc-4737	13	6	and	and	CCONJ
dpc-4737	13	7	is	be	AUX
dpc-4737	13	8	rarely	rarely	ADV
dpc-4737	13	9	fatal	fatal	ADJ
dpc-4737	13	10	.	.	PUNCT
dpc-4737	14	1	there	there	PRON
dpc-4737	14	2	is	be	VERB
dpc-4737	14	3	no	no	DET
dpc-4737	14	4	definitive	definitive	ADJ
dpc-4737	14	5	cure	cure	NOUN
dpc-4737	14	6	for	for	ADP
dpc-4737	14	7	ks	ks	NOUN
dpc-4737	14	8	.	.	PUNCT
dpc-4737	15	1	beta	beta	ADJ
dpc-4737	15	2	blockers	blocker	NOUN
dpc-4737	15	3	were	be	AUX
dpc-4737	15	4	used	use	VERB
dpc-4737	15	5	with	with	ADP
dpc-4737	15	6	great	great	ADJ
dpc-4737	15	7	success	success	NOUN
dpc-4737	15	8	in	in	ADP
dpc-4737	15	9	the	the	DET
dpc-4737	15	10	treatment	treatment	NOUN
dpc-4737	15	11	of	of	ADP
dpc-4737	15	12	infantile	infantile	ADJ
dpc-4737	15	13	hemangioma	hemangioma	NOUN
dpc-4737	15	14	.	.	PUNCT
dpc-4737	16	1	because	because	SCONJ
dpc-4737	16	2	of	of	ADP
dpc-4737	16	3	some	some	DET
dpc-4737	16	4	similarity	similarity	NOUN
dpc-4737	16	5	between	between	ADP
dpc-4737	16	6	infantile	infantile	ADJ
dpc-4737	16	7	hemangioma	hemangioma	NOUN
dpc-4737	16	8	and	and	CCONJ
dpc-4737	16	9	ks	ks	NOUN
dpc-4737	16	10	,	,	PUNCT
dpc-4737	16	11	topical	topical	ADJ
dpc-4737	16	12	beta	beta	ADJ
dpc-4737	16	13	blockers	blocker	NOUN
dpc-4737	16	14	were	be	AUX
dpc-4737	16	15	tried	try	VERB
dpc-4737	16	16	with	with	ADP
dpc-4737	16	17	variable	variable	ADJ
dpc-4737	16	18	success	success	NOUN
dpc-4737	16	19	rate	rate	NOUN
dpc-4737	16	20	.	.	PUNCT
dpc-4737	17	1	objectives	objective	NOUN
dpc-4737	17	2	:	:	PUNCT
dpc-4737	17	3	we	we	PRON
dpc-4737	17	4	aimed	aim	VERB
dpc-4737	17	5	to	to	PART
dpc-4737	17	6	assess	assess	VERB
dpc-4737	17	7	the	the	DET
dpc-4737	17	8	efficacy	efficacy	NOUN
dpc-4737	17	9	and	and	CCONJ
dpc-4737	17	10	safety	safety	NOUN
dpc-4737	17	11	of	of	ADP
dpc-4737	17	12	oral	oral	ADJ
dpc-4737	17	13	propranolol	propranolol	NOUN
dpc-4737	17	14	in	in	ADP
dpc-4737	17	15	the	the	DET
dpc-4737	17	16	treatment	treatment	NOUN
dpc-4737	17	17	of	of	ADP
dpc-4737	17	18	classic	classic	ADJ
dpc-4737	17	19	ks	ks	PROPN
dpc-4737	17	20	.	.	PROPN
dpc-4737	17	21	methods	method	NOUN
dpc-4737	17	22	:	:	PUNCT
dpc-4737	17	23	fifteen	fifteen	NUM
dpc-4737	17	24	patients	patient	NOUN
dpc-4737	17	25	diagnosed	diagnose	VERB
dpc-4737	17	26	with	with	ADP
dpc-4737	17	27	classic	classic	ADJ
dpc-4737	17	28	ks	k	NOUN
dpc-4737	17	29	were	be	AUX
dpc-4737	17	30	prospectively	prospectively	ADV
dpc-4737	17	31	enrolled	enrol	VERB
dpc-4737	17	32	in	in	ADP
dpc-4737	17	33	the	the	DET
dpc-4737	17	34	study	study	NOUN
dpc-4737	17	35	.	.	PUNCT
dpc-4737	18	1	detailed	detailed	ADJ
dpc-4737	18	2	history	history	NOUN
dpc-4737	18	3	and	and	CCONJ
dpc-4737	18	4	full	full	ADJ
dpc-4737	18	5	clinical	clinical	ADJ
dpc-4737	18	6	examination	examination	NOUN
dpc-4737	18	7	were	be	AUX
dpc-4737	18	8	conducted	conduct	VERB
dpc-4737	18	9	.	.	PUNCT
dpc-4737	19	1	histopathological	histopathological	ADJ
dpc-4737	19	2	diagnosis	diagnosis	NOUN
dpc-4737	19	3	with	with	ADP
dpc-4737	19	4	confirmatory	confirmatory	ADJ
dpc-4737	19	5	immune	immune	ADJ
dpc-4737	19	6	staining	stain	VERB
dpc-4737	19	7	was	be	AUX
dpc-4737	19	8	done	do	VERB
dpc-4737	19	9	for	for	ADP
dpc-4737	19	10	all	all	DET
dpc-4737	19	11	patients	patient	NOUN
dpc-4737	19	12	.	.	PUNCT
dpc-4737	20	1	oral	oral	ADJ
dpc-4737	20	2	propranolol	propranolol	NOUN
dpc-4737	20	3	in	in	ADP
dpc-4737	20	4	a	a	DET
dpc-4737	20	5	dose	dose	NOUN
dpc-4737	20	6	of	of	ADP
dpc-4737	20	7	60	60	NUM
dpc-4737	20	8	mg	mg	NOUN
dpc-4737	20	9	was	be	AUX
dpc-4737	20	10	given	give	VERB
dpc-4737	20	11	per	per	ADP
dpc-4737	20	12	day	day	NOUN
dpc-4737	20	13	for	for	ADP
dpc-4737	20	14	6	6	NUM
dpc-4737	20	15	months	month	NOUN
dpc-4737	20	16	.	.	PUNCT
dpc-4737	21	1	the	the	DET
dpc-4737	21	2	patients	patient	NOUN
dpc-4737	21	3	assessed	assess	VERB
dpc-4737	21	4	clinically	clinically	ADV
dpc-4737	21	5	as	as	ADP
dpc-4737	21	6	complete	complete	ADJ
dpc-4737	21	7	responders	responder	NOUN
dpc-4737	21	8	,	,	PUNCT
dpc-4737	21	9	partial	partial	ADJ
dpc-4737	21	10	responders	responder	NOUN
dpc-4737	21	11	,	,	PUNCT
dpc-4737	21	12	and	and	CCONJ
dpc-4737	21	13	non	non	ADJ
dpc-4737	21	14	responders	responder	NOUN
dpc-4737	21	15	.	.	PUNCT
dpc-4737	22	1	results	result	NOUN
dpc-4737	22	2	:	:	PUNCT
dpc-4737	22	3	nine	nine	NUM
dpc-4737	22	4	patients	patient	NOUN
dpc-4737	22	5	(	(	PUNCT
dpc-4737	22	6	60	60	NUM
dpc-4737	22	7	%	%	NOUN
dpc-4737	22	8	)	)	PUNCT
dpc-4737	22	9	were	be	AUX
dpc-4737	22	10	partial	partial	ADJ
dpc-4737	22	11	responders	responder	NOUN
dpc-4737	22	12	;	;	PUNCT
dpc-4737	22	13	showed	show	VERB
dpc-4737	22	14	50	50	NUM
dpc-4737	22	15	%	%	NOUN
dpc-4737	22	16	reduction	reduction	NOUN
dpc-4737	22	17	in	in	ADP
dpc-4737	22	18	the	the	DET
dpc-4737	22	19	number	number	NOUN
dpc-4737	22	20	of	of	ADP
dpc-4737	22	21	the	the	DET
dpc-4737	22	22	existing	exist	VERB
dpc-4737	22	23	lesions	lesion	NOUN
dpc-4737	22	24	,	,	PUNCT
dpc-4737	22	25	and	and	CCONJ
dpc-4737	22	26	6	6	NUM
dpc-4737	22	27	patients	patient	NOUN
dpc-4737	22	28	(	(	PUNCT
dpc-4737	22	29	40	40	NUM
dpc-4737	22	30	%	%	NOUN
dpc-4737	22	31	)	)	PUNCT
dpc-4737	22	32	were	be	AUX
dpc-4737	22	33	considered	consider	VERB
dpc-4737	22	34	non	non	NOUN
dpc-4737	22	35	-	-	NOUN
dpc-4737	22	36	responders	responder	NOUN
dpc-4737	22	37	;	;	PUNCT
dpc-4737	22	38	3	3	NUM
dpc-4737	22	39	with	with	ADP
dpc-4737	22	40	stable	stable	ADJ
dpc-4737	22	41	disease	disease	NOUN
dpc-4737	22	42	and	and	CCONJ
dpc-4737	22	43	3	3	NUM
dpc-4737	22	44	with	with	ADP
dpc-4737	22	45	progressive	progressive	ADJ
dpc-4737	22	46	disease	disease	NOUN
dpc-4737	22	47	.	.	PUNCT
dpc-4737	23	1	lymphedema	lymphedema	NOUN
dpc-4737	23	2	partially	partially	ADV
dpc-4737	23	3	improved	improve	VERB
dpc-4737	23	4	in	in	ADP
dpc-4737	23	5	1	1	NUM
dpc-4737	23	6	patient	patient	NOUN
dpc-4737	23	7	.	.	PUNCT
dpc-4737	24	1	conclusions	conclusion	NOUN
dpc-4737	24	2	:	:	PUNCT
dpc-4737	24	3	oral	oral	ADJ
dpc-4737	24	4	propranolol	propranolol	NOUN
dpc-4737	24	5	is	be	AUX
dpc-4737	24	6	a	a	DET
dpc-4737	24	7	safe	safe	ADJ
dpc-4737	24	8	and	and	CCONJ
dpc-4737	24	9	good	good	ADJ
dpc-4737	24	10	option	option	NOUN
dpc-4737	24	11	for	for	ADP
dpc-4737	24	12	treatment	treatment	NOUN
dpc-4737	24	13	of	of	ADP
dpc-4737	24	14	patients	patient	NOUN
dpc-4737	24	15	with	with	ADP
dpc-4737	24	16	non	non	X
dpc-4737	24	17	complicated	complicated	ADJ
dpc-4737	24	18	classic	classic	ADJ
dpc-4737	24	19	ks	ks	NOUN
dpc-4737	24	20	,	,	PUNCT
dpc-4737	24	21	especially	especially	ADV
dpc-4737	24	22	elderly	elderly	ADJ
dpc-4737	24	23	with	with	ADP
dpc-4737	24	24	multiple	multiple	ADJ
dpc-4737	24	25	comorbidities	comorbiditie	NOUN
dpc-4737	24	26	.	.	PUNCT
dpc-4737	25	1	abstract	abstract	ADJ
dpc-4737	25	2	2	2	NUM
dpc-4737	25	3	original	original	ADJ
dpc-4737	25	4	article	article	NOUN
dpc-4737	25	5	|	|	ADV
dpc-4737	25	6	dermatol	dermatol	ADJ
dpc-4737	25	7	pract	pract	NOUN
dpc-4737	25	8	concept	concept	NOUN
dpc-4737	25	9	.	.	PUNCT
dpc-4737	26	1	2025;15(1):4737	2025;15(1):4737	NUM
dpc-4737	26	2	introduction	introduction	NOUN
dpc-4737	26	3	kaposi	kaposi	PROPN
dpc-4737	26	4	sarcoma	sarcoma	PROPN
dpc-4737	26	5	(	(	PUNCT
dpc-4737	26	6	ks	ks	NOUN
dpc-4737	26	7	)	)	PUNCT
dpc-4737	26	8	is	be	AUX
dpc-4737	26	9	a	a	DET
dpc-4737	26	10	low	low	ADJ
dpc-4737	26	11	grade	grade	NOUN
dpc-4737	26	12	angio	angio	NOUN
dpc-4737	26	13	-	-	ADJ
dpc-4737	26	14	proliferative	proliferative	ADJ
dpc-4737	26	15	tumor	tumor	NOUN
dpc-4737	26	16	of	of	ADP
dpc-4737	26	17	endothelial	endothelial	ADJ
dpc-4737	26	18	origin	origin	NOUN
dpc-4737	26	19	.	.	PUNCT
dpc-4737	27	1	human	human	ADJ
dpc-4737	27	2	herpesvirus	herpesvirus	NOUN
dpc-4737	27	3	8	8	NUM
dpc-4737	27	4	(	(	PUNCT
dpc-4737	27	5	hhv8	hhv8	PROPN
dpc-4737	27	6	)	)	PUNCT
dpc-4737	27	7	plays	play	VERB
dpc-4737	27	8	a	a	DET
dpc-4737	27	9	major	major	ADJ
dpc-4737	27	10	role	role	NOUN
dpc-4737	27	11	in	in	ADP
dpc-4737	27	12	the	the	DET
dpc-4737	27	13	pathogenesis	pathogenesis	NOUN
dpc-4737	27	14	of	of	ADP
dpc-4737	27	15	ks	ks	PROPN
dpc-4737	27	16	in	in	ADP
dpc-4737	27	17	association	association	NOUN
dpc-4737	27	18	with	with	ADP
dpc-4737	27	19	genetic	genetic	ADJ
dpc-4737	27	20	,	,	PUNCT
dpc-4737	27	21	immunologic	immunologic	ADJ
dpc-4737	27	22	,	,	PUNCT
dpc-4737	27	23	and	and	CCONJ
dpc-4737	27	24	environmental	environmental	ADJ
dpc-4737	27	25	factors	factor	NOUN
dpc-4737	27	26	[	[	X
dpc-4737	27	27	1	1	NUM
dpc-4737	27	28	]	]	PUNCT
dpc-4737	27	29	.	.	PUNCT
dpc-4737	28	1	clinically	clinically	ADV
dpc-4737	28	2	,	,	PUNCT
dpc-4737	28	3	most	most	ADJ
dpc-4737	28	4	ks	ks	NOUN
dpc-4737	28	5	lesions	lesion	NOUN
dpc-4737	28	6	initially	initially	ADV
dpc-4737	28	7	appear	appear	VERB
dpc-4737	28	8	as	as	ADP
dpc-4737	28	9	violaceous	violaceous	ADJ
dpc-4737	28	10	patches	patch	NOUN
dpc-4737	28	11	that	that	PRON
dpc-4737	28	12	progress	progress	VERB
dpc-4737	28	13	into	into	ADP
dpc-4737	28	14	plaques	plaque	NOUN
dpc-4737	28	15	,	,	PUNCT
dpc-4737	28	16	and	and	CCONJ
dpc-4737	28	17	later	later	ADV
dpc-4737	28	18	develop	develop	VERB
dpc-4737	28	19	into	into	ADP
dpc-4737	28	20	larger	large	ADJ
dpc-4737	28	21	nodules	nodule	NOUN
dpc-4737	28	22	(	(	PUNCT
dpc-4737	28	23	tumor	tumor	NOUN
dpc-4737	28	24	stage	stage	NOUN
dpc-4737	28	25	)	)	PUNCT
dpc-4737	28	26	.	.	PUNCT
dpc-4737	29	1	it	it	PRON
dpc-4737	29	2	is	be	AUX
dpc-4737	29	3	important	important	ADJ
dpc-4737	29	4	to	to	PART
dpc-4737	29	5	note	note	VERB
dpc-4737	29	6	that	that	SCONJ
dpc-4737	29	7	different	different	ADJ
dpc-4737	29	8	stages	stage	NOUN
dpc-4737	29	9	can	can	AUX
dpc-4737	29	10	coexist	coexist	VERB
dpc-4737	29	11	concomitantly	concomitantly	ADV
dpc-4737	29	12	in	in	ADP
dpc-4737	29	13	the	the	DET
dpc-4737	29	14	same	same	ADJ
dpc-4737	29	15	patient	patient	NOUN
dpc-4737	29	16	.	.	PUNCT
dpc-4737	30	1	mucous	mucous	ADJ
dpc-4737	30	2	membrane	membrane	NOUN
dpc-4737	30	3	,	,	PUNCT
dpc-4737	30	4	lymph	lymph	NOUN
dpc-4737	30	5	nodes	node	NOUN
dpc-4737	30	6	and	and	CCONJ
dpc-4737	30	7	viscera	viscera	NOUN
dpc-4737	30	8	may	may	AUX
dpc-4737	30	9	also	also	ADV
dpc-4737	30	10	be	be	AUX
dpc-4737	30	11	affected	affect	VERB
dpc-4737	30	12	[	[	PUNCT
dpc-4737	30	13	2	2	NUM
dpc-4737	30	14	]	]	PUNCT
dpc-4737	30	15	.	.	PUNCT
dpc-4737	31	1	four	four	NUM
dpc-4737	31	2	distinctive	distinctive	ADJ
dpc-4737	31	3	subtypes	subtype	NOUN
dpc-4737	31	4	of	of	ADP
dpc-4737	31	5	ks	k	NOUN
dpc-4737	31	6	have	have	AUX
dpc-4737	31	7	been	be	AUX
dpc-4737	31	8	described	describe	VERB
dpc-4737	31	9	.	.	PUNCT
dpc-4737	32	1	they	they	PRON
dpc-4737	32	2	include	include	VERB
dpc-4737	32	3	classic	classic	ADJ
dpc-4737	32	4	,	,	PUNCT
dpc-4737	32	5	endemic	endemic	ADJ
dpc-4737	32	6	,	,	PUNCT
dpc-4737	32	7	iatrogenic	iatrogenic	ADJ
dpc-4737	32	8	,	,	PUNCT
dpc-4737	32	9	and	and	CCONJ
dpc-4737	32	10	aids	aid	NOUN
dpc-4737	32	11	-	-	PUNCT
dpc-4737	32	12	related	relate	VERB
dpc-4737	32	13	ks	ks	NOUN
dpc-4737	32	14	[	[	X
dpc-4737	32	15	1	1	NUM
dpc-4737	32	16	]	]	PUNCT
dpc-4737	32	17	.	.	PUNCT
dpc-4737	33	1	classic	classic	ADJ
dpc-4737	33	2	kaposi	kaposi	PROPN
dpc-4737	33	3	sarcoma	sarcoma	PROPN
dpc-4737	33	4	(	(	PUNCT
dpc-4737	33	5	cks	ck	NOUN
dpc-4737	33	6	)	)	PUNCT
dpc-4737	33	7	is	be	AUX
dpc-4737	33	8	commonly	commonly	ADV
dpc-4737	33	9	seen	see	VERB
dpc-4737	33	10	among	among	ADP
dpc-4737	33	11	elderly	elderly	ADJ
dpc-4737	33	12	of	of	ADP
dpc-4737	33	13	mediterranean	mediterranean	PROPN
dpc-4737	33	14	origin	origin	NOUN
dpc-4737	33	15	.	.	PUNCT
dpc-4737	34	1	lesions	lesion	NOUN
dpc-4737	34	2	are	be	AUX
dpc-4737	34	3	usually	usually	ADV
dpc-4737	34	4	slowly	slowly	ADV
dpc-4737	34	5	progressive	progressive	ADJ
dpc-4737	34	6	and	and	CCONJ
dpc-4737	34	7	located	locate	VERB
dpc-4737	34	8	on	on	ADP
dpc-4737	34	9	the	the	DET
dpc-4737	34	10	distal	distal	ADJ
dpc-4737	34	11	extremities	extremity	NOUN
dpc-4737	34	12	[	[	X
dpc-4737	34	13	1	1	NUM
dpc-4737	34	14	]	]	PUNCT
dpc-4737	34	15	.	.	PUNCT
dpc-4737	35	1	although	although	SCONJ
dpc-4737	35	2	the	the	DET
dpc-4737	35	3	disease	disease	NOUN
dpc-4737	35	4	is	be	AUX
dpc-4737	35	5	rarely	rarely	ADV
dpc-4737	35	6	fatal	fatal	ADJ
dpc-4737	35	7	,	,	PUNCT
dpc-4737	35	8	it	it	PRON
dpc-4737	35	9	may	may	AUX
dpc-4737	35	10	be	be	AUX
dpc-4737	35	11	accompanied	accompany	VERB
dpc-4737	35	12	by	by	ADP
dpc-4737	35	13	various	various	ADJ
dpc-4737	35	14	complications	complication	NOUN
dpc-4737	35	15	such	such	ADJ
dpc-4737	35	16	as	as	ADP
dpc-4737	35	17	edema	edema	NOUN
dpc-4737	35	18	,	,	PUNCT
dpc-4737	35	19	ulceration	ulceration	NOUN
dpc-4737	35	20	,	,	PUNCT
dpc-4737	35	21	and	and	CCONJ
dpc-4737	35	22	bleeding	bleed	VERB
dpc-4737	35	23	[	[	X
dpc-4737	35	24	2	2	NUM
dpc-4737	35	25	]	]	PUNCT
dpc-4737	35	26	.	.	PUNCT
dpc-4737	36	1	on	on	ADP
dpc-4737	36	2	the	the	DET
dpc-4737	36	3	other	other	ADJ
dpc-4737	36	4	hand	hand	NOUN
dpc-4737	36	5	,	,	PUNCT
dpc-4737	36	6	endemic	endemic	ADJ
dpc-4737	36	7	ks	k	NOUN
dpc-4737	36	8	is	be	AUX
dpc-4737	36	9	seen	see	VERB
dpc-4737	36	10	in	in	ADP
dpc-4737	36	11	the	the	DET
dpc-4737	36	12	young	young	ADJ
dpc-4737	36	13	population	population	NOUN
dpc-4737	36	14	of	of	ADP
dpc-4737	36	15	sub	sub	ADJ
dpc-4737	36	16	-	-	ADJ
dpc-4737	36	17	saharan	saharan	ADJ
dpc-4737	36	18	africa	africa	PROPN
dpc-4737	36	19	and	and	CCONJ
dpc-4737	36	20	may	may	AUX
dpc-4737	36	21	acquire	acquire	VERB
dpc-4737	36	22	an	an	DET
dpc-4737	36	23	aggressive	aggressive	ADJ
dpc-4737	36	24	and	and	CCONJ
dpc-4737	36	25	lethal	lethal	ADJ
dpc-4737	36	26	course	course	NOUN
dpc-4737	37	1	[	[	X
dpc-4737	37	2	1	1	NUM
dpc-4737	37	3	]	]	PUNCT
dpc-4737	37	4	.	.	PUNCT
dpc-4737	38	1	iatrogenic	iatrogenic	ADJ
dpc-4737	38	2	ks	k	NOUN
dpc-4737	38	3	has	have	AUX
dpc-4737	38	4	been	be	AUX
dpc-4737	38	5	reported	report	VERB
dpc-4737	38	6	in	in	ADP
dpc-4737	38	7	patients	patient	NOUN
dpc-4737	38	8	with	with	ADP
dpc-4737	38	9	solid	solid	ADJ
dpc-4737	38	10	organ	organ	NOUN
dpc-4737	38	11	transplants	transplant	NOUN
dpc-4737	38	12	as	as	ADV
dpc-4737	38	13	well	well	ADV
dpc-4737	38	14	as	as	ADP
dpc-4737	38	15	other	other	ADJ
dpc-4737	38	16	patients	patient	NOUN
dpc-4737	38	17	on	on	ADP
dpc-4737	38	18	immunosuppressive	immunosuppressive	ADJ
dpc-4737	38	19	treatments	treatment	NOUN
dpc-4737	38	20	.	.	PUNCT
dpc-4737	39	1	in	in	ADP
dpc-4737	39	2	this	this	DET
dpc-4737	39	3	variant	variant	NOUN
dpc-4737	39	4	,	,	PUNCT
dpc-4737	39	5	the	the	DET
dpc-4737	39	6	cutaneous	cutaneous	ADJ
dpc-4737	39	7	lesions	lesion	NOUN
dpc-4737	39	8	usually	usually	ADV
dpc-4737	39	9	regress	regress	ADJ
dpc-4737	39	10	after	after	ADP
dpc-4737	39	11	stoppage	stoppage	NOUN
dpc-4737	39	12	of	of	ADP
dpc-4737	39	13	therapy	therapy	NOUN
dpc-4737	39	14	[	[	X
dpc-4737	39	15	2	2	NUM
dpc-4737	39	16	]	]	PUNCT
dpc-4737	39	17	.	.	PUNCT
dpc-4737	40	1	finally	finally	ADV
dpc-4737	40	2	,	,	PUNCT
dpc-4737	40	3	aidsrelated	aidsrelate	VERB
dpc-4737	40	4	ks	ks	NOUN
dpc-4737	40	5	is	be	AUX
dpc-4737	40	6	an	an	DET
dpc-4737	40	7	aggressive	aggressive	ADJ
dpc-4737	40	8	type	type	NOUN
dpc-4737	40	9	which	which	PRON
dpc-4737	40	10	is	be	AUX
dpc-4737	40	11	characterized	characterize	VERB
dpc-4737	40	12	by	by	ADP
dpc-4737	40	13	multifocal	multifocal	ADJ
dpc-4737	40	14	skin	skin	NOUN
dpc-4737	40	15	affection	affection	NOUN
dpc-4737	40	16	,	,	PUNCT
dpc-4737	40	17	frequent	frequent	ADJ
dpc-4737	40	18	visceral	visceral	ADJ
dpc-4737	40	19	involvement	involvement	NOUN
dpc-4737	40	20	,	,	PUNCT
dpc-4737	40	21	and	and	CCONJ
dpc-4737	40	22	subsequently	subsequently	ADV
dpc-4737	40	23	carries	carry	VERB
dpc-4737	40	24	a	a	DET
dpc-4737	40	25	poor	poor	ADJ
dpc-4737	40	26	prognosis	prognosis	NOUN
dpc-4737	41	1	[	[	X
dpc-4737	41	2	3	3	NUM
dpc-4737	41	3	]	]	PUNCT
dpc-4737	41	4	.	.	PUNCT
dpc-4737	42	1	although	although	SCONJ
dpc-4737	42	2	there	there	PRON
dpc-4737	42	3	are	be	VERB
dpc-4737	42	4	many	many	ADJ
dpc-4737	42	5	available	available	ADJ
dpc-4737	42	6	therapeutic	therapeutic	ADJ
dpc-4737	42	7	options	option	NOUN
dpc-4737	42	8	for	for	ADP
dpc-4737	42	9	management	management	NOUN
dpc-4737	42	10	of	of	ADP
dpc-4737	42	11	ks	ks	NOUN
dpc-4737	42	12	there	there	PRON
dpc-4737	42	13	is	be	VERB
dpc-4737	42	14	no	no	DET
dpc-4737	42	15	definitive	definitive	ADJ
dpc-4737	42	16	cure	cure	NOUN
dpc-4737	42	17	.	.	PUNCT
dpc-4737	43	1	alternatively	alternatively	ADV
dpc-4737	43	2	,	,	PUNCT
dpc-4737	43	3	the	the	DET
dpc-4737	43	4	current	current	ADJ
dpc-4737	43	5	treatments	treatment	NOUN
dpc-4737	43	6	aim	aim	VERB
dpc-4737	43	7	is	be	AUX
dpc-4737	43	8	limited	limit	VERB
dpc-4737	43	9	to	to	ADP
dpc-4737	43	10	stopping	stop	VERB
dpc-4737	43	11	disease	disease	NOUN
dpc-4737	43	12	progression	progression	NOUN
dpc-4737	43	13	,	,	PUNCT
dpc-4737	43	14	decreasing	decrease	VERB
dpc-4737	43	15	lesions	lesion	NOUN
dpc-4737	43	16	size	size	NOUN
dpc-4737	43	17	,	,	PUNCT
dpc-4737	43	18	and	and	CCONJ
dpc-4737	43	19	improving	improve	VERB
dpc-4737	43	20	lymphedema	lymphedema	NOUN
dpc-4737	43	21	.	.	PUNCT
dpc-4737	44	1	considering	consider	VERB
dpc-4737	44	2	the	the	DET
dpc-4737	44	3	variable	variable	ADJ
dpc-4737	44	4	presentations	presentation	NOUN
dpc-4737	44	5	of	of	ADP
dpc-4737	44	6	ks	ks	PROPN
dpc-4737	44	7	,	,	PUNCT
dpc-4737	44	8	the	the	DET
dpc-4737	44	9	treatment	treatment	NOUN
dpc-4737	44	10	approach	approach	NOUN
dpc-4737	44	11	must	must	AUX
dpc-4737	44	12	be	be	AUX
dpc-4737	44	13	tailored	tailor	VERB
dpc-4737	44	14	according	accord	VERB
dpc-4737	44	15	to	to	ADP
dpc-4737	44	16	the	the	DET
dpc-4737	44	17	clinical	clinical	ADJ
dpc-4737	44	18	type	type	NOUN
dpc-4737	44	19	,	,	PUNCT
dpc-4737	44	20	the	the	DET
dpc-4737	44	21	extent	extent	NOUN
dpc-4737	44	22	of	of	ADP
dpc-4737	44	23	ks	ks	NOUN
dpc-4737	44	24	lesions	lesion	NOUN
dpc-4737	44	25	,	,	PUNCT
dpc-4737	44	26	their	their	PRON
dpc-4737	44	27	anatomical	anatomical	ADJ
dpc-4737	44	28	location	location	NOUN
dpc-4737	44	29	,	,	PUNCT
dpc-4737	44	30	and	and	CCONJ
dpc-4737	44	31	the	the	DET
dpc-4737	44	32	presence	presence	NOUN
dpc-4737	44	33	of	of	ADP
dpc-4737	44	34	comorbidities	comorbiditie	NOUN
dpc-4737	44	35	.	.	PUNCT
dpc-4737	45	1	despite	despite	SCONJ
dpc-4737	45	2	the	the	DET
dpc-4737	45	3	promising	promising	ADJ
dpc-4737	45	4	results	result	NOUN
dpc-4737	45	5	of	of	ADP
dpc-4737	45	6	the	the	DET
dpc-4737	45	7	different	different	ADJ
dpc-4737	45	8	treatment	treatment	NOUN
dpc-4737	45	9	modalities	modality	NOUN
dpc-4737	45	10	,	,	PUNCT
dpc-4737	45	11	the	the	DET
dpc-4737	45	12	high	high	ADJ
dpc-4737	45	13	cost	cost	NOUN
dpc-4737	45	14	and	and	CCONJ
dpc-4737	45	15	potential	potential	ADJ
dpc-4737	45	16	side	side	NOUN
dpc-4737	45	17	effects	effect	NOUN
dpc-4737	45	18	may	may	AUX
dpc-4737	45	19	be	be	AUX
dpc-4737	45	20	a	a	DET
dpc-4737	45	21	barrier	barrier	NOUN
dpc-4737	45	22	against	against	ADP
dpc-4737	45	23	their	their	PRON
dpc-4737	45	24	use	use	NOUN
dpc-4737	45	25	in	in	ADP
dpc-4737	45	26	many	many	ADJ
dpc-4737	45	27	patients	patient	NOUN
dpc-4737	45	28	.	.	PUNCT
dpc-4737	46	1	in	in	ADP
dpc-4737	46	2	the	the	DET
dpc-4737	46	3	last	last	ADJ
dpc-4737	46	4	couple	couple	NOUN
dpc-4737	46	5	of	of	ADP
dpc-4737	46	6	decades	decade	NOUN
dpc-4737	46	7	beta	beta	ADJ
dpc-4737	46	8	blockers	blocker	NOUN
dpc-4737	46	9	became	become	VERB
dpc-4737	46	10	part	part	NOUN
dpc-4737	46	11	of	of	ADP
dpc-4737	46	12	the	the	DET
dpc-4737	46	13	treatment	treatment	NOUN
dpc-4737	46	14	armamentarium	armamentarium	NOUN
dpc-4737	46	15	of	of	ADP
dpc-4737	46	16	dermatologic	dermatologic	ADJ
dpc-4737	46	17	diseases	disease	NOUN
dpc-4737	46	18	mostly	mostly	ADV
dpc-4737	46	19	due	due	ADP
dpc-4737	46	20	to	to	ADP
dpc-4737	46	21	their	their	PRON
dpc-4737	46	22	effectiveness	effectiveness	NOUN
dpc-4737	46	23	in	in	ADP
dpc-4737	46	24	the	the	DET
dpc-4737	46	25	treatment	treatment	NOUN
dpc-4737	46	26	of	of	ADP
dpc-4737	46	27	infantile	infantile	ADJ
dpc-4737	46	28	hemangiomas	hemangioma	NOUN
dpc-4737	46	29	(	(	PUNCT
dpc-4737	46	30	ih	ih	NOUN
dpc-4737	46	31	)	)	PUNCT
dpc-4737	47	1	[	[	X
dpc-4737	47	2	4	4	NUM
dpc-4737	47	3	]	]	PUNCT
dpc-4737	47	4	.	.	PUNCT
dpc-4737	47	5	propranolol	propranolol	PROPN
dpc-4737	47	6	and	and	CCONJ
dpc-4737	47	7	timolol	timolol	NOUN
dpc-4737	47	8	were	be	AUX
dpc-4737	47	9	among	among	ADP
dpc-4737	47	10	the	the	DET
dpc-4737	47	11	first	first	ADJ
dpc-4737	47	12	-	-	PUNCT
dpc-4737	47	13	generation	generation	NOUN
dpc-4737	47	14	nonselective	nonselective	ADJ
dpc-4737	47	15	beta	beta	NOUN
dpc-4737	47	16	blockers	blocker	NOUN
dpc-4737	47	17	that	that	PRON
dpc-4737	47	18	were	be	AUX
dpc-4737	47	19	effectively	effectively	ADV
dpc-4737	47	20	used	use	VERB
dpc-4737	47	21	in	in	ADP
dpc-4737	47	22	the	the	DET
dpc-4737	47	23	treatment	treatment	NOUN
dpc-4737	47	24	of	of	ADP
dpc-4737	47	25	such	such	ADJ
dpc-4737	47	26	conditions	condition	NOUN
dpc-4737	47	27	[	[	X
dpc-4737	47	28	5	5	NUM
dpc-4737	47	29	]	]	PUNCT
dpc-4737	47	30	.	.	PUNCT
dpc-4737	48	1	nevertheless	nevertheless	ADV
dpc-4737	48	2	,	,	PUNCT
dpc-4737	48	3	their	their	PRON
dpc-4737	48	4	mechanism	mechanism	NOUN
dpc-4737	48	5	of	of	ADP
dpc-4737	48	6	action	action	NOUN
dpc-4737	48	7	remains	remains	AUX
dpc-4737	48	8	not	not	PART
dpc-4737	48	9	fully	fully	ADV
dpc-4737	48	10	understood	understand	VERB
dpc-4737	48	11	.	.	PUNCT
dpc-4737	49	1	it	it	PRON
dpc-4737	49	2	has	have	AUX
dpc-4737	49	3	been	be	AUX
dpc-4737	49	4	postulated	postulate	VERB
dpc-4737	49	5	that	that	SCONJ
dpc-4737	49	6	endothelial	endothelial	ADJ
dpc-4737	49	7	cells	cell	NOUN
dpc-4737	49	8	of	of	ADP
dpc-4737	49	9	ih	ih	PRON
dpc-4737	49	10	express	express	VERB
dpc-4737	49	11	beta	beta	ADJ
dpc-4737	49	12	2	2	NUM
dpc-4737	49	13	adrenergic	adrenergic	ADJ
dpc-4737	49	14	receptors	receptor	NOUN
dpc-4737	49	15	(	(	PUNCT
dpc-4737	49	16	b2	b2	NOUN
dpc-4737	49	17	-	-	PUNCT
dpc-4737	49	18	ar	ar	NOUN
dpc-4737	49	19	)	)	PUNCT
dpc-4737	49	20	,	,	PUNCT
dpc-4737	49	21	therefore	therefore	ADV
dpc-4737	49	22	,	,	PUNCT
dpc-4737	49	23	beta	beta	ADJ
dpc-4737	49	24	blockers	blocker	NOUN
dpc-4737	49	25	may	may	AUX
dpc-4737	49	26	act	act	VERB
dpc-4737	49	27	through	through	ADP
dpc-4737	49	28	vasoconstriction	vasoconstriction	NOUN
dpc-4737	49	29	and	and	CCONJ
dpc-4737	49	30	inhibition	inhibition	NOUN
dpc-4737	49	31	of	of	ADP
dpc-4737	49	32	vascular	vascular	ADJ
dpc-4737	49	33	endothelial	endothelial	ADJ
dpc-4737	49	34	growth	growth	NOUN
dpc-4737	49	35	factors	factor	NOUN
dpc-4737	49	36	,	,	PUNCT
dpc-4737	49	37	which	which	PRON
dpc-4737	49	38	leads	lead	VERB
dpc-4737	49	39	to	to	ADP
dpc-4737	49	40	reduction	reduction	NOUN
dpc-4737	49	41	in	in	ADP
dpc-4737	49	42	angiogenesis	angiogenesis	NOUN
dpc-4737	49	43	and	and	CCONJ
dpc-4737	49	44	induction	induction	NOUN
dpc-4737	49	45	of	of	ADP
dpc-4737	49	46	endothelial	endothelial	ADJ
dpc-4737	49	47	cell	cell	NOUN
dpc-4737	49	48	apoptosis	apoptosis	NOUN
dpc-4737	50	1	[	[	X
dpc-4737	50	2	6	6	NUM
dpc-4737	50	3	]	]	PUNCT
dpc-4737	50	4	.	.	PUNCT
dpc-4737	51	1	the	the	DET
dpc-4737	51	2	success	success	NOUN
dpc-4737	51	3	of	of	ADP
dpc-4737	51	4	beta	beta	ADJ
dpc-4737	51	5	blockers	blocker	NOUN
dpc-4737	51	6	in	in	ADP
dpc-4737	51	7	treatment	treatment	NOUN
dpc-4737	51	8	of	of	ADP
dpc-4737	51	9	ih	ih	NOUN
dpc-4737	51	10	has	have	AUX
dpc-4737	51	11	advocated	advocate	VERB
dpc-4737	51	12	their	their	PRON
dpc-4737	51	13	introduction	introduction	NOUN
dpc-4737	51	14	as	as	ADP
dpc-4737	51	15	a	a	DET
dpc-4737	51	16	treatment	treatment	NOUN
dpc-4737	51	17	modality	modality	NOUN
dpc-4737	51	18	in	in	ADP
dpc-4737	51	19	other	other	ADJ
dpc-4737	51	20	proliferative	proliferative	ADJ
dpc-4737	51	21	vascular	vascular	ADJ
dpc-4737	51	22	lesions	lesion	NOUN
dpc-4737	51	23	,	,	PUNCT
dpc-4737	51	24	whether	whether	SCONJ
dpc-4737	51	25	as	as	ADP
dpc-4737	51	26	a	a	DET
dpc-4737	51	27	monoor	monoor	NOUN
dpc-4737	51	28	as	as	ADP
dpc-4737	51	29	an	an	DET
dpc-4737	51	30	adjuvant	adjuvant	ADJ
dpc-4737	51	31	therapy	therapy	NOUN
dpc-4737	51	32	[	[	X
dpc-4737	51	33	7	7	NUM
dpc-4737	51	34	]	]	PUNCT
dpc-4737	51	35	.	.	PUNCT
dpc-4737	52	1	since	since	SCONJ
dpc-4737	52	2	similarities	similarity	NOUN
dpc-4737	52	3	exist	exist	VERB
dpc-4737	52	4	between	between	ADP
dpc-4737	52	5	ih	ih	NOUN
dpc-4737	52	6	and	and	CCONJ
dpc-4737	52	7	ks	ks	PROPN
dpc-4737	52	8	including	include	VERB
dpc-4737	52	9	the	the	DET
dpc-4737	52	10	high	high	ADJ
dpc-4737	52	11	badrenergic	badrenergic	NOUN
dpc-4737	52	12	receptor	receptor	NOUN
dpc-4737	52	13	expression	expression	NOUN
dpc-4737	52	14	and	and	CCONJ
dpc-4737	52	15	the	the	DET
dpc-4737	52	16	possible	possible	ADJ
dpc-4737	52	17	role	role	NOUN
dpc-4737	52	18	of	of	ADP
dpc-4737	52	19	vascular	vascular	ADJ
dpc-4737	52	20	endothelial	endothelial	ADJ
dpc-4737	52	21	growth	growth	NOUN
dpc-4737	52	22	factor	factor	NOUN
dpc-4737	52	23	(	(	PUNCT
dpc-4737	52	24	vegf	vegf	PROPN
dpc-4737	52	25	)	)	PUNCT
dpc-4737	53	1	[	[	X
dpc-4737	53	2	8	8	NUM
dpc-4737	53	3	]	]	PUNCT
dpc-4737	53	4	,	,	PUNCT
dpc-4737	53	5	it	it	PRON
dpc-4737	53	6	is	be	AUX
dpc-4737	53	7	hypothesized	hypothesize	VERB
dpc-4737	53	8	that	that	SCONJ
dpc-4737	53	9	b2	b2	NOUN
dpc-4737	53	10	-	-	PUNCT
dpc-4737	53	11	ar	ar	NOUN
dpc-4737	53	12	antagonists	antagonist	NOUN
dpc-4737	53	13	(	(	PUNCT
dpc-4737	53	14	b2	b2	NOUN
dpc-4737	53	15	-	-	PUNCT
dpc-4737	53	16	aras	aras	X
dpc-4737	53	17	)	)	PUNCT
dpc-4737	53	18	may	may	AUX
dpc-4737	53	19	be	be	AUX
dpc-4737	53	20	useful	useful	ADJ
dpc-4737	53	21	for	for	ADP
dpc-4737	53	22	the	the	DET
dpc-4737	53	23	treatment	treatment	NOUN
dpc-4737	53	24	of	of	ADP
dpc-4737	53	25	ks	ks	PROPN
dpc-4737	53	26	.	.	PUNCT
dpc-4737	54	1	in	in	ADP
dpc-4737	54	2	this	this	DET
dpc-4737	54	3	context	context	NOUN
dpc-4737	54	4	,	,	PUNCT
dpc-4737	54	5	topical	topical	ADJ
dpc-4737	54	6	timolol	timolol	NOUN
dpc-4737	54	7	in	in	ADP
dpc-4737	54	8	different	different	ADJ
dpc-4737	54	9	formulations	formulation	NOUN
dpc-4737	54	10	and	and	CCONJ
dpc-4737	54	11	concentrations	concentration	NOUN
dpc-4737	54	12	has	have	AUX
dpc-4737	54	13	been	be	AUX
dpc-4737	54	14	used	use	VERB
dpc-4737	54	15	in	in	ADP
dpc-4737	54	16	the	the	DET
dpc-4737	54	17	treatment	treatment	NOUN
dpc-4737	54	18	of	of	ADP
dpc-4737	54	19	iatrogenic	iatrogenic	ADJ
dpc-4737	54	20	,	,	PUNCT
dpc-4737	54	21	epidemic	epidemic	NOUN
dpc-4737	54	22	,	,	PUNCT
dpc-4737	54	23	and	and	CCONJ
dpc-4737	54	24	cks	ck	NOUN
dpc-4737	54	25	with	with	ADP
dpc-4737	54	26	variable	variable	ADJ
dpc-4737	54	27	success	success	NOUN
dpc-4737	54	28	rates	rate	NOUN
dpc-4737	54	29	[	[	X
dpc-4737	54	30	9,10	9,10	NUM
dpc-4737	54	31	]	]	X
dpc-4737	54	32	.	.	PUNCT
dpc-4737	55	1	topical	topical	ADJ
dpc-4737	55	2	timolol	timolol	NOUN
dpc-4737	55	3	has	have	VERB
dpc-4737	55	4	the	the	DET
dpc-4737	55	5	advantage	advantage	NOUN
dpc-4737	55	6	of	of	ADP
dpc-4737	55	7	being	be	AUX
dpc-4737	55	8	inexpensive	inexpensive	ADJ
dpc-4737	55	9	,	,	PUNCT
dpc-4737	55	10	painless	painless	ADJ
dpc-4737	55	11	,	,	PUNCT
dpc-4737	55	12	and	and	CCONJ
dpc-4737	55	13	well	well	ADV
dpc-4737	55	14	tolerated	tolerate	VERB
dpc-4737	55	15	[	[	X
dpc-4737	55	16	9,10	9,10	NUM
dpc-4737	55	17	]	]	X
dpc-4737	55	18	.	.	PUNCT
dpc-4737	56	1	a	a	DET
dpc-4737	56	2	recent	recent	ADJ
dpc-4737	56	3	study	study	NOUN
dpc-4737	56	4	demonstrated	demonstrate	VERB
dpc-4737	56	5	that	that	SCONJ
dpc-4737	56	6	topical	topical	ADJ
dpc-4737	56	7	propranolol	propranolol	NOUN
dpc-4737	56	8	2	2	NUM
dpc-4737	56	9	%	%	NOUN
dpc-4737	56	10	cream	cream	NOUN
dpc-4737	56	11	was	be	AUX
dpc-4737	56	12	more	more	ADV
dpc-4737	56	13	effective	effective	ADJ
dpc-4737	56	14	than	than	ADP
dpc-4737	56	15	topical	topical	ADJ
dpc-4737	56	16	timolol	timolol	NOUN
dpc-4737	56	17	gel	gel	NOUN
dpc-4737	56	18	0.5	0.5	NUM
dpc-4737	56	19	%	%	NOUN
dpc-4737	56	20	in	in	ADP
dpc-4737	56	21	the	the	DET
dpc-4737	56	22	treatment	treatment	NOUN
dpc-4737	56	23	of	of	ADP
dpc-4737	56	24	patients	patient	NOUN
dpc-4737	56	25	with	with	ADP
dpc-4737	56	26	cks	ck	NOUN
dpc-4737	56	27	[	[	X
dpc-4737	56	28	11	11	NUM
dpc-4737	56	29	]	]	PUNCT
dpc-4737	56	30	.	.	PUNCT
dpc-4737	57	1	on	on	ADP
dpc-4737	57	2	the	the	DET
dpc-4737	57	3	other	other	ADJ
dpc-4737	57	4	hand	hand	NOUN
dpc-4737	57	5	,	,	PUNCT
dpc-4737	57	6	there	there	PRON
dpc-4737	57	7	are	be	VERB
dpc-4737	57	8	limited	limited	ADJ
dpc-4737	57	9	reports	report	NOUN
dpc-4737	57	10	regarding	regard	VERB
dpc-4737	57	11	the	the	DET
dpc-4737	57	12	use	use	NOUN
dpc-4737	57	13	of	of	ADP
dpc-4737	57	14	systemic	systemic	ADJ
dpc-4737	57	15	propranolol	propranolol	NOUN
dpc-4737	57	16	in	in	ADP
dpc-4737	57	17	the	the	DET
dpc-4737	57	18	treatment	treatment	NOUN
dpc-4737	57	19	of	of	ADP
dpc-4737	57	20	ks	ks	NOUN
dpc-4737	57	21	[	[	X
dpc-4737	57	22	12,13	12,13	NUM
dpc-4737	57	23	]	]	PUNCT
dpc-4737	57	24	.	.	PUNCT
dpc-4737	58	1	objectives	objective	VERB
dpc-4737	58	2	the	the	DET
dpc-4737	58	3	aim	aim	NOUN
dpc-4737	58	4	of	of	ADP
dpc-4737	58	5	the	the	DET
dpc-4737	58	6	present	present	ADJ
dpc-4737	58	7	work	work	NOUN
dpc-4737	58	8	was	be	AUX
dpc-4737	58	9	to	to	PART
dpc-4737	58	10	assess	assess	VERB
dpc-4737	58	11	the	the	DET
dpc-4737	58	12	efficacy	efficacy	NOUN
dpc-4737	58	13	and	and	CCONJ
dpc-4737	58	14	safety	safety	NOUN
dpc-4737	58	15	of	of	ADP
dpc-4737	58	16	oral	oral	ADJ
dpc-4737	58	17	propranolol	propranolol	NOUN
dpc-4737	58	18	in	in	ADP
dpc-4737	58	19	the	the	DET
dpc-4737	58	20	treatment	treatment	NOUN
dpc-4737	58	21	of	of	ADP
dpc-4737	58	22	cks	ck	NOUN
dpc-4737	58	23	.	.	PUNCT
dpc-4737	59	1	methods	method	NOUN
dpc-4737	59	2	patient	patient	ADJ
dpc-4737	59	3	selection	selection	NOUN
dpc-4737	59	4	all	all	DET
dpc-4737	59	5	clinically	clinically	ADV
dpc-4737	59	6	suspected	suspect	VERB
dpc-4737	59	7	cases	case	NOUN
dpc-4737	59	8	of	of	ADP
dpc-4737	59	9	ks	k	NOUN
dpc-4737	59	10	were	be	AUX
dpc-4737	59	11	biopsied	biopsie	VERB
dpc-4737	59	12	for	for	ADP
dpc-4737	59	13	histopathological	histopathological	ADJ
dpc-4737	59	14	diagnosis	diagnosis	NOUN
dpc-4737	59	15	,	,	PUNCT
dpc-4737	59	16	followed	follow	VERB
dpc-4737	59	17	by	by	ADP
dpc-4737	59	18	immunohistochemistry	immunohistochemistry	NOUN
dpc-4737	59	19	confirmation	confirmation	NOUN
dpc-4737	59	20	using	use	VERB
dpc-4737	59	21	hhv8	hhv8	PROPN
dpc-4737	59	22	and	and	CCONJ
dpc-4737	59	23	d2	d2	PROPN
dpc-4737	59	24	-	-	PUNCT
dpc-4737	59	25	40	40	NUM
dpc-4737	59	26	stains	stain	NOUN
dpc-4737	59	27	.	.	PUNCT
dpc-4737	60	1	only	only	ADV
dpc-4737	60	2	cases	case	NOUN
dpc-4737	60	3	diagnosed	diagnose	VERB
dpc-4737	60	4	with	with	ADP
dpc-4737	60	5	cks	ck	NOUN
dpc-4737	60	6	were	be	AUX
dpc-4737	60	7	included	include	VERB
dpc-4737	60	8	in	in	ADP
dpc-4737	60	9	this	this	DET
dpc-4737	60	10	study	study	NOUN
dpc-4737	60	11	.	.	PUNCT
dpc-4737	61	1	all	all	DET
dpc-4737	61	2	patients	patient	NOUN
dpc-4737	61	3	underwent	undergo	VERB
dpc-4737	61	4	a	a	DET
dpc-4737	61	5	thorough	thorough	ADJ
dpc-4737	61	6	history	history	NOUN
dpc-4737	61	7	taking	taking	NOUN
dpc-4737	61	8	(	(	PUNCT
dpc-4737	61	9	age	age	NOUN
dpc-4737	61	10	,	,	PUNCT
dpc-4737	61	11	duration	duration	NOUN
dpc-4737	61	12	of	of	ADP
dpc-4737	61	13	the	the	DET
dpc-4737	61	14	disease	disease	NOUN
dpc-4737	61	15	,	,	PUNCT
dpc-4737	61	16	its	its	PRON
dpc-4737	61	17	progression	progression	NOUN
dpc-4737	61	18	,	,	PUNCT
dpc-4737	61	19	present	present	ADJ
dpc-4737	61	20	and	and	CCONJ
dpc-4737	61	21	previous	previous	ADJ
dpc-4737	61	22	medications	medication	NOUN
dpc-4737	61	23	,	,	PUNCT
dpc-4737	61	24	comorbid	comorbid	NOUN
dpc-4737	61	25	conditions	condition	NOUN
dpc-4737	61	26	)	)	PUNCT
dpc-4737	61	27	.	.	PUNCT
dpc-4737	62	1	physical	physical	ADJ
dpc-4737	62	2	examination	examination	NOUN
dpc-4737	62	3	entailed	entail	VERB
dpc-4737	62	4	the	the	DET
dpc-4737	62	5	type	type	NOUN
dpc-4737	62	6	,	,	PUNCT
dpc-4737	62	7	distribution	distribution	NOUN
dpc-4737	62	8	,	,	PUNCT
dpc-4737	62	9	and	and	CCONJ
dpc-4737	62	10	number	number	NOUN
dpc-4737	62	11	of	of	ADP
dpc-4737	62	12	the	the	DET
dpc-4737	62	13	lesions	lesion	NOUN
dpc-4737	62	14	,	,	PUNCT
dpc-4737	62	15	presence	presence	NOUN
dpc-4737	62	16	of	of	ADP
dpc-4737	62	17	lymphedema	lymphedema	NOUN
dpc-4737	62	18	and	and	CCONJ
dpc-4737	62	19	mucous	mucous	ADJ
dpc-4737	62	20	membrane	membrane	NOUN
dpc-4737	62	21	lesions	lesion	NOUN
dpc-4737	62	22	.	.	PUNCT
dpc-4737	63	1	cardiac	cardiac	ADJ
dpc-4737	63	2	assessment	assessment	NOUN
dpc-4737	63	3	by	by	ADP
dpc-4737	63	4	a	a	DET
dpc-4737	63	5	cardiologist	cardiologist	NOUN
dpc-4737	63	6	was	be	AUX
dpc-4737	63	7	administered	administer	VERB
dpc-4737	63	8	to	to	PART
dpc-4737	63	9	exclude	exclude	VERB
dpc-4737	63	10	any	any	DET
dpc-4737	63	11	heart	heart	NOUN
dpc-4737	63	12	morbidities	morbidity	NOUN
dpc-4737	63	13	.	.	PUNCT
dpc-4737	64	1	additionally	additionally	ADV
dpc-4737	64	2	,	,	PUNCT
dpc-4737	64	3	general	general	ADJ
dpc-4737	64	4	examination	examination	NOUN
dpc-4737	64	5	was	be	AUX
dpc-4737	64	6	done	do	VERB
dpc-4737	64	7	mainly	mainly	ADV
dpc-4737	64	8	to	to	PART
dpc-4737	64	9	assess	assess	VERB
dpc-4737	64	10	the	the	DET
dpc-4737	64	11	lymph	lymph	NOUN
dpc-4737	64	12	nodes	node	NOUN
dpc-4737	64	13	.	.	PUNCT
dpc-4737	65	1	routine	routine	ADJ
dpc-4737	65	2	blood	blood	NOUN
dpc-4737	65	3	tests	test	NOUN
dpc-4737	65	4	and	and	CCONJ
dpc-4737	65	5	hiv	hiv	PROPN
dpc-4737	65	6	serology	serology	NOUN
dpc-4737	65	7	were	be	AUX
dpc-4737	65	8	done	do	VERB
dpc-4737	65	9	for	for	SCONJ
dpc-4737	65	10	all	all	DET
dpc-4737	65	11	patients	patient	NOUN
dpc-4737	65	12	to	to	PART
dpc-4737	65	13	exclude	exclude	VERB
dpc-4737	65	14	hiv	hiv	PROPN
dpc-4737	65	15	related	related	ADJ
dpc-4737	65	16	ks	ks	PROPN
dpc-4737	65	17	.	.	PROPN
dpc-4737	65	18	exclusion	exclusion	NOUN
dpc-4737	65	19	criteria	criterion	NOUN
dpc-4737	65	20	patients	patient	NOUN
dpc-4737	65	21	with	with	ADP
dpc-4737	65	22	symptomatic	symptomatic	ADJ
dpc-4737	65	23	visceral	visceral	ADJ
dpc-4737	65	24	ks	k	NOUN
dpc-4737	65	25	,	,	PUNCT
dpc-4737	65	26	hiv	hiv	PROPN
dpc-4737	65	27	positive	positive	ADJ
dpc-4737	65	28	patients	patient	NOUN
dpc-4737	65	29	,	,	PUNCT
dpc-4737	65	30	those	those	PRON
dpc-4737	65	31	on	on	ADP
dpc-4737	65	32	immunosuppressive	immunosuppressive	ADJ
dpc-4737	65	33	therapies	therapy	NOUN
dpc-4737	65	34	,	,	PUNCT
dpc-4737	65	35	or	or	CCONJ
dpc-4737	65	36	on	on	ADP
dpc-4737	65	37	any	any	DET
dpc-4737	65	38	other	other	ADJ
dpc-4737	65	39	ks	ks	NOUN
dpc-4737	65	40	treatments	treatment	NOUN
dpc-4737	65	41	were	be	AUX
dpc-4737	65	42	excluded	exclude	VERB
dpc-4737	65	43	.	.	PUNCT
dpc-4737	66	1	patients	patient	NOUN
dpc-4737	66	2	with	with	ADP
dpc-4737	66	3	cardiac	cardiac	ADJ
dpc-4737	66	4	abnormalities	abnormality	NOUN
dpc-4737	66	5	including	include	VERB
dpc-4737	66	6	abnormal	abnormal	ADJ
dpc-4737	66	7	ecg	ecg	PROPN
dpc-4737	66	8	,	,	PUNCT
dpc-4737	66	9	bradycardia	bradycardia	NOUN
dpc-4737	66	10	,	,	PUNCT
dpc-4737	66	11	on	on	ADP
dpc-4737	66	12	other	other	ADJ
dpc-4737	66	13	antihypertensive	antihypertensive	ADJ
dpc-4737	66	14	drugs	drug	NOUN
dpc-4737	66	15	,	,	PUNCT
dpc-4737	66	16	or	or	CCONJ
dpc-4737	66	17	having	have	VERB
dpc-4737	66	18	any	any	DET
dpc-4737	66	19	other	other	ADJ
dpc-4737	66	20	contraindications	contraindication	NOUN
dpc-4737	66	21	for	for	ADP
dpc-4737	66	22	systemic	systemic	ADJ
dpc-4737	66	23	beta	beta	ADJ
dpc-4737	66	24	blockers	blocker	NOUN
dpc-4737	66	25	were	be	AUX
dpc-4737	66	26	also	also	ADV
dpc-4737	66	27	excluded	exclude	VERB
dpc-4737	66	28	from	from	ADP
dpc-4737	66	29	this	this	DET
dpc-4737	66	30	study	study	NOUN
dpc-4737	66	31	.	.	PUNCT
dpc-4737	67	1	other	other	ADJ
dpc-4737	67	2	exclusion	exclusion	NOUN
dpc-4737	67	3	criteria	criterion	NOUN
dpc-4737	67	4	included	include	VERB
dpc-4737	67	5	pregnancy	pregnancy	NOUN
dpc-4737	67	6	and	and	CCONJ
dpc-4737	67	7	breastfeeding	breastfeeding	NOUN
dpc-4737	67	8	.	.	PUNCT
dpc-4737	68	1	original	original	ADJ
dpc-4737	68	2	article	article	NOUN
dpc-4737	68	3	|	|	ADV
dpc-4737	68	4	dermatol	dermatol	ADJ
dpc-4737	68	5	pract	pract	NOUN
dpc-4737	68	6	concept	concept	NOUN
dpc-4737	68	7	.	.	PUNCT
dpc-4737	69	1	2025;15(1):4737	2025;15(1):4737	NUM
dpc-4737	69	2	3	3	NUM
dpc-4737	69	3	treatment	treatment	NOUN
dpc-4737	69	4	protocol	protocol	NOUN
dpc-4737	69	5	the	the	DET
dpc-4737	69	6	dose	dose	NOUN
dpc-4737	69	7	of	of	ADP
dpc-4737	69	8	propranolol	propranolol	PROPN
dpc-4737	69	9	was	be	AUX
dpc-4737	69	10	selected	select	VERB
dpc-4737	69	11	based	base	VERB
dpc-4737	69	12	on	on	ADP
dpc-4737	69	13	similar	similar	ADJ
dpc-4737	69	14	doses	dose	NOUN
dpc-4737	69	15	used	use	VERB
dpc-4737	69	16	in	in	ADP
dpc-4737	69	17	the	the	DET
dpc-4737	69	18	treatment	treatment	NOUN
dpc-4737	69	19	of	of	ADP
dpc-4737	69	20	other	other	ADJ
dpc-4737	69	21	vascular	vascular	ADJ
dpc-4737	69	22	proliferations	proliferation	NOUN
dpc-4737	70	1	[	[	X
dpc-4737	70	2	14,15	14,15	NUM
dpc-4737	70	3	]	]	PUNCT
dpc-4737	70	4	.	.	PUNCT
dpc-4737	71	1	patients	patient	NOUN
dpc-4737	71	2	were	be	AUX
dpc-4737	71	3	given	give	VERB
dpc-4737	71	4	oral	oral	ADJ
dpc-4737	71	5	propranolol	propranolol	NOUN
dpc-4737	71	6	in	in	ADP
dpc-4737	71	7	a	a	DET
dpc-4737	71	8	starting	starting	NOUN
dpc-4737	71	9	dose	dose	NOUN
dpc-4737	71	10	of	of	ADP
dpc-4737	71	11	40	40	NUM
dpc-4737	71	12	mg	mg	NOUN
dpc-4737	71	13	per	per	ADP
dpc-4737	71	14	day	day	NOUN
dpc-4737	71	15	for	for	ADP
dpc-4737	71	16	2	2	NUM
dpc-4737	71	17	weeks	week	NOUN
dpc-4737	71	18	.	.	PUNCT
dpc-4737	72	1	thereafter	thereafter	ADV
dpc-4737	72	2	,	,	PUNCT
dpc-4737	72	3	the	the	DET
dpc-4737	72	4	dose	dose	NOUN
dpc-4737	72	5	was	be	AUX
dpc-4737	72	6	increased	increase	VERB
dpc-4737	72	7	to	to	ADP
dpc-4737	72	8	60	60	NUM
dpc-4737	72	9	mg	mg	NOUN
dpc-4737	72	10	per	per	ADP
dpc-4737	72	11	day	day	NOUN
dpc-4737	72	12	in	in	ADP
dpc-4737	72	13	2	2	NUM
dpc-4737	72	14	divided	divide	VERB
dpc-4737	72	15	doses	dose	NOUN
dpc-4737	72	16	half	half	DET
dpc-4737	72	17	hour	hour	NOUN
dpc-4737	72	18	after	after	ADP
dpc-4737	72	19	meals	meal	NOUN
dpc-4737	72	20	for	for	ADP
dpc-4737	72	21	a	a	DET
dpc-4737	72	22	total	total	ADJ
dpc-4737	72	23	duration	duration	NOUN
dpc-4737	72	24	of	of	ADP
dpc-4737	72	25	24	24	NUM
dpc-4737	72	26	weeks	week	NOUN
dpc-4737	72	27	.	.	PUNCT
dpc-4737	73	1	cardiac	cardiac	ADJ
dpc-4737	73	2	reassessment	reassessment	NOUN
dpc-4737	73	3	including	include	VERB
dpc-4737	73	4	heart	heart	NOUN
dpc-4737	73	5	rate	rate	NOUN
dpc-4737	73	6	,	,	PUNCT
dpc-4737	73	7	blood	blood	NOUN
dpc-4737	73	8	pressure	pressure	NOUN
dpc-4737	73	9	and	and	CCONJ
dpc-4737	73	10	ecg	ecg	PROPN
dpc-4737	73	11	were	be	AUX
dpc-4737	73	12	done	do	VERB
dpc-4737	73	13	after	after	ADP
dpc-4737	73	14	the	the	DET
dpc-4737	73	15	initiation	initiation	NOUN
dpc-4737	73	16	of	of	ADP
dpc-4737	73	17	therapy	therapy	NOUN
dpc-4737	73	18	and	and	CCONJ
dpc-4737	73	19	repeated	repeat	VERB
dpc-4737	73	20	in	in	ADP
dpc-4737	73	21	the	the	DET
dpc-4737	73	22	monthly	monthly	ADJ
dpc-4737	73	23	visits	visit	NOUN
dpc-4737	73	24	throughout	throughout	ADP
dpc-4737	73	25	the	the	DET
dpc-4737	73	26	treatment	treatment	NOUN
dpc-4737	73	27	.	.	PUNCT
dpc-4737	74	1	outcome	outcome	NOUN
dpc-4737	74	2	assessment	assessment	NOUN
dpc-4737	74	3	currently	currently	ADV
dpc-4737	74	4	there	there	PRON
dpc-4737	74	5	is	be	VERB
dpc-4737	74	6	no	no	DET
dpc-4737	74	7	accepted	accepted	ADJ
dpc-4737	74	8	response	response	NOUN
dpc-4737	74	9	assessment	assessment	NOUN
dpc-4737	74	10	system	system	NOUN
dpc-4737	74	11	for	for	ADP
dpc-4737	74	12	cks	ck	NOUN
dpc-4737	74	13	.	.	PUNCT
dpc-4737	75	1	the	the	DET
dpc-4737	75	2	approved	approve	VERB
dpc-4737	75	3	system	system	NOUN
dpc-4737	75	4	is	be	AUX
dpc-4737	75	5	from	from	ADP
dpc-4737	75	6	aids	aids	PROPN
dpc-4737	75	7	clinical	clinical	ADJ
dpc-4737	75	8	trial	trial	NOUN
dpc-4737	75	9	group	group	NOUN
dpc-4737	75	10	oncology	oncology	NOUN
dpc-4737	75	11	committee	committee	NOUN
dpc-4737	76	1	[	[	X
dpc-4737	76	2	16	16	NUM
dpc-4737	76	3	]	]	X
dpc-4737	76	4	,	,	PUNCT
dpc-4737	76	5	which	which	PRON
dpc-4737	76	6	is	be	AUX
dpc-4737	76	7	not	not	PART
dpc-4737	76	8	entirely	entirely	ADV
dpc-4737	76	9	suitable	suitable	ADJ
dpc-4737	76	10	to	to	PART
dpc-4737	76	11	apply	apply	VERB
dpc-4737	76	12	for	for	ADP
dpc-4737	76	13	cks	ck	NOUN
dpc-4737	76	14	because	because	SCONJ
dpc-4737	76	15	of	of	ADP
dpc-4737	76	16	its	its	PRON
dpc-4737	76	17	different	different	ADJ
dpc-4737	76	18	clinical	clinical	ADJ
dpc-4737	76	19	presentation	presentation	NOUN
dpc-4737	76	20	and	and	CCONJ
dpc-4737	76	21	different	different	ADJ
dpc-4737	76	22	prognosis	prognosis	NOUN
dpc-4737	76	23	.	.	PUNCT
dpc-4737	77	1	so	so	ADV
dpc-4737	77	2	,	,	PUNCT
dpc-4737	77	3	we	we	PRON
dpc-4737	77	4	depend	depend	VERB
dpc-4737	77	5	on	on	ADP
dpc-4737	77	6	assessment	assessment	NOUN
dpc-4737	77	7	methods	method	NOUN
dpc-4737	77	8	used	use	VERB
dpc-4737	77	9	in	in	ADP
dpc-4737	77	10	previous	previous	ADJ
dpc-4737	77	11	publications	publication	NOUN
dpc-4737	77	12	addressing	address	VERB
dpc-4737	77	13	the	the	DET
dpc-4737	77	14	treatment	treatment	NOUN
dpc-4737	77	15	of	of	ADP
dpc-4737	77	16	cks	ck	NOUN
dpc-4737	77	17	[	[	X
dpc-4737	77	18	17,18	17,18	X
dpc-4737	77	19	]	]	PUNCT
dpc-4737	77	20	.	.	PUNCT
dpc-4737	78	1	digital	digital	ADJ
dpc-4737	78	2	photographs	photograph	NOUN
dpc-4737	78	3	were	be	AUX
dpc-4737	78	4	taken	take	VERB
dpc-4737	78	5	before	before	ADP
dpc-4737	78	6	the	the	DET
dpc-4737	78	7	start	start	NOUN
dpc-4737	78	8	of	of	ADP
dpc-4737	78	9	therapy	therapy	NOUN
dpc-4737	78	10	,	,	PUNCT
dpc-4737	78	11	during	during	ADP
dpc-4737	78	12	each	each	DET
dpc-4737	78	13	monthly	monthly	ADJ
dpc-4737	78	14	visit	visit	NOUN
dpc-4737	78	15	and	and	CCONJ
dpc-4737	78	16	at	at	ADP
dpc-4737	78	17	the	the	DET
dpc-4737	78	18	end	end	NOUN
dpc-4737	78	19	of	of	ADP
dpc-4737	78	20	the	the	DET
dpc-4737	78	21	24	24	NUM
dpc-4737	78	22	weeks	week	NOUN
dpc-4737	78	23	.	.	PUNCT
dpc-4737	79	1	response	response	NOUN
dpc-4737	79	2	to	to	ADP
dpc-4737	79	3	treatment	treatment	NOUN
dpc-4737	79	4	was	be	AUX
dpc-4737	79	5	assessed	assess	VERB
dpc-4737	79	6	clinically	clinically	ADV
dpc-4737	79	7	and	and	CCONJ
dpc-4737	79	8	photographically	photographically	ADV
dpc-4737	79	9	based	base	VERB
dpc-4737	79	10	on	on	ADP
dpc-4737	79	11	the	the	DET
dpc-4737	79	12	total	total	ADJ
dpc-4737	79	13	number	number	NOUN
dpc-4737	79	14	,	,	PUNCT
dpc-4737	79	15	size	size	NOUN
dpc-4737	79	16	,	,	PUNCT
dpc-4737	79	17	and	and	CCONJ
dpc-4737	79	18	color	color	NOUN
dpc-4737	79	19	of	of	ADP
dpc-4737	79	20	the	the	DET
dpc-4737	79	21	lesions	lesion	NOUN
dpc-4737	79	22	before	before	ADP
dpc-4737	79	23	the	the	DET
dpc-4737	79	24	start	start	NOUN
dpc-4737	79	25	of	of	ADP
dpc-4737	79	26	oral	oral	ADJ
dpc-4737	79	27	propranolol	propranolol	NOUN
dpc-4737	79	28	and	and	CCONJ
dpc-4737	79	29	during	during	ADP
dpc-4737	79	30	each	each	PRON
dpc-4737	79	31	of	of	ADP
dpc-4737	79	32	the	the	DET
dpc-4737	79	33	follow	follow	NOUN
dpc-4737	79	34	-	-	PUNCT
dpc-4737	79	35	up	up	NOUN
dpc-4737	79	36	visits	visit	NOUN
dpc-4737	79	37	and	and	CCONJ
dpc-4737	79	38	at	at	ADP
dpc-4737	79	39	end	end	NOUN
dpc-4737	79	40	of	of	ADP
dpc-4737	79	41	the	the	DET
dpc-4737	79	42	treatment	treatment	NOUN
dpc-4737	79	43	.	.	PUNCT
dpc-4737	80	1	clinical	clinical	ADJ
dpc-4737	80	2	response	response	NOUN
dpc-4737	80	3	to	to	ADP
dpc-4737	80	4	treatment	treatment	NOUN
dpc-4737	80	5	was	be	AUX
dpc-4737	80	6	defined	define	VERB
dpc-4737	80	7	as	as	ADP
dpc-4737	80	8	;	;	PUNCT
dpc-4737	80	9	complete	complete	ADJ
dpc-4737	80	10	clinical	clinical	ADJ
dpc-4737	80	11	response	response	NOUN
dpc-4737	80	12	;	;	PUNCT
dpc-4737	80	13	complete	complete	ADJ
dpc-4737	80	14	resolution	resolution	NOUN
dpc-4737	80	15	of	of	ADP
dpc-4737	80	16	all	all	DET
dpc-4737	80	17	cutaneous	cutaneous	ADJ
dpc-4737	80	18	lesions	lesion	NOUN
dpc-4737	80	19	,	,	PUNCT
dpc-4737	80	20	and	and	CCONJ
dpc-4737	80	21	no	no	DET
dpc-4737	80	22	new	new	ADJ
dpc-4737	80	23	lesions	lesion	NOUN
dpc-4737	80	24	(	(	PUNCT
dpc-4737	80	25	complete	complete	ADJ
dpc-4737	80	26	responders	responder	NOUN
dpc-4737	80	27	)	)	PUNCT
dpc-4737	80	28	,	,	PUNCT
dpc-4737	80	29	partial	partial	ADJ
dpc-4737	80	30	response	response	NOUN
dpc-4737	80	31	;	;	PUNCT
dpc-4737	80	32	a	a	DET
dpc-4737	80	33	50	50	NUM
dpc-4737	80	34	%	%	NOUN
dpc-4737	80	35	reduction	reduction	NOUN
dpc-4737	80	36	in	in	ADP
dpc-4737	80	37	the	the	DET
dpc-4737	80	38	total	total	ADJ
dpc-4737	80	39	number	number	NOUN
dpc-4737	80	40	of	of	ADP
dpc-4737	80	41	cutaneous	cutaneous	ADJ
dpc-4737	80	42	lesions	lesion	NOUN
dpc-4737	80	43	,	,	PUNCT
dpc-4737	80	44	and	and	CCONJ
dpc-4737	80	45	no	no	DET
dpc-4737	80	46	new	new	ADJ
dpc-4737	80	47	lesions	lesion	NOUN
dpc-4737	80	48	,	,	PUNCT
dpc-4737	80	49	or	or	CCONJ
dpc-4737	80	50	at	at	ADP
dpc-4737	80	51	least	least	ADJ
dpc-4737	80	52	reduction	reduction	NOUN
dpc-4737	80	53	of	of	ADP
dpc-4737	80	54	>	>	X
dpc-4737	80	55	25	25	NUM
dpc-4737	80	56	%	%	NOUN
dpc-4737	80	57	in	in	ADP
dpc-4737	80	58	the	the	DET
dpc-4737	80	59	size	size	NOUN
dpc-4737	80	60	of	of	ADP
dpc-4737	80	61	previously	previously	ADV
dpc-4737	80	62	existing	exist	VERB
dpc-4737	80	63	measurable	measurable	ADJ
dpc-4737	80	64	lesions	lesion	NOUN
dpc-4737	80	65	(	(	PUNCT
dpc-4737	80	66	partial	partial	ADJ
dpc-4737	80	67	responders	responder	NOUN
dpc-4737	80	68	)	)	PUNCT
dpc-4737	80	69	,	,	PUNCT
dpc-4737	80	70	and	and	CCONJ
dpc-4737	80	71	(	(	PUNCT
dpc-4737	80	72	non	non	ADJ
dpc-4737	80	73	-	-	NOUN
dpc-4737	80	74	responders	responder	NOUN
dpc-4737	80	75	)	)	PUNCT
dpc-4737	80	76	which	which	PRON
dpc-4737	80	77	included	include	VERB
dpc-4737	80	78	patients	patient	NOUN
dpc-4737	80	79	with	with	ADP
dpc-4737	80	80	stable	stable	ADJ
dpc-4737	80	81	disease	disease	NOUN
dpc-4737	80	82	;	;	PUNCT
dpc-4737	80	83	no	no	DET
dpc-4737	80	84	response	response	NOUN
dpc-4737	80	85	to	to	ADP
dpc-4737	80	86	treatment	treatment	NOUN
dpc-4737	80	87	and	and	CCONJ
dpc-4737	80	88	no	no	DET
dpc-4737	80	89	new	new	ADJ
dpc-4737	80	90	lesions	lesion	NOUN
dpc-4737	80	91	,	,	PUNCT
dpc-4737	80	92	and	and	CCONJ
dpc-4737	80	93	progressive	progressive	ADJ
dpc-4737	80	94	disease	disease	NOUN
dpc-4737	80	95	;	;	PUNCT
dpc-4737	80	96	a	a	DET
dpc-4737	80	97	25	25	NUM
dpc-4737	80	98	%	%	NOUN
dpc-4737	80	99	increase	increase	NOUN
dpc-4737	80	100	in	in	ADP
dpc-4737	80	101	the	the	DET
dpc-4737	80	102	number	number	NOUN
dpc-4737	80	103	or	or	CCONJ
dpc-4737	80	104	the	the	DET
dpc-4737	80	105	size	size	NOUN
dpc-4737	80	106	of	of	ADP
dpc-4737	80	107	the	the	DET
dpc-4737	80	108	lesions	lesion	NOUN
dpc-4737	80	109	from	from	ADP
dpc-4737	80	110	the	the	DET
dpc-4737	80	111	baseline	baseline	NOUN
dpc-4737	80	112	.	.	PUNCT
dpc-4737	81	1	all	all	DET
dpc-4737	81	2	drug	drug	NOUN
dpc-4737	81	3	related	relate	VERB
dpc-4737	81	4	adverse	adverse	ADJ
dpc-4737	81	5	events	event	NOUN
dpc-4737	81	6	were	be	AUX
dpc-4737	81	7	recorded	record	VERB
dpc-4737	81	8	.	.	PUNCT
dpc-4737	82	1	results	result	NOUN
dpc-4737	82	2	eighteen	eighteen	NUM
dpc-4737	82	3	patients	patient	NOUN
dpc-4737	82	4	were	be	AUX
dpc-4737	82	5	clinically	clinically	ADV
dpc-4737	82	6	and	and	CCONJ
dpc-4737	82	7	histopathologically	histopathologically	ADV
dpc-4737	82	8	diagnosed	diagnose	VERB
dpc-4737	82	9	with	with	ADP
dpc-4737	82	10	ks	ks	PROPN
dpc-4737	82	11	.	.	PUNCT
dpc-4737	82	12	however	however	ADV
dpc-4737	82	13	,	,	PUNCT
dpc-4737	82	14	3	3	NUM
dpc-4737	82	15	of	of	ADP
dpc-4737	82	16	them	they	PRON
dpc-4737	82	17	were	be	AUX
dpc-4737	82	18	found	find	VERB
dpc-4737	82	19	to	to	PART
dpc-4737	82	20	be	be	AUX
dpc-4737	82	21	hiv	hiv	PROPN
dpc-4737	82	22	positive	positive	ADJ
dpc-4737	82	23	and	and	CCONJ
dpc-4737	82	24	were	be	AUX
dpc-4737	82	25	subsequently	subsequently	ADV
dpc-4737	82	26	excluded	exclude	VERB
dpc-4737	82	27	from	from	ADP
dpc-4737	82	28	the	the	DET
dpc-4737	82	29	study	study	NOUN
dpc-4737	82	30	.	.	PUNCT
dpc-4737	83	1	thus	thus	ADV
dpc-4737	83	2	,	,	PUNCT
dpc-4737	83	3	the	the	DET
dpc-4737	83	4	total	total	ADJ
dpc-4737	83	5	number	number	NOUN
dpc-4737	83	6	of	of	ADP
dpc-4737	83	7	patients	patient	NOUN
dpc-4737	83	8	enrolled	enrol	VERB
dpc-4737	83	9	in	in	ADP
dpc-4737	83	10	the	the	DET
dpc-4737	83	11	present	present	ADJ
dpc-4737	83	12	prospective	prospective	ADJ
dpc-4737	83	13	study	study	NOUN
dpc-4737	83	14	was	be	AUX
dpc-4737	83	15	15	15	NUM
dpc-4737	83	16	,	,	PUNCT
dpc-4737	83	17	all	all	PRON
dpc-4737	83	18	with	with	ADP
dpc-4737	83	19	cks	ck	NOUN
dpc-4737	83	20	.	.	PUNCT
dpc-4737	84	1	among	among	ADP
dpc-4737	84	2	the	the	DET
dpc-4737	84	3	participating	participate	VERB
dpc-4737	84	4	patients	patient	NOUN
dpc-4737	84	5	were	be	AUX
dpc-4737	84	6	13	13	NUM
dpc-4737	84	7	males	male	NOUN
dpc-4737	84	8	(	(	PUNCT
dpc-4737	84	9	86.7	86.7	NUM
dpc-4737	84	10	%	%	NOUN
dpc-4737	84	11	)	)	PUNCT
dpc-4737	84	12	,	,	PUNCT
dpc-4737	84	13	and	and	CCONJ
dpc-4737	84	14	2	2	NUM
dpc-4737	84	15	females	female	NOUN
dpc-4737	84	16	(	(	PUNCT
dpc-4737	84	17	13.3	13.3	NUM
dpc-4737	84	18	%	%	NOUN
dpc-4737	84	19	)	)	PUNCT
dpc-4737	84	20	.	.	PUNCT
dpc-4737	85	1	the	the	DET
dpc-4737	85	2	average	average	ADJ
dpc-4737	85	3	age	age	NOUN
dpc-4737	85	4	was	be	AUX
dpc-4737	85	5	62.6	62.6	NUM
dpc-4737	85	6	(	(	PUNCT
dpc-4737	85	7	range	range	VERB
dpc-4737	85	8	from	from	ADP
dpc-4737	85	9	48	48	NUM
dpc-4737	85	10	-	-	SYM
dpc-4737	85	11	72	72	NUM
dpc-4737	85	12	years	year	NOUN
dpc-4737	85	13	)	)	PUNCT
dpc-4737	85	14	.	.	PUNCT
dpc-4737	86	1	the	the	DET
dpc-4737	86	2	duration	duration	NOUN
dpc-4737	86	3	of	of	ADP
dpc-4737	86	4	the	the	DET
dpc-4737	86	5	disease	disease	NOUN
dpc-4737	86	6	ranged	range	VERB
dpc-4737	86	7	from	from	ADP
dpc-4737	86	8	5	5	NUM
dpc-4737	86	9	months	month	NOUN
dpc-4737	86	10	to	to	ADP
dpc-4737	86	11	36	36	NUM
dpc-4737	86	12	months	month	NOUN
dpc-4737	86	13	.	.	PUNCT
dpc-4737	87	1	before	before	ADP
dpc-4737	87	2	enrollment	enrollment	NOUN
dpc-4737	87	3	in	in	ADP
dpc-4737	87	4	the	the	DET
dpc-4737	87	5	study	study	NOUN
dpc-4737	87	6	,	,	PUNCT
dpc-4737	87	7	6	6	NUM
dpc-4737	87	8	of	of	ADP
dpc-4737	87	9	the	the	DET
dpc-4737	87	10	selected	select	VERB
dpc-4737	87	11	patients	patient	NOUN
dpc-4737	87	12	used	use	VERB
dpc-4737	87	13	nonspecific	nonspecific	ADJ
dpc-4737	87	14	topical	topical	ADJ
dpc-4737	87	15	treatments	treatment	NOUN
dpc-4737	87	16	such	such	ADJ
dpc-4737	87	17	as	as	ADP
dpc-4737	87	18	topical	topical	ADJ
dpc-4737	87	19	steroids	steroid	NOUN
dpc-4737	87	20	and	and	CCONJ
dpc-4737	87	21	moisturizers	moisturizer	NOUN
dpc-4737	87	22	.	.	PUNCT
dpc-4737	88	1	eight	eight	NUM
dpc-4737	88	2	patients	patient	NOUN
dpc-4737	88	3	had	have	AUX
dpc-4737	88	4	received	receive	VERB
dpc-4737	88	5	specific	specific	ADJ
dpc-4737	88	6	treatments	treatment	NOUN
dpc-4737	88	7	in	in	ADP
dpc-4737	88	8	the	the	DET
dpc-4737	88	9	form	form	NOUN
dpc-4737	88	10	of	of	ADP
dpc-4737	88	11	topical	topical	ADJ
dpc-4737	88	12	imiquimod	imiquimod	ADJ
dpc-4737	88	13	,	,	PUNCT
dpc-4737	88	14	local	local	ADJ
dpc-4737	88	15	radiation	radiation	NOUN
dpc-4737	88	16	therapy	therapy	NOUN
dpc-4737	88	17	,	,	PUNCT
dpc-4737	88	18	intralesional	intralesional	ADJ
dpc-4737	88	19	chemotherapy	chemotherapy	NOUN
dpc-4737	88	20	and	and	CCONJ
dpc-4737	88	21	1	1	NUM
dpc-4737	88	22	patient	patient	NOUN
dpc-4737	88	23	received	receive	VERB
dpc-4737	88	24	systemic	systemic	ADJ
dpc-4737	88	25	chemotherapy	chemotherapy	NOUN
dpc-4737	88	26	with	with	ADP
dpc-4737	88	27	subsequent	subsequent	ADJ
dpc-4737	88	28	recurrence	recurrence	NOUN
dpc-4737	88	29	after	after	ADP
dpc-4737	88	30	stoppage	stoppage	NOUN
dpc-4737	88	31	of	of	ADP
dpc-4737	88	32	treatment	treatment	NOUN
dpc-4737	88	33	.	.	PUNCT
dpc-4737	89	1	none	none	NOUN
dpc-4737	89	2	were	be	AUX
dpc-4737	89	3	on	on	ADP
dpc-4737	89	4	active	active	ADJ
dpc-4737	89	5	treatment	treatment	NOUN
dpc-4737	89	6	for	for	ADP
dpc-4737	89	7	ks	ks	PROPN
dpc-4737	89	8	.	.	PUNCT
dpc-4737	89	9	dermatologic	dermatologic	ADJ
dpc-4737	89	10	examination	examination	NOUN
dpc-4737	89	11	fourteen	fourteen	NUM
dpc-4737	89	12	patients	patient	NOUN
dpc-4737	89	13	(	(	PUNCT
dpc-4737	89	14	93.3	93.3	NUM
dpc-4737	89	15	%	%	NOUN
dpc-4737	89	16	)	)	PUNCT
dpc-4737	89	17	exhibited	exhibit	VERB
dpc-4737	89	18	lesions	lesion	NOUN
dpc-4737	89	19	on	on	ADP
dpc-4737	89	20	their	their	PRON
dpc-4737	89	21	lower	low	ADJ
dpc-4737	89	22	extremities	extremity	NOUN
dpc-4737	89	23	,	,	PUNCT
dpc-4737	89	24	1	1	NUM
dpc-4737	89	25	of	of	ADP
dpc-4737	89	26	those	those	DET
dpc-4737	89	27	patients	patient	NOUN
dpc-4737	89	28	had	have	VERB
dpc-4737	89	29	additional	additional	ADJ
dpc-4737	89	30	lesions	lesion	NOUN
dpc-4737	89	31	on	on	ADP
dpc-4737	89	32	the	the	DET
dpc-4737	89	33	upper	upper	ADJ
dpc-4737	89	34	extremities	extremity	NOUN
dpc-4737	89	35	,	,	PUNCT
dpc-4737	89	36	whereas	whereas	SCONJ
dpc-4737	89	37	only	only	ADV
dpc-4737	89	38	1	1	NUM
dpc-4737	89	39	patient	patient	NOUN
dpc-4737	89	40	had	have	VERB
dpc-4737	89	41	lesions	lesion	NOUN
dpc-4737	89	42	limited	limit	VERB
dpc-4737	89	43	to	to	ADP
dpc-4737	89	44	the	the	DET
dpc-4737	89	45	upper	upper	ADJ
dpc-4737	89	46	extremities	extremity	NOUN
dpc-4737	89	47	(	(	PUNCT
dpc-4737	89	48	6.7	6.7	NUM
dpc-4737	89	49	%	%	NOUN
dpc-4737	89	50	)	)	PUNCT
dpc-4737	89	51	.	.	PUNCT
dpc-4737	90	1	these	these	DET
dpc-4737	90	2	lesions	lesion	NOUN
dpc-4737	90	3	manifested	manifest	VERB
dpc-4737	90	4	as	as	ADP
dpc-4737	90	5	multiple	multiple	ADJ
dpc-4737	90	6	violaceous	violaceous	ADJ
dpc-4737	90	7	papules	papule	NOUN
dpc-4737	90	8	,	,	PUNCT
dpc-4737	90	9	nodules	nodule	NOUN
dpc-4737	90	10	,	,	PUNCT
dpc-4737	90	11	and	and	CCONJ
dpc-4737	90	12	plaques	plaque	NOUN
dpc-4737	90	13	,	,	PUNCT
dpc-4737	90	14	with	with	ADP
dpc-4737	90	15	2	2	NUM
dpc-4737	90	16	patients	patient	NOUN
dpc-4737	90	17	displaying	display	VERB
dpc-4737	90	18	exophytic	exophytic	ADJ
dpc-4737	90	19	lesions	lesion	NOUN
dpc-4737	90	20	and	and	CCONJ
dpc-4737	90	21	another	another	DET
dpc-4737	90	22	presenting	presenting	NOUN
dpc-4737	90	23	with	with	ADP
dpc-4737	90	24	ecchymosis	ecchymosis	NOUN
dpc-4737	90	25	-	-	PUNCT
dpc-4737	90	26	like	like	ADJ
dpc-4737	90	27	lesions	lesion	NOUN
dpc-4737	90	28	on	on	ADP
dpc-4737	90	29	one	one	NUM
dpc-4737	90	30	lower	low	ADJ
dpc-4737	90	31	extremity	extremity	NOUN
dpc-4737	90	32	.	.	PUNCT
dpc-4737	91	1	the	the	DET
dpc-4737	91	2	number	number	NOUN
dpc-4737	91	3	of	of	ADP
dpc-4737	91	4	lesions	lesion	NOUN
dpc-4737	91	5	varied	varied	ADJ
dpc-4737	91	6	from	from	ADP
dpc-4737	91	7	7	7	NUM
dpc-4737	91	8	to	to	ADP
dpc-4737	91	9	more	more	ADJ
dpc-4737	91	10	than	than	ADP
dpc-4737	91	11	50	50	NUM
dpc-4737	91	12	per	per	ADP
dpc-4737	91	13	patient	patient	NOUN
dpc-4737	91	14	.	.	PUNCT
dpc-4737	92	1	according	accord	VERB
dpc-4737	92	2	to	to	ADP
dpc-4737	92	3	brambilla	brambilla	NOUN
dpc-4737	92	4	et	et	PROPN
dpc-4737	92	5	al	al	PROPN
dpc-4737	92	6	[	[	X
dpc-4737	92	7	19	19	NUM
dpc-4737	92	8	]	]	PUNCT
dpc-4737	92	9	,	,	PUNCT
dpc-4737	92	10	5	5	NUM
dpc-4737	92	11	cks	ck	NOUN
dpc-4737	92	12	patients	patient	NOUN
dpc-4737	92	13	(	(	PUNCT
dpc-4737	92	14	33.3	33.3	NUM
dpc-4737	92	15	%	%	NOUN
dpc-4737	92	16	)	)	PUNCT
dpc-4737	92	17	were	be	AUX
dpc-4737	92	18	classified	classify	VERB
dpc-4737	92	19	as	as	ADP
dpc-4737	92	20	stage	stage	NOUN
dpc-4737	92	21	іa	іa	PROPN
dpc-4737	92	22	,	,	PUNCT
dpc-4737	92	23	seven	seven	NUM
dpc-4737	92	24	patients	patient	NOUN
dpc-4737	92	25	(	(	PUNCT
dpc-4737	92	26	46.7	46.7	NUM
dpc-4737	92	27	%	%	NOUN
dpc-4737	92	28	)	)	PUNCT
dpc-4737	92	29	as	as	ADP
dpc-4737	92	30	stage	stage	NOUN
dpc-4737	92	31	iia	iia	NOUN
dpc-4737	92	32	,	,	PUNCT
dpc-4737	92	33	and	and	CCONJ
dpc-4737	92	34	3	3	NUM
dpc-4737	92	35	patients	patient	NOUN
dpc-4737	92	36	(	(	PUNCT
dpc-4737	92	37	20	20	NUM
dpc-4737	92	38	%	%	NOUN
dpc-4737	92	39	)	)	PUNCT
dpc-4737	92	40	as	as	ADP
dpc-4737	92	41	stage	stage	NOUN
dpc-4737	92	42	iib	iib	NOUN
dpc-4737	92	43	.	.	PUNCT
dpc-4737	93	1	all	all	DET
dpc-4737	93	2	patients	patient	NOUN
dpc-4737	93	3	were	be	AUX
dpc-4737	93	4	presented	present	VERB
dpc-4737	93	5	with	with	ADP
dpc-4737	93	6	variable	variable	ADJ
dpc-4737	93	7	stages	stage	NOUN
dpc-4737	93	8	of	of	ADP
dpc-4737	93	9	lymphedema	lymphedema	NOUN
dpc-4737	93	10	,	,	PUNCT
dpc-4737	93	11	with	with	ADP
dpc-4737	93	12	1	1	NUM
dpc-4737	93	13	patient	patient	NOUN
dpc-4737	93	14	classified	classify	VERB
dpc-4737	93	15	as	as	ADP
dpc-4737	93	16	stage	stage	NOUN
dpc-4737	93	17	1	1	NUM
dpc-4737	93	18	(	(	PUNCT
dpc-4737	93	19	6.7	6.7	NUM
dpc-4737	93	20	%	%	NOUN
dpc-4737	93	21	)	)	PUNCT
dpc-4737	93	22	and	and	CCONJ
dpc-4737	93	23	14	14	NUM
dpc-4737	93	24	patients	patient	NOUN
dpc-4737	93	25	classified	classify	VERB
dpc-4737	93	26	as	as	ADP
dpc-4737	93	27	stage	stage	NOUN
dpc-4737	93	28	2	2	NUM
dpc-4737	93	29	(	(	PUNCT
dpc-4737	93	30	93.3	93.3	NUM
dpc-4737	93	31	%	%	NOUN
dpc-4737	93	32	)	)	PUNCT
dpc-4737	94	1	[	[	X
dpc-4737	94	2	20	20	NUM
dpc-4737	94	3	]	]	PUNCT
dpc-4737	94	4	.	.	PUNCT
dpc-4737	95	1	notably	notably	ADV
dpc-4737	95	2	,	,	PUNCT
dpc-4737	95	3	all	all	DET
dpc-4737	95	4	patients	patient	NOUN
dpc-4737	95	5	reported	report	VERB
dpc-4737	95	6	that	that	SCONJ
dpc-4737	95	7	the	the	DET
dpc-4737	95	8	onset	onset	NOUN
dpc-4737	95	9	of	of	ADP
dpc-4737	95	10	edema	edema	NOUN
dpc-4737	95	11	coincided	coincide	VERB
dpc-4737	95	12	with	with	ADP
dpc-4737	95	13	the	the	DET
dpc-4737	95	14	appearance	appearance	NOUN
dpc-4737	95	15	of	of	ADP
dpc-4737	95	16	cutaneous	cutaneous	ADJ
dpc-4737	95	17	lesions	lesion	NOUN
dpc-4737	95	18	.	.	PUNCT
dpc-4737	96	1	bilateral	bilateral	ADJ
dpc-4737	96	2	inguinal	inguinal	ADJ
dpc-4737	96	3	lymphadenopathy	lymphadenopathy	NOUN
dpc-4737	96	4	was	be	AUX
dpc-4737	96	5	observed	observe	VERB
dpc-4737	96	6	in	in	ADP
dpc-4737	96	7	3	3	NUM
dpc-4737	96	8	patients	patient	NOUN
dpc-4737	96	9	.	.	PUNCT
dpc-4737	97	1	subsequent	subsequent	ADJ
dpc-4737	97	2	lymph	lymph	NOUN
dpc-4737	97	3	node	node	NOUN
dpc-4737	97	4	biopsies	biopsy	NOUN
dpc-4737	97	5	revealed	reveal	VERB
dpc-4737	97	6	nonspecific	nonspecific	ADJ
dpc-4737	97	7	inflammatory	inflammatory	ADJ
dpc-4737	97	8	infiltrates	infiltrate	NOUN
dpc-4737	97	9	in	in	ADP
dpc-4737	97	10	these	these	DET
dpc-4737	97	11	cases	case	NOUN
dpc-4737	97	12	.	.	PUNCT
dpc-4737	98	1	the	the	DET
dpc-4737	98	2	detailed	detailed	ADJ
dpc-4737	98	3	demographic	demographic	ADJ
dpc-4737	98	4	and	and	CCONJ
dpc-4737	98	5	clinical	clinical	ADJ
dpc-4737	98	6	data	datum	NOUN
dpc-4737	98	7	of	of	ADP
dpc-4737	98	8	the	the	DET
dpc-4737	98	9	patients	patient	NOUN
dpc-4737	98	10	is	be	AUX
dpc-4737	98	11	presented	present	VERB
dpc-4737	98	12	in	in	ADP
dpc-4737	98	13	table	table	NOUN
dpc-4737	98	14	1	1	NUM
dpc-4737	98	15	.	.	PUNCT
dpc-4737	98	16	histopathological	histopathological	ADJ
dpc-4737	98	17	examination	examination	NOUN
dpc-4737	98	18	of	of	ADP
dpc-4737	98	19	the	the	DET
dpc-4737	98	20	skin	skin	NOUN
dpc-4737	98	21	lesions	lesion	NOUN
dpc-4737	98	22	showed	show	VERB
dpc-4737	98	23	interlacing	interlace	VERB
dpc-4737	98	24	bundles	bundle	NOUN
dpc-4737	98	25	of	of	ADP
dpc-4737	98	26	spindle	spindle	NOUN
dpc-4737	98	27	shaped	shape	VERB
dpc-4737	98	28	cells	cell	NOUN
dpc-4737	98	29	,	,	PUNCT
dpc-4737	98	30	dilated	dilate	VERB
dpc-4737	98	31	vascular	vascular	ADJ
dpc-4737	98	32	spaces	space	NOUN
dpc-4737	98	33	,	,	PUNCT
dpc-4737	98	34	extravasated	extravasate	VERB
dpc-4737	98	35	red	red	ADJ
dpc-4737	98	36	blood	blood	NOUN
dpc-4737	98	37	cells	cell	NOUN
dpc-4737	98	38	,	,	PUNCT
dpc-4737	98	39	and	and	CCONJ
dpc-4737	98	40	hemosiderin	hemosiderin	ADJ
dpc-4737	98	41	deposition	deposition	NOUN
dpc-4737	98	42	(	(	PUNCT
dpc-4737	98	43	figure	figure	NOUN
dpc-4737	98	44	1	1	NUM
dpc-4737	98	45	,	,	PUNCT
dpc-4737	98	46	a	a	DET
dpc-4737	98	47	-	-	PUNCT
dpc-4737	98	48	d	d	NOUN
dpc-4737	98	49	)	)	PUNCT
dpc-4737	98	50	immuno	immuno	ADJ
dpc-4737	98	51	-	-	ADJ
dpc-4737	98	52	histochemical	histochemical	ADJ
dpc-4737	98	53	staining	stain	VERB
dpc-4737	98	54	with	with	ADP
dpc-4737	98	55	hhv8	hhv8	NOUN
dpc-4737	98	56	,	,	PUNCT
dpc-4737	98	57	and	and	CCONJ
dpc-4737	98	58	d2	d2	PROPN
dpc-4737	98	59	-	-	PUNCT
dpc-4737	98	60	40	40	NUM
dpc-4737	98	61	are	be	AUX
dpc-4737	98	62	presented	present	VERB
dpc-4737	98	63	in	in	ADP
dpc-4737	98	64	figure	figure	NOUN
dpc-4737	98	65	2	2	NUM
dpc-4737	98	66	,	,	PUNCT
dpc-4737	98	67	a	a	DET
dpc-4737	98	68	and	and	CCONJ
dpc-4737	98	69	b.	b.	PROPN
dpc-4737	98	70	therapeutic	therapeutic	ADJ
dpc-4737	98	71	outcomes	outcome	NOUN
dpc-4737	98	72	out	out	ADP
dpc-4737	98	73	of	of	ADP
dpc-4737	98	74	the	the	DET
dpc-4737	98	75	15	15	NUM
dpc-4737	98	76	patients	patient	NOUN
dpc-4737	98	77	included	include	VERB
dpc-4737	98	78	in	in	ADP
dpc-4737	98	79	the	the	DET
dpc-4737	98	80	study	study	NOUN
dpc-4737	98	81	,	,	PUNCT
dpc-4737	98	82	9	9	NUM
dpc-4737	98	83	were	be	AUX
dpc-4737	98	84	classified	classify	VERB
dpc-4737	98	85	as	as	ADP
dpc-4737	98	86	partial	partial	ADJ
dpc-4737	98	87	responders	responder	NOUN
dpc-4737	98	88	,	,	PUNCT
dpc-4737	98	89	representing	represent	VERB
dpc-4737	98	90	60	60	NUM
dpc-4737	98	91	%	%	NOUN
dpc-4737	98	92	of	of	ADP
dpc-4737	98	93	the	the	DET
dpc-4737	98	94	cohort	cohort	NOUN
dpc-4737	98	95	.	.	PUNCT
dpc-4737	99	1	these	these	DET
dpc-4737	99	2	patients	patient	NOUN
dpc-4737	99	3	exhibited	exhibit	VERB
dpc-4737	99	4	a	a	DET
dpc-4737	99	5	reduction	reduction	NOUN
dpc-4737	99	6	of	of	ADP
dpc-4737	99	7	more	more	ADJ
dpc-4737	99	8	than	than	ADP
dpc-4737	99	9	50	50	NUM
dpc-4737	99	10	%	%	NOUN
dpc-4737	99	11	in	in	ADP
dpc-4737	99	12	the	the	DET
dpc-4737	99	13	total	total	ADJ
dpc-4737	99	14	number	number	NOUN
dpc-4737	99	15	of	of	ADP
dpc-4737	99	16	lesions	lesion	NOUN
dpc-4737	99	17	with	with	ADP
dpc-4737	99	18	residual	residual	ADJ
dpc-4737	99	19	pigmentation	pigmentation	NOUN
dpc-4737	99	20	.	.	PUNCT
dpc-4737	100	1	the	the	DET
dpc-4737	100	2	size	size	NOUN
dpc-4737	100	3	of	of	ADP
dpc-4737	100	4	large	large	ADJ
dpc-4737	100	5	exophytic	exophytic	ADJ
dpc-4737	100	6	lesions	lesion	NOUN
dpc-4737	100	7	was	be	AUX
dpc-4737	100	8	decreased	decrease	VERB
dpc-4737	100	9	by	by	ADP
dpc-4737	100	10	>	>	X
dpc-4737	100	11	25	25	NUM
dpc-4737	100	12	%	%	NOUN
dpc-4737	100	13	,	,	PUNCT
dpc-4737	100	14	which	which	PRON
dpc-4737	100	15	were	be	AUX
dpc-4737	100	16	subsequently	subsequently	ADV
dpc-4737	100	17	surgically	surgically	ADV
dpc-4737	100	18	removed	remove	VERB
dpc-4737	100	19	(	(	PUNCT
dpc-4737	100	20	figures	figure	NOUN
dpc-4737	100	21	3	3	NUM
dpc-4737	100	22	-	-	SYM
dpc-4737	100	23	5	5	NUM
dpc-4737	100	24	)	)	PUNCT
dpc-4737	100	25	.	.	PUNCT
dpc-4737	101	1	six	six	NUM
dpc-4737	101	2	patients	patient	NOUN
dpc-4737	101	3	(	(	PUNCT
dpc-4737	101	4	40	40	NUM
dpc-4737	101	5	%	%	NOUN
dpc-4737	101	6	)	)	PUNCT
dpc-4737	101	7	were	be	AUX
dpc-4737	101	8	considered	consider	VERB
dpc-4737	101	9	nonresponders	nonresponder	NOUN
dpc-4737	101	10	;	;	PUNCT
dpc-4737	101	11	3	3	NUM
dpc-4737	101	12	patients	patient	NOUN
dpc-4737	101	13	(	(	PUNCT
dpc-4737	101	14	20	20	NUM
dpc-4737	101	15	%	%	NOUN
dpc-4737	101	16	)	)	PUNCT
dpc-4737	101	17	were	be	AUX
dpc-4737	101	18	stable	stable	ADJ
dpc-4737	101	19	,	,	PUNCT
dpc-4737	101	20	and	and	CCONJ
dpc-4737	101	21	the	the	DET
dpc-4737	101	22	remaining	remain	VERB
dpc-4737	101	23	3	3	NUM
dpc-4737	101	24	patients	patient	NOUN
dpc-4737	101	25	(	(	PUNCT
dpc-4737	101	26	20	20	NUM
dpc-4737	101	27	%	%	NOUN
dpc-4737	101	28	)	)	PUNCT
dpc-4737	101	29	were	be	AUX
dpc-4737	101	30	categorized	categorize	VERB
dpc-4737	101	31	as	as	SCONJ
dpc-4737	101	32	stage	stage	NOUN
dpc-4737	101	33	iib	iib	PROPN
dpc-4737	101	34	experienced	experience	VERB
dpc-4737	101	35	early	early	ADJ
dpc-4737	101	36	progression	progression	NOUN
dpc-4737	101	37	of	of	ADP
dpc-4737	101	38	lesions	lesion	NOUN
dpc-4737	101	39	within	within	ADP
dpc-4737	101	40	3	3	NUM
dpc-4737	101	41	weeks	week	NOUN
dpc-4737	101	42	of	of	ADP
dpc-4737	101	43	initiating	initiate	VERB
dpc-4737	101	44	therapy	therapy	NOUN
dpc-4737	101	45	,	,	PUNCT
dpc-4737	101	46	prompting	prompt	VERB
dpc-4737	101	47	immediate	immediate	ADJ
dpc-4737	101	48	referral	referral	NOUN
dpc-4737	101	49	to	to	ADP
dpc-4737	101	50	oncology	oncology	NOUN
dpc-4737	101	51	upon	upon	SCONJ
dpc-4737	101	52	discontinuation	discontinuation	NOUN
dpc-4737	101	53	of	of	ADP
dpc-4737	101	54	treatment	treatment	NOUN
dpc-4737	101	55	.	.	PUNCT
dpc-4737	102	1	the	the	DET
dpc-4737	102	2	3	3	NUM
dpc-4737	102	3	patients	patient	NOUN
dpc-4737	102	4	in	in	ADP
dpc-4737	102	5	stable	stable	ADJ
dpc-4737	102	6	disease	disease	NOUN
dpc-4737	102	7	declined	decline	VERB
dpc-4737	102	8	further	further	ADJ
dpc-4737	102	9	referral	referral	NOUN
dpc-4737	102	10	for	for	ADP
dpc-4737	102	11	alternative	alternative	ADJ
dpc-4737	102	12	therapy	therapy	NOUN
dpc-4737	102	13	.	.	PUNCT
dpc-4737	103	1	despite	despite	SCONJ
dpc-4737	103	2	none	none	NOUN
dpc-4737	103	3	achieving	achieve	VERB
dpc-4737	103	4	complete	complete	ADJ
dpc-4737	103	5	response	response	NOUN
dpc-4737	103	6	,	,	PUNCT
dpc-4737	103	7	1	1	NUM
dpc-4737	103	8	patient	patient	NOUN
dpc-4737	103	9	demonstrated	demonstrate	VERB
dpc-4737	103	10	more	more	ADJ
dpc-4737	103	11	than	than	ADP
dpc-4737	103	12	90	90	NUM
dpc-4737	103	13	%	%	NOUN
dpc-4737	103	14	disappearance	disappearance	NOUN
dpc-4737	103	15	of	of	ADP
dpc-4737	103	16	lesions	lesion	NOUN
dpc-4737	103	17	.	.	PUNCT
dpc-4737	104	1	partial	partial	ADJ
dpc-4737	104	2	responders	responder	NOUN
dpc-4737	104	3	began	begin	VERB
dpc-4737	104	4	showing	show	VERB
dpc-4737	104	5	signs	sign	NOUN
dpc-4737	104	6	of	of	ADP
dpc-4737	104	7	improvement	improvement	NOUN
dpc-4737	104	8	between	between	ADP
dpc-4737	104	9	the	the	DET
dpc-4737	104	10	fourth	fourth	ADJ
dpc-4737	104	11	and	and	CCONJ
dpc-4737	104	12	seventh	seventh	ADJ
dpc-4737	104	13	weeks	week	NOUN
dpc-4737	104	14	,	,	PUNCT
dpc-4737	104	15	with	with	ADP
dpc-4737	104	16	an	an	DET
dpc-4737	104	17	average	average	NOUN
dpc-4737	104	18	of	of	ADP
dpc-4737	104	19	5.7	5.7	NUM
dpc-4737	104	20	weeks	week	NOUN
dpc-4737	104	21	,	,	PUNCT
dpc-4737	104	22	characterized	characterize	VERB
dpc-4737	104	23	by	by	ADP
dpc-4737	104	24	flattening	flattening	NOUN
dpc-4737	104	25	of	of	ADP
dpc-4737	104	26	some	some	DET
dpc-4737	104	27	lesions	lesion	NOUN
dpc-4737	104	28	and	and	CCONJ
dpc-4737	104	29	fading	fading	NOUN
dpc-4737	104	30	of	of	ADP
dpc-4737	104	31	violaceous	violaceous	ADJ
dpc-4737	104	32	coloration	coloration	NOUN
dpc-4737	104	33	.	.	PUNCT
dpc-4737	105	1	maximum	maximum	ADJ
dpc-4737	105	2	response	response	NOUN
dpc-4737	105	3	was	be	AUX
dpc-4737	105	4	observed	observe	VERB
dpc-4737	105	5	between	between	ADP
dpc-4737	105	6	12	12	NUM
dpc-4737	105	7	and	and	CCONJ
dpc-4737	105	8	16	16	NUM
dpc-4737	105	9	weeks	week	NOUN
dpc-4737	105	10	,	,	PUNCT
dpc-4737	105	11	with	with	ADP
dpc-4737	105	12	an	an	DET
dpc-4737	105	13	average	average	NOUN
dpc-4737	105	14	of	of	ADP
dpc-4737	105	15	14.1	14.1	NUM
dpc-4737	105	16	4	4	NUM
dpc-4737	105	17	original	original	ADJ
dpc-4737	105	18	article	article	NOUN
dpc-4737	105	19	|	|	ADV
dpc-4737	105	20	dermatol	dermatol	ADJ
dpc-4737	105	21	pract	pract	NOUN
dpc-4737	105	22	concept	concept	NOUN
dpc-4737	105	23	.	.	PUNCT
dpc-4737	106	1	2025;15(1):4737	2025;15(1):4737	NUM
dpc-4737	106	2	evidence	evidence	NOUN
dpc-4737	106	3	-	-	PUNCT
dpc-4737	106	4	based	base	VERB
dpc-4737	106	5	treatment	treatment	NOUN
dpc-4737	106	6	options	option	NOUN
dpc-4737	106	7	for	for	ADP
dpc-4737	106	8	other	other	ADJ
dpc-4737	106	9	forms	form	NOUN
dpc-4737	106	10	of	of	ADP
dpc-4737	106	11	ks	k	NOUN
dpc-4737	106	12	are	be	AUX
dpc-4737	106	13	limited	limited	ADJ
dpc-4737	106	14	,	,	PUNCT
dpc-4737	106	15	and	and	CCONJ
dpc-4737	106	16	generally	generally	ADV
dpc-4737	106	17	limited	limit	VERB
dpc-4737	106	18	to	to	ADP
dpc-4737	106	19	case	case	NOUN
dpc-4737	106	20	series	series	NOUN
dpc-4737	106	21	or	or	CCONJ
dpc-4737	106	22	case	case	NOUN
dpc-4737	106	23	reports	report	VERB
dpc-4737	106	24	 	 	SPACE
dpc-4737	107	1	[	[	PUNCT
dpc-4737	107	2	22	22	NUM
dpc-4737	107	3	]	]	PUNCT
dpc-4737	107	4	,	,	PUNCT
dpc-4737	107	5	consequently	consequently	ADV
dpc-4737	107	6	the	the	DET
dpc-4737	107	7	other	other	ADJ
dpc-4737	107	8	forms	form	NOUN
dpc-4737	107	9	of	of	ADP
dpc-4737	107	10	ks	ks	NOUN
dpc-4737	107	11	usually	usually	ADV
dpc-4737	107	12	managed	manage	VERB
dpc-4737	107	13	in	in	ADP
dpc-4737	107	14	a	a	DET
dpc-4737	107	15	comparable	comparable	ADJ
dpc-4737	107	16	way	way	NOUN
dpc-4737	107	17	.	.	PUNCT
dpc-4737	108	1	considering	consider	VERB
dpc-4737	108	2	the	the	DET
dpc-4737	108	3	chronic	chronic	NOUN
dpc-4737	108	4	,	,	PUNCT
dpc-4737	108	5	non	non	ADJ
dpc-4737	108	6	-	-	ADJ
dpc-4737	108	7	aggressive	aggressive	ADJ
dpc-4737	108	8	course	course	NOUN
dpc-4737	108	9	of	of	ADP
dpc-4737	108	10	cks	ck	NOUN
dpc-4737	108	11	,	,	PUNCT
dpc-4737	108	12	as	as	ADV
dpc-4737	108	13	well	well	ADV
dpc-4737	108	14	as	as	ADP
dpc-4737	108	15	the	the	DET
dpc-4737	108	16	patients	patient	NOUN
dpc-4737	108	17	old	old	ADJ
dpc-4737	108	18	age	age	NOUN
dpc-4737	108	19	and	and	CCONJ
dpc-4737	108	20	the	the	DET
dpc-4737	108	21	associated	associated	ADJ
dpc-4737	108	22	comorbidities	comorbiditie	NOUN
dpc-4737	108	23	,	,	PUNCT
dpc-4737	108	24	it	it	PRON
dpc-4737	108	25	is	be	AUX
dpc-4737	108	26	important	important	ADJ
dpc-4737	108	27	to	to	PART
dpc-4737	108	28	identify	identify	VERB
dpc-4737	108	29	new	new	ADJ
dpc-4737	108	30	treatment	treatment	NOUN
dpc-4737	108	31	options	option	NOUN
dpc-4737	108	32	with	with	ADP
dpc-4737	108	33	a	a	DET
dpc-4737	108	34	good	good	ADJ
dpc-4737	108	35	safety	safety	NOUN
dpc-4737	108	36	profile	profile	NOUN
dpc-4737	108	37	that	that	PRON
dpc-4737	108	38	could	could	AUX
dpc-4737	108	39	be	be	AUX
dpc-4737	108	40	used	use	VERB
dpc-4737	108	41	for	for	ADP
dpc-4737	108	42	a	a	DET
dpc-4737	108	43	longer	long	ADJ
dpc-4737	108	44	period	period	NOUN
dpc-4737	108	45	aiming	aim	VERB
dpc-4737	108	46	at	at	ADP
dpc-4737	108	47	control	control	NOUN
dpc-4737	108	48	of	of	ADP
dpc-4737	108	49	the	the	DET
dpc-4737	108	50	disease	disease	NOUN
dpc-4737	108	51	and	and	CCONJ
dpc-4737	108	52	amelioration	amelioration	NOUN
dpc-4737	108	53	of	of	ADP
dpc-4737	108	54	the	the	DET
dpc-4737	108	55	signs	sign	NOUN
dpc-4737	108	56	and	and	CCONJ
dpc-4737	108	57	symptoms	symptom	NOUN
dpc-4737	108	58	rather	rather	ADV
dpc-4737	108	59	than	than	ADP
dpc-4737	108	60	cure	cure	NOUN
dpc-4737	108	61	.	.	PUNCT
dpc-4737	109	1	based	base	VERB
dpc-4737	109	2	on	on	ADP
dpc-4737	109	3	previous	previous	ADJ
dpc-4737	109	4	case	case	NOUN
dpc-4737	109	5	reports	report	NOUN
dpc-4737	109	6	and	and	CCONJ
dpc-4737	109	7	series	series	NOUN
dpc-4737	109	8	demonstrating	demonstrate	VERB
dpc-4737	109	9	the	the	DET
dpc-4737	109	10	efficacy	efficacy	NOUN
dpc-4737	109	11	and	and	CCONJ
dpc-4737	109	12	safety	safety	NOUN
dpc-4737	109	13	of	of	ADP
dpc-4737	109	14	topical	topical	ADJ
dpc-4737	109	15	betablockers	betablocker	NOUN
dpc-4737	109	16	in	in	ADP
dpc-4737	109	17	the	the	DET
dpc-4737	109	18	treatment	treatment	NOUN
dpc-4737	109	19	of	of	ADP
dpc-4737	109	20	ks	ks	NOUN
dpc-4737	109	21	[	[	X
dpc-4737	109	22	9	9	NUM
dpc-4737	109	23	-	-	SYM
dpc-4737	109	24	11	11	NUM
dpc-4737	109	25	]	]	PUNCT
dpc-4737	109	26	,	,	PUNCT
dpc-4737	109	27	systemic	systemic	ADJ
dpc-4737	109	28	propranolol	propranolol	PROPN
dpc-4737	109	29	may	may	AUX
dpc-4737	109	30	have	have	VERB
dpc-4737	109	31	a	a	DET
dpc-4737	109	32	potential	potential	ADJ
dpc-4737	109	33	role	role	NOUN
dpc-4737	109	34	in	in	ADP
dpc-4737	109	35	the	the	DET
dpc-4737	109	36	treatment	treatment	NOUN
dpc-4737	109	37	of	of	ADP
dpc-4737	109	38	such	such	ADJ
dpc-4737	109	39	cases	case	NOUN
dpc-4737	109	40	,	,	PUNCT
dpc-4737	109	41	and	and	CCONJ
dpc-4737	109	42	it	it	PRON
dpc-4737	109	43	may	may	AUX
dpc-4737	109	44	add	add	VERB
dpc-4737	109	45	the	the	DET
dpc-4737	109	46	benefit	benefit	NOUN
dpc-4737	109	47	of	of	ADP
dpc-4737	109	48	treating	treat	VERB
dpc-4737	109	49	patients	patient	NOUN
dpc-4737	109	50	with	with	ADP
dpc-4737	109	51	a	a	DET
dpc-4737	109	52	large	large	ADJ
dpc-4737	109	53	number	number	NOUN
dpc-4737	109	54	and	and	CCONJ
dpc-4737	109	55	disseminated	disseminate	VERB
dpc-4737	109	56	cutaneous	cutaneous	ADJ
dpc-4737	109	57	lesions	lesion	NOUN
dpc-4737	109	58	.	.	PUNCT
dpc-4737	110	1	in	in	ADP
dpc-4737	110	2	the	the	DET
dpc-4737	110	3	present	present	ADJ
dpc-4737	110	4	study	study	NOUN
dpc-4737	110	5	,	,	PUNCT
dpc-4737	110	6	we	we	PRON
dpc-4737	110	7	report	report	VERB
dpc-4737	110	8	the	the	DET
dpc-4737	110	9	treatment	treatment	NOUN
dpc-4737	110	10	of	of	ADP
dpc-4737	110	11	15	15	NUM
dpc-4737	110	12	cases	case	NOUN
dpc-4737	110	13	of	of	ADP
dpc-4737	110	14	cks	ck	NOUN
dpc-4737	110	15	.	.	PUNCT
dpc-4737	111	1	oral	oral	ADJ
dpc-4737	111	2	propranolol	propranolol	PROPN
dpc-4737	111	3	was	be	AUX
dpc-4737	111	4	given	give	VERB
dpc-4737	111	5	in	in	ADP
dpc-4737	111	6	a	a	DET
dpc-4737	111	7	dose	dose	NOUN
dpc-4737	111	8	of	of	ADP
dpc-4737	111	9	60	60	NUM
dpc-4737	111	10	mg	mg	NOUN
dpc-4737	111	11	per	per	ADP
dpc-4737	111	12	day	day	NOUN
dpc-4737	111	13	for	for	ADP
dpc-4737	111	14	a	a	DET
dpc-4737	111	15	period	period	NOUN
dpc-4737	111	16	of	of	ADP
dpc-4737	111	17	6	6	NUM
dpc-4737	111	18	months	month	NOUN
dpc-4737	111	19	.	.	PUNCT
dpc-4737	112	1	the	the	DET
dpc-4737	112	2	overall	overall	ADJ
dpc-4737	112	3	response	response	NOUN
dpc-4737	112	4	rate	rate	NOUN
dpc-4737	112	5	was	be	AUX
dpc-4737	112	6	60	60	NUM
dpc-4737	112	7	%	%	NOUN
dpc-4737	112	8	,	,	PUNCT
dpc-4737	112	9	and	and	CCONJ
dpc-4737	112	10	no	no	DET
dpc-4737	112	11	side	side	NOUN
dpc-4737	112	12	effects	effect	NOUN
dpc-4737	112	13	were	be	AUX
dpc-4737	112	14	reported	report	VERB
dpc-4737	112	15	during	during	ADP
dpc-4737	112	16	the	the	DET
dpc-4737	112	17	study	study	NOUN
dpc-4737	112	18	period	period	NOUN
dpc-4737	112	19	.	.	PUNCT
dpc-4737	113	1	two	two	NUM
dpc-4737	113	2	previous	previous	ADJ
dpc-4737	113	3	publications	publication	NOUN
dpc-4737	113	4	report	report	VERB
dpc-4737	113	5	the	the	DET
dpc-4737	113	6	use	use	NOUN
dpc-4737	113	7	of	of	ADP
dpc-4737	113	8	oral	oral	ADJ
dpc-4737	113	9	propranolol	propranolol	NOUN
dpc-4737	113	10	in	in	ADP
dpc-4737	113	11	the	the	DET
dpc-4737	113	12	treatment	treatment	NOUN
dpc-4737	113	13	of	of	ADP
dpc-4737	113	14	ks	ks	PROPN
dpc-4737	113	15	.	.	PROPN
dpc-4737	113	16	sharquie	sharquie	PROPN
dpc-4737	113	17	and	and	CCONJ
dpc-4737	113	18	colleague	colleague	NOUN
dpc-4737	113	19	in	in	ADP
dpc-4737	113	20	2018	2018	NUM
dpc-4737	113	21	demonstrated	demonstrate	VERB
dpc-4737	113	22	the	the	DET
dpc-4737	113	23	successful	successful	ADJ
dpc-4737	113	24	treatment	treatment	NOUN
dpc-4737	113	25	of	of	ADP
dpc-4737	113	26	4	4	NUM
dpc-4737	113	27	cases	case	NOUN
dpc-4737	113	28	of	of	ADP
dpc-4737	113	29	cks	ck	NOUN
dpc-4737	113	30	with	with	ADP
dpc-4737	113	31	oral	oral	ADJ
dpc-4737	113	32	propranolol	propranolol	NOUN
dpc-4737	113	33	60	60	NUM
dpc-4737	113	34	mg	mg	NOUN
dpc-4737	113	35	per	per	ADP
dpc-4737	113	36	day	day	NOUN
dpc-4737	113	37	in	in	ADP
dpc-4737	113	38	combination	combination	NOUN
dpc-4737	113	39	with	with	ADP
dpc-4737	113	40	oral	oral	ADJ
dpc-4737	113	41	zinc	zinc	NOUN
dpc-4737	113	42	sulphate	sulphate	NOUN
dpc-4737	113	43	100	100	NUM
dpc-4737	113	44	mg	mg	NUM
dpc-4737	113	45	3	3	NUM
dpc-4737	113	46	times	time	NOUN
dpc-4737	113	47	per	per	ADP
dpc-4737	113	48	day	day	NOUN
dpc-4737	113	49	for	for	ADP
dpc-4737	113	50	a	a	DET
dpc-4737	113	51	duration	duration	NOUN
dpc-4737	113	52	of	of	ADP
dpc-4737	113	53	6	6	NUM
dpc-4737	113	54	to	to	PART
dpc-4737	113	55	12	12	NUM
dpc-4737	113	56	months	month	NOUN
dpc-4737	114	1	[	[	X
dpc-4737	114	2	12	12	NUM
dpc-4737	114	3	]	]	PUNCT
dpc-4737	114	4	.	.	PUNCT
dpc-4737	115	1	the	the	DET
dpc-4737	115	2	authors	author	NOUN
dpc-4737	115	3	indicated	indicate	VERB
dpc-4737	115	4	a	a	DET
dpc-4737	115	5	subtle	subtle	ADJ
dpc-4737	115	6	response	response	NOUN
dpc-4737	115	7	following	follow	VERB
dpc-4737	115	8	one	one	NUM
dpc-4737	115	9	month	month	NOUN
dpc-4737	115	10	of	of	ADP
dpc-4737	115	11	therapy	therapy	NOUN
dpc-4737	115	12	without	without	ADP
dpc-4737	115	13	notable	notable	ADJ
dpc-4737	115	14	adverse	adverse	ADJ
dpc-4737	115	15	effects	effect	NOUN
dpc-4737	115	16	.	.	PUNCT
dpc-4737	116	1	similarly	similarly	ADV
dpc-4737	116	2	,	,	PUNCT
dpc-4737	116	3	vallejo	vallejo	PROPN
dpc-4737	116	4	et	et	PROPN
dpc-4737	116	5	al	al	PROPN
dpc-4737	116	6	reported	report	VERB
dpc-4737	116	7	on	on	ADP
dpc-4737	116	8	;	;	PUNCT
dpc-4737	116	9	a	a	DET
dpc-4737	116	10	case	case	NOUN
dpc-4737	116	11	of	of	ADP
dpc-4737	116	12	a	a	DET
dpc-4737	116	13	refractory	refractory	NOUN
dpc-4737	116	14	classic	classic	ADJ
dpc-4737	116	15	cutaneous	cutaneous	ADJ
dpc-4737	116	16	ks	ks	NOUN
dpc-4737	116	17	with	with	ADP
dpc-4737	116	18	multiple	multiple	ADJ
dpc-4737	116	19	comorbidities	comorbiditie	NOUN
dpc-4737	116	20	[	[	X
dpc-4737	116	21	13	13	NUM
dpc-4737	116	22	]	]	PUNCT
dpc-4737	116	23	,	,	PUNCT
dpc-4737	116	24	10	10	NUM
dpc-4737	116	25	mg	mg	PROPN
dpc-4737	116	26	propranolol	propranolol	PROPN
dpc-4737	116	27	was	be	AUX
dpc-4737	116	28	given	give	VERB
dpc-4737	116	29	per	per	ADP
dpc-4737	116	30	day	day	NOUN
dpc-4737	116	31	for	for	ADP
dpc-4737	116	32	7	7	NUM
dpc-4737	116	33	months	month	NOUN
dpc-4737	116	34	.	.	PUNCT
dpc-4737	117	1	marked	mark	VERB
dpc-4737	117	2	improvement	improvement	NOUN
dpc-4737	117	3	was	be	AUX
dpc-4737	117	4	noted	note	VERB
dpc-4737	117	5	after	after	ADP
dpc-4737	117	6	6	6	NUM
dpc-4737	117	7	months	month	NOUN
dpc-4737	117	8	with	with	ADP
dpc-4737	117	9	no	no	DET
dpc-4737	117	10	recurrence	recurrence	NOUN
dpc-4737	117	11	up	up	ADP
dpc-4737	117	12	to	to	PART
dpc-4737	117	13	20	20	NUM
dpc-4737	117	14	months	month	NOUN
dpc-4737	117	15	of	of	ADP
dpc-4737	117	16	follow	follow	NOUN
dpc-4737	117	17	-	-	PUNCT
dpc-4737	117	18	up	up	NOUN
dpc-4737	117	19	.	.	PUNCT
dpc-4737	118	1	our	our	PRON
dpc-4737	118	2	study	study	NOUN
dpc-4737	118	3	builds	build	VERB
dpc-4737	118	4	on	on	ADP
dpc-4737	118	5	the	the	DET
dpc-4737	118	6	previous	previous	ADJ
dpc-4737	118	7	reports	report	NOUN
dpc-4737	118	8	and	and	CCONJ
dpc-4737	118	9	has	have	VERB
dpc-4737	118	10	the	the	DET
dpc-4737	118	11	advantage	advantage	NOUN
dpc-4737	118	12	of	of	ADP
dpc-4737	118	13	including	include	VERB
dpc-4737	118	14	more	more	ADJ
dpc-4737	118	15	patients	patient	NOUN
dpc-4737	118	16	,	,	PUNCT
dpc-4737	118	17	which	which	PRON
dpc-4737	118	18	further	far	ADV
dpc-4737	118	19	solidifies	solidify	VERB
dpc-4737	118	20	the	the	DET
dpc-4737	118	21	beneficial	beneficial	ADJ
dpc-4737	118	22	effects	effect	NOUN
dpc-4737	118	23	of	of	ADP
dpc-4737	118	24	systemic	systemic	ADJ
dpc-4737	118	25	propranolol	propranolol	NOUN
dpc-4737	118	26	for	for	ADP
dpc-4737	118	27	control	control	NOUN
dpc-4737	118	28	of	of	ADP
dpc-4737	118	29	cks	ck	NOUN
dpc-4737	118	30	.	.	PUNCT
dpc-4737	119	1	the	the	DET
dpc-4737	119	2	concept	concept	NOUN
dpc-4737	119	3	of	of	ADP
dpc-4737	119	4	using	use	VERB
dpc-4737	119	5	propranolol	propranolol	NOUN
dpc-4737	119	6	in	in	ADP
dpc-4737	119	7	ks	ks	PROPN
dpc-4737	119	8	was	be	AUX
dpc-4737	119	9	initially	initially	ADV
dpc-4737	119	10	derived	derive	VERB
dpc-4737	119	11	from	from	ADP
dpc-4737	119	12	its	its	PRON
dpc-4737	119	13	efficacy	efficacy	NOUN
dpc-4737	119	14	in	in	ADP
dpc-4737	119	15	the	the	DET
dpc-4737	119	16	treatment	treatment	NOUN
dpc-4737	119	17	of	of	ADP
dpc-4737	119	18	other	other	ADJ
dpc-4737	119	19	vascular	vascular	ADJ
dpc-4737	119	20	tumors	tumor	NOUN
dpc-4737	119	21	since	since	SCONJ
dpc-4737	119	22	it	it	PRON
dpc-4737	119	23	is	be	AUX
dpc-4737	119	24	a	a	DET
dpc-4737	119	25	drug	drug	NOUN
dpc-4737	119	26	with	with	ADP
dpc-4737	119	27	antiangiogenic	antiangiogenic	ADJ
dpc-4737	119	28	activity	activity	NOUN
dpc-4737	119	29	[	[	X
dpc-4737	119	30	23,24	23,24	NOUN
dpc-4737	119	31	]	]	PUNCT
dpc-4737	119	32	.	.	PUNCT
dpc-4737	120	1	angiogenesis	angiogenesis	NOUN
dpc-4737	120	2	plays	play	VERB
dpc-4737	120	3	a	a	DET
dpc-4737	120	4	key	key	ADJ
dpc-4737	120	5	role	role	NOUN
dpc-4737	120	6	in	in	ADP
dpc-4737	120	7	ks	ks	NOUN
dpc-4737	120	8	pathogenesis	pathogenesis	NOUN
dpc-4737	120	9	which	which	PRON
dpc-4737	120	10	is	be	AUX
dpc-4737	120	11	recently	recently	ADV
dpc-4737	120	12	more	more	ADV
dpc-4737	120	13	regarded	regard	VERB
dpc-4737	120	14	as	as	ADP
dpc-4737	120	15	a	a	DET
dpc-4737	120	16	reactive	reactive	NOUN
dpc-4737	120	17	rather	rather	ADV
dpc-4737	120	18	than	than	ADP
dpc-4737	120	19	neoplastic	neoplastic	ADJ
dpc-4737	120	20	condition	condition	NOUN
dpc-4737	120	21	.	.	PUNCT
dpc-4737	121	1	ample	ample	ADJ
dpc-4737	121	2	evidence	evidence	NOUN
dpc-4737	121	3	is	be	AUX
dpc-4737	121	4	seen	see	VERB
dpc-4737	121	5	microscopically	microscopically	ADV
dpc-4737	121	6	in	in	ADP
dpc-4737	121	7	the	the	DET
dpc-4737	121	8	form	form	NOUN
dpc-4737	121	9	of	of	ADP
dpc-4737	121	10	leaky	leaky	ADJ
dpc-4737	121	11	and	and	CCONJ
dpc-4737	121	12	poorly	poorly	ADV
dpc-4737	121	13	organized	organize	VERB
dpc-4737	121	14	,	,	PUNCT
dpc-4737	121	15	newly	newly	ADV
dpc-4737	121	16	developed	develop	VERB
dpc-4737	121	17	vessels	vessel	NOUN
dpc-4737	121	18	,	,	PUNCT
dpc-4737	121	19	with	with	ADP
dpc-4737	121	20	extravasated	extravasate	VERB
dpc-4737	121	21	blood	blood	NOUN
dpc-4737	121	22	and	and	CCONJ
dpc-4737	121	23	hemosiderin	hemosiderin	ADJ
dpc-4737	121	24	deposition	deposition	NOUN
dpc-4737	121	25	which	which	PRON
dpc-4737	121	26	result	result	VERB
dpc-4737	121	27	in	in	ADP
dpc-4737	121	28	the	the	DET
dpc-4737	121	29	characteristic	characteristic	ADJ
dpc-4737	121	30	purple	purple	ADJ
dpc-4737	121	31	lesions	lesion	NOUN
dpc-4737	121	32	[	[	X
dpc-4737	121	33	25	25	NUM
dpc-4737	121	34	]	]	PUNCT
dpc-4737	121	35	.	.	PUNCT
dpc-4737	122	1	these	these	DET
dpc-4737	122	2	findings	finding	NOUN
dpc-4737	122	3	collectively	collectively	ADV
dpc-4737	122	4	point	point	VERB
dpc-4737	122	5	to	to	PART
dpc-4737	122	6	propranolol	propranolol	VERB
dpc-4737	122	7	as	as	ADP
dpc-4737	122	8	a	a	DET
dpc-4737	122	9	good	good	ADJ
dpc-4737	122	10	option	option	NOUN
dpc-4737	122	11	for	for	ADP
dpc-4737	122	12	treatment	treatment	NOUN
dpc-4737	122	13	of	of	ADP
dpc-4737	122	14	ks	ks	PROPN
dpc-4737	122	15	.	.	PUNCT
dpc-4737	123	1	chisholm	chisholm	PROPN
dpc-4737	123	2	et	et	PROPN
dpc-4737	123	3	al	al	PROPN
dpc-4737	124	1	[	[	X
dpc-4737	124	2	8	8	NUM
dpc-4737	124	3	]	]	PUNCT
dpc-4737	124	4	demonstrated	demonstrate	VERB
dpc-4737	124	5	the	the	DET
dpc-4737	124	6	expression	expression	NOUN
dpc-4737	124	7	of	of	ADP
dpc-4737	124	8	the	the	DET
dpc-4737	124	9	phosphorylated	phosphorylate	VERB
dpc-4737	124	10	form	form	NOUN
dpc-4737	124	11	b2	b2	NOUN
dpc-4737	124	12	ar	ar	NOUN
dpc-4737	124	13	in	in	ADP
dpc-4737	124	14	60	60	NUM
dpc-4737	124	15	%	%	NOUN
dpc-4737	124	16	of	of	ADP
dpc-4737	124	17	their	their	PRON
dpc-4737	124	18	studied	study	VERB
dpc-4737	124	19	ks	ks	NOUN
dpc-4737	124	20	cases	case	NOUN
dpc-4737	124	21	as	as	ADV
dpc-4737	124	22	well	well	ADV
dpc-4737	124	23	as	as	ADP
dpc-4737	124	24	the	the	DET
dpc-4737	124	25	expression	expression	NOUN
dpc-4737	124	26	of	of	ADP
dpc-4737	124	27	all	all	DET
dpc-4737	124	28	three	three	NUM
dpc-4737	124	29	beta	beta	ADJ
dpc-4737	124	30	adrenergic	adrenergic	ADJ
dpc-4737	124	31	receptors	receptor	NOUN
dpc-4737	124	32	in	in	ADP
dpc-4737	124	33	all	all	DET
dpc-4737	124	34	phases	phase	NOUN
dpc-4737	124	35	of	of	ADP
dpc-4737	124	36	ih	ih	NOUN
dpc-4737	124	37	,	,	PUNCT
dpc-4737	124	38	in	in	ADP
dpc-4737	124	39	which	which	PRON
dpc-4737	124	40	the	the	DET
dpc-4737	124	41	efficacy	efficacy	NOUN
dpc-4737	124	42	of	of	ADP
dpc-4737	124	43	propranolol	propranolol	PROPN
dpc-4737	124	44	is	be	AUX
dpc-4737	124	45	well	well	ADV
dpc-4737	124	46	documented	document	VERB
dpc-4737	124	47	[	[	X
dpc-4737	124	48	5	5	NUM
dpc-4737	124	49	]	]	PUNCT
dpc-4737	124	50	.	.	PUNCT
dpc-4737	125	1	this	this	PRON
dpc-4737	125	2	further	further	ADJ
dpc-4737	125	3	supports	support	VERB
dpc-4737	125	4	oral	oral	ADJ
dpc-4737	125	5	propranolol	propranolol	NOUN
dpc-4737	125	6	as	as	ADP
dpc-4737	125	7	a	a	DET
dpc-4737	125	8	potential	potential	ADJ
dpc-4737	125	9	treatment	treatment	NOUN
dpc-4737	125	10	option	option	NOUN
dpc-4737	125	11	for	for	ADP
dpc-4737	125	12	ks	k	NOUN
dpc-4737	125	13	.	.	PUNCT
dpc-4737	126	1	more	more	ADJ
dpc-4737	126	2	evidence	evidence	NOUN
dpc-4737	126	3	supports	support	VERB
dpc-4737	126	4	the	the	DET
dpc-4737	126	5	utility	utility	NOUN
dpc-4737	126	6	of	of	ADP
dpc-4737	126	7	propranolol	propranolol	NOUN
dpc-4737	126	8	as	as	ADP
dpc-4737	126	9	an	an	DET
dpc-4737	126	10	effective	effective	ADJ
dpc-4737	126	11	therapeutic	therapeutic	NOUN
dpc-4737	126	12	in	in	ADP
dpc-4737	126	13	ks	ks	NOUN
dpc-4737	126	14	;	;	PUNCT
dpc-4737	126	15	the	the	DET
dpc-4737	126	16	role	role	NOUN
dpc-4737	126	17	of	of	ADP
dpc-4737	126	18	beta	beta	ADJ
dpc-4737	126	19	adrenergic	adrenergic	ADJ
dpc-4737	126	20	weeks	week	NOUN
dpc-4737	126	21	.	.	PUNCT
dpc-4737	127	1	following	follow	VERB
dpc-4737	127	2	completion	completion	NOUN
dpc-4737	127	3	of	of	ADP
dpc-4737	127	4	the	the	DET
dpc-4737	127	5	6	6	NUM
dpc-4737	127	6	-	-	PUNCT
dpc-4737	127	7	month	month	NOUN
dpc-4737	127	8	treatment	treatment	NOUN
dpc-4737	127	9	period	period	NOUN
dpc-4737	127	10	,	,	PUNCT
dpc-4737	127	11	responders	responder	NOUN
dpc-4737	127	12	continued	continue	VERB
dpc-4737	127	13	the	the	DET
dpc-4737	127	14	same	same	ADJ
dpc-4737	127	15	dose	dose	NOUN
dpc-4737	127	16	of	of	ADP
dpc-4737	127	17	propranolol	propranolol	PROPN
dpc-4737	127	18	but	but	CCONJ
dpc-4737	127	19	were	be	AUX
dpc-4737	127	20	not	not	PART
dpc-4737	127	21	regularly	regularly	ADV
dpc-4737	127	22	monitored	monitor	VERB
dpc-4737	127	23	after	after	ADP
dpc-4737	127	24	the	the	DET
dpc-4737	127	25	conclusion	conclusion	NOUN
dpc-4737	127	26	of	of	ADP
dpc-4737	127	27	the	the	DET
dpc-4737	127	28	study	study	NOUN
dpc-4737	127	29	.	.	PUNCT
dpc-4737	128	1	lymphedema	lymphedema	NOUN
dpc-4737	128	2	showed	show	VERB
dpc-4737	128	3	partial	partial	ADJ
dpc-4737	128	4	improvement	improvement	NOUN
dpc-4737	128	5	in	in	ADP
dpc-4737	128	6	only	only	ADV
dpc-4737	128	7	1	1	NUM
dpc-4737	128	8	patient	patient	NOUN
dpc-4737	128	9	.	.	PUNCT
dpc-4737	129	1	no	no	DET
dpc-4737	129	2	adverse	adverse	ADJ
dpc-4737	129	3	events	event	NOUN
dpc-4737	129	4	were	be	AUX
dpc-4737	129	5	reported	report	VERB
dpc-4737	129	6	during	during	ADP
dpc-4737	129	7	the	the	DET
dpc-4737	129	8	study	study	NOUN
dpc-4737	129	9	duration	duration	NOUN
dpc-4737	129	10	.	.	PUNCT
dpc-4737	130	1	conclusions	conclusion	NOUN
dpc-4737	130	2	high	high	ADJ
dpc-4737	130	3	quality	quality	NOUN
dpc-4737	130	4	evidence	evidence	NOUN
dpc-4737	130	5	for	for	ADP
dpc-4737	130	6	management	management	NOUN
dpc-4737	130	7	of	of	ADP
dpc-4737	130	8	ks	ks	PROPN
dpc-4737	130	9	is	be	AUX
dpc-4737	130	10	confined	confine	VERB
dpc-4737	130	11	to	to	ADP
dpc-4737	130	12	the	the	DET
dpc-4737	130	13	more	more	ADV
dpc-4737	130	14	aggressive	aggressive	ADJ
dpc-4737	130	15	aids	aid	NOUN
dpc-4737	130	16	-	-	PUNCT
dpc-4737	130	17	related	relate	VERB
dpc-4737	130	18	ks	ks	NOUN
dpc-4737	130	19	[	[	X
dpc-4737	130	20	21	21	NUM
dpc-4737	130	21	]	]	PUNCT
dpc-4737	130	22	.	.	PUNCT
dpc-4737	131	1	conversely	conversely	ADV
dpc-4737	131	2	,	,	PUNCT
dpc-4737	131	3	table	table	NOUN
dpc-4737	131	4	1	1	NUM
dpc-4737	131	5	.	.	PUNCT
dpc-4737	132	1	demographic	demographic	ADJ
dpc-4737	132	2	and	and	CCONJ
dpc-4737	132	3	clinical	clinical	ADJ
dpc-4737	132	4	data	datum	NOUN
dpc-4737	132	5	of	of	ADP
dpc-4737	132	6	the	the	DET
dpc-4737	132	7	studied	studied	ADJ
dpc-4737	132	8	patients	patient	NOUN
dpc-4737	132	9	.	.	PUNCT
dpc-4737	133	1	patient	patient	ADJ
dpc-4737	133	2	characteristics	characteristic	NOUN
dpc-4737	133	3	total	total	ADJ
dpc-4737	133	4	number	number	NOUN
dpc-4737	133	5	of	of	ADP
dpc-4737	133	6	patients	patient	NOUN
dpc-4737	133	7	15	15	NUM
dpc-4737	133	8	age	age	NOUN
dpc-4737	133	9	(	(	PUNCT
dpc-4737	133	10	years	year	NOUN
dpc-4737	133	11	)	)	PUNCT
dpc-4737	133	12	average	average	ADJ
dpc-4737	133	13	48	48	NUM
dpc-4737	133	14	-	-	SYM
dpc-4737	133	15	73	73	NUM
dpc-4737	133	16	62.6	62.6	NUM
dpc-4737	133	17	gender	gender	NOUN
dpc-4737	133	18	male	male	ADJ
dpc-4737	133	19	female	female	ADJ
dpc-4737	133	20	13	13	NUM
dpc-4737	133	21	(	(	PUNCT
dpc-4737	133	22	86.7	86.7	NUM
dpc-4737	133	23	%	%	NOUN
dpc-4737	133	24	)	)	PUNCT
dpc-4737	133	25	2	2	NUM
dpc-4737	133	26	(	(	PUNCT
dpc-4737	133	27	13.3	13.3	NUM
dpc-4737	133	28	%	%	NOUN
dpc-4737	133	29	)	)	PUNCT
dpc-4737	133	30	duration	duration	NOUN
dpc-4737	133	31	of	of	ADP
dpc-4737	133	32	the	the	DET
dpc-4737	133	33	disease	disease	NOUN
dpc-4737	133	34	(	(	PUNCT
dpc-4737	133	35	months	month	NOUN
dpc-4737	133	36	)	)	PUNCT
dpc-4737	133	37	average	average	ADJ
dpc-4737	133	38	range	range	NOUN
dpc-4737	133	39	(	(	PUNCT
dpc-4737	133	40	5	5	NUM
dpc-4737	133	41	-	-	SYM
dpc-4737	133	42	36	36	NUM
dpc-4737	133	43	)	)	PUNCT
dpc-4737	133	44	22.3	22.3	NUM
dpc-4737	133	45	type	type	NOUN
dpc-4737	133	46	of	of	ADP
dpc-4737	133	47	the	the	DET
dpc-4737	133	48	lesions	lesion	NOUN
dpc-4737	133	49	papulonodular	papulonodular	ADJ
dpc-4737	133	50	papulo	papulo	VERB
dpc-4737	133	51	nodular	nodular	ADJ
dpc-4737	133	52	and	and	CCONJ
dpc-4737	133	53	plaques	plaque	VERB
dpc-4737	133	54	exophytic	exophytic	ADJ
dpc-4737	133	55	lesions	lesion	NOUN
dpc-4737	133	56	ecchymosis	ecchymosis	NOUN
dpc-4737	133	57	like	like	ADP
dpc-4737	133	58	lesions	lesion	NOUN
dpc-4737	133	59	15	15	NUM
dpc-4737	133	60	(	(	PUNCT
dpc-4737	133	61	100	100	NUM
dpc-4737	133	62	%	%	NOUN
dpc-4737	133	63	)	)	PUNCT
dpc-4737	133	64	3	3	NUM
dpc-4737	133	65	(	(	PUNCT
dpc-4737	133	66	20	20	NUM
dpc-4737	133	67	%	%	NOUN
dpc-4737	133	68	)	)	PUNCT
dpc-4737	133	69	2	2	NUM
dpc-4737	133	70	(	(	PUNCT
dpc-4737	133	71	13.3	13.3	NUM
dpc-4737	133	72	%	%	NOUN
dpc-4737	133	73	)	)	PUNCT
dpc-4737	133	74	1	1	NUM
dpc-4737	133	75	(	(	PUNCT
dpc-4737	133	76	6.7	6.7	NUM
dpc-4737	133	77	%	%	NOUN
dpc-4737	133	78	)	)	PUNCT
dpc-4737	133	79	distribution	distribution	NOUN
dpc-4737	133	80	lower	low	ADJ
dpc-4737	133	81	extremities	extremity	NOUN
dpc-4737	133	82	alone	alone	ADV
dpc-4737	133	83	lower	low	ADJ
dpc-4737	133	84	extremities	extremity	NOUN
dpc-4737	133	85	and	and	CCONJ
dpc-4737	133	86	upper	upper	ADJ
dpc-4737	133	87	extremities	extremity	NOUN
dpc-4737	133	88	upper	upper	ADJ
dpc-4737	133	89	extremities	extremity	NOUN
dpc-4737	133	90	alone	alone	ADV
dpc-4737	133	91	other	other	ADJ
dpc-4737	133	92	body	body	NOUN
dpc-4737	133	93	sites	site	NOUN
dpc-4737	133	94	13	13	NUM
dpc-4737	133	95	(	(	PUNCT
dpc-4737	133	96	86.7	86.7	NUM
dpc-4737	133	97	%	%	NOUN
dpc-4737	133	98	)	)	PUNCT
dpc-4737	133	99	1	1	NUM
dpc-4737	133	100	(	(	PUNCT
dpc-4737	133	101	6.7	6.7	NUM
dpc-4737	133	102	%	%	NOUN
dpc-4737	133	103	)	)	PUNCT
dpc-4737	133	104	1	1	NUM
dpc-4737	133	105	(	(	PUNCT
dpc-4737	133	106	6.7	6.7	NUM
dpc-4737	133	107	%	%	NOUN
dpc-4737	133	108	)	)	PUNCT
dpc-4737	134	1	none	none	NOUN
dpc-4737	134	2	number	number	NOUN
dpc-4737	134	3	of	of	ADP
dpc-4737	134	4	the	the	DET
dpc-4737	134	5	lesions	lesion	NOUN
dpc-4737	134	6	less	less	ADJ
dpc-4737	134	7	than	than	ADP
dpc-4737	134	8	10	10	NUM
dpc-4737	134	9	more	more	ADJ
dpc-4737	134	10	than	than	ADP
dpc-4737	134	11	10	10	NUM
dpc-4737	134	12	1	1	NUM
dpc-4737	134	13	(	(	PUNCT
dpc-4737	134	14	6.7	6.7	NUM
dpc-4737	134	15	%	%	NOUN
dpc-4737	134	16	)	)	PUNCT
dpc-4737	134	17	14	14	NUM
dpc-4737	134	18	(	(	PUNCT
dpc-4737	134	19	93.3	93.3	NUM
dpc-4737	134	20	%	%	NOUN
dpc-4737	134	21	)	)	PUNCT
dpc-4737	134	22	lymphedema	lymphedema	NOUN
dpc-4737	135	1	yes	yes	INTJ
dpc-4737	135	2	no	no	DET
dpc-4737	135	3	15	15	NUM
dpc-4737	135	4	(	(	PUNCT
dpc-4737	135	5	100	100	NUM
dpc-4737	135	6	%	%	NOUN
dpc-4737	135	7	)	)	PUNCT
dpc-4737	135	8	0	0	NUM
dpc-4737	136	1	lymph	lymph	NOUN
dpc-4737	136	2	nodes	node	NOUN
dpc-4737	136	3	yes	yes	INTJ
dpc-4737	137	1	no	no	DET
dpc-4737	137	2	3	3	NUM
dpc-4737	137	3	(	(	PUNCT
dpc-4737	137	4	20	20	NUM
dpc-4737	137	5	%	%	NOUN
dpc-4737	137	6	)	)	PUNCT
dpc-4737	137	7	12	12	NUM
dpc-4737	137	8	(	(	PUNCT
dpc-4737	137	9	80	80	NUM
dpc-4737	137	10	%	%	NOUN
dpc-4737	137	11	)	)	PUNCT
dpc-4737	137	12	mucus	mucus	NOUN
dpc-4737	137	13	membrane	membrane	NOUN
dpc-4737	138	1	yes	yes	INTJ
dpc-4737	138	2	no	no	DET
dpc-4737	138	3	15	15	NUM
dpc-4737	138	4	(	(	PUNCT
dpc-4737	138	5	100	100	NUM
dpc-4737	138	6	%	%	NOUN
dpc-4737	138	7	)	)	PUNCT
dpc-4737	138	8	comorbid	comorbid	NOUN
dpc-4737	138	9	conditions	condition	NOUN
dpc-4737	138	10	diabetes	diabete	VERB
dpc-4737	138	11	liver	liver	NOUN
dpc-4737	138	12	cirrhosis	cirrhosis	NOUN
dpc-4737	138	13	chronic	chronic	ADJ
dpc-4737	138	14	obstructive	obstructive	ADJ
dpc-4737	138	15	pulmonary	pulmonary	ADJ
dpc-4737	138	16	disease	disease	NOUN
dpc-4737	138	17	hypothyroidism	hypothyroidism	NOUN
dpc-4737	138	18	6	6	NUM
dpc-4737	138	19	(	(	PUNCT
dpc-4737	138	20	40	40	NUM
dpc-4737	138	21	%	%	NOUN
dpc-4737	138	22	)	)	PUNCT
dpc-4737	138	23	2	2	NUM
dpc-4737	138	24	(	(	PUNCT
dpc-4737	138	25	13.3	13.3	NUM
dpc-4737	138	26	%	%	NOUN
dpc-4737	138	27	)	)	PUNCT
dpc-4737	138	28	2	2	NUM
dpc-4737	138	29	(	(	PUNCT
dpc-4737	138	30	13.3	13.3	NUM
dpc-4737	138	31	%	%	NOUN
dpc-4737	138	32	)	)	PUNCT
dpc-4737	138	33	1	1	NUM
dpc-4737	138	34	(	(	PUNCT
dpc-4737	138	35	6.7	6.7	NUM
dpc-4737	138	36	%	%	NOUN
dpc-4737	138	37	)	)	PUNCT
dpc-4737	138	38	complications	complication	NOUN
dpc-4737	138	39	oedema	oedema	VERB
dpc-4737	138	40	heaviness	heaviness	NOUN
dpc-4737	138	41	pain	pain	NOUN
dpc-4737	138	42	cellulitis	cellulitis	NOUN
dpc-4737	138	43	15	15	NUM
dpc-4737	138	44	(	(	PUNCT
dpc-4737	138	45	100	100	NUM
dpc-4737	138	46	%	%	NOUN
dpc-4737	138	47	)	)	PUNCT
dpc-4737	138	48	7	7	NUM
dpc-4737	138	49	(	(	PUNCT
dpc-4737	138	50	46.7	46.7	NUM
dpc-4737	138	51	%	%	NOUN
dpc-4737	138	52	)	)	PUNCT
dpc-4737	138	53	2	2	NUM
dpc-4737	138	54	(	(	PUNCT
dpc-4737	138	55	13.3	13.3	NUM
dpc-4737	138	56	%	%	NOUN
dpc-4737	138	57	)	)	PUNCT
dpc-4737	138	58	1	1	NUM
dpc-4737	138	59	(	(	PUNCT
dpc-4737	138	60	6.7	6.7	NUM
dpc-4737	138	61	%	%	NOUN
dpc-4737	138	62	)	)	PUNCT
dpc-4737	138	63	original	original	ADJ
dpc-4737	138	64	article	article	NOUN
dpc-4737	139	1	|	|	ADV
dpc-4737	139	2	dermatol	dermatol	ADJ
dpc-4737	139	3	pract	pract	NOUN
dpc-4737	139	4	concept	concept	NOUN
dpc-4737	139	5	.	.	PUNCT
dpc-4737	140	1	2025;15(1):4737	2025;15(1):4737	NUM
dpc-4737	140	2	5	5	NUM
dpc-4737	140	3	figure	figure	NOUN
dpc-4737	140	4	1	1	NUM
dpc-4737	140	5	.	.	PUNCT
dpc-4737	141	1	kaposi	kaposi	PROPN
dpc-4737	141	2	sarcoma	sarcoma	PROPN
dpc-4737	141	3	(	(	PUNCT
dpc-4737	141	4	ks	ks	NOUN
dpc-4737	141	5	)	)	PUNCT
dpc-4737	141	6	histopathology	histopathology	NOUN
dpc-4737	141	7	,	,	PUNCT
dpc-4737	141	8	plaque	plaque	NOUN
dpc-4737	141	9	stage	stage	NOUN
dpc-4737	141	10	.	.	PUNCT
dpc-4737	142	1	(	(	PUNCT
dpc-4737	142	2	a	a	X
dpc-4737	142	3	)	)	PUNCT
dpc-4737	142	4	diffuse	diffuse	NOUN
dpc-4737	142	5	infiltrate	infiltrate	ADJ
dpc-4737	142	6	occupying	occupy	VERB
dpc-4737	142	7	the	the	DET
dpc-4737	142	8	upper	upper	ADJ
dpc-4737	142	9	and	and	CCONJ
dpc-4737	142	10	mid	mid	ADJ
dpc-4737	142	11	dermis	dermis	NOUN
dpc-4737	142	12	(	(	PUNCT
dpc-4737	142	13	h&e	h&e	PROPN
dpc-4737	142	14	×100	×100	PROPN
dpc-4737	142	15	)	)	PUNCT
dpc-4737	142	16	.	.	PUNCT
dpc-4737	143	1	(	(	PUNCT
dpc-4737	143	2	b	b	X
dpc-4737	143	3	)	)	PUNCT
dpc-4737	143	4	higher	high	ADJ
dpc-4737	143	5	magnification	magnification	NOUN
dpc-4737	143	6	showing	show	VERB
dpc-4737	143	7	slit	slit	NOUN
dpc-4737	143	8	-	-	PUNCT
dpc-4737	143	9	like	like	ADJ
dpc-4737	143	10	vascular	vascular	ADJ
dpc-4737	143	11	spaces	space	NOUN
dpc-4737	143	12	and	and	CCONJ
dpc-4737	143	13	extravasated	extravasate	VERB
dpc-4737	143	14	red	red	ADJ
dpc-4737	143	15	blood	blood	NOUN
dpc-4737	143	16	cells	cell	NOUN
dpc-4737	143	17	(	(	PUNCT
dpc-4737	143	18	rbcs	rbc	NOUN
dpc-4737	143	19	)	)	PUNCT
dpc-4737	143	20	,	,	PUNCT
dpc-4737	143	21	admixed	admix	VERB
dpc-4737	143	22	with	with	ADP
dpc-4737	143	23	inflammatory	inflammatory	ADJ
dpc-4737	143	24	cells	cell	NOUN
dpc-4737	143	25	(	(	PUNCT
dpc-4737	143	26	h&e	h&e	PROPN
dpc-4737	143	27	×400	×400	NOUN
dpc-4737	143	28	)	)	PUNCT
dpc-4737	143	29	.	.	PUNCT
dpc-4737	144	1	ks	ks	PROPN
dpc-4737	144	2	nodular	nodular	ADJ
dpc-4737	144	3	stage	stage	NOUN
dpc-4737	144	4	(	(	PUNCT
dpc-4737	144	5	c	c	X
dpc-4737	144	6	)	)	PUNCT
dpc-4737	144	7	the	the	DET
dpc-4737	144	8	whole	whole	ADJ
dpc-4737	144	9	dermis	dermis	NOUN
dpc-4737	144	10	is	be	AUX
dpc-4737	144	11	expanded	expand	VERB
dpc-4737	144	12	with	with	ADP
dpc-4737	144	13	a	a	DET
dpc-4737	144	14	solid	solid	ADJ
dpc-4737	144	15	nodule	nodule	NOUN
dpc-4737	144	16	,	,	PUNCT
dpc-4737	144	17	with	with	ADP
dpc-4737	144	18	thinning	thinning	NOUN
dpc-4737	144	19	of	of	ADP
dpc-4737	144	20	the	the	DET
dpc-4737	144	21	overlying	overlying	ADJ
dpc-4737	144	22	epidermis	epidermis	NOUN
dpc-4737	144	23	(	(	PUNCT
dpc-4737	144	24	h&e	h&e	PROPN
dpc-4737	144	25	×40	×40	PROPN
dpc-4737	144	26	)	)	PUNCT
dpc-4737	144	27	.	.	PUNCT
dpc-4737	145	1	(	(	PUNCT
dpc-4737	145	2	d	d	X
dpc-4737	145	3	)	)	PUNCT
dpc-4737	145	4	storiform	storiform	NOUN
dpc-4737	145	5	pattern	pattern	NOUN
dpc-4737	145	6	of	of	ADP
dpc-4737	145	7	the	the	DET
dpc-4737	145	8	infiltrated	infiltrate	VERB
dpc-4737	145	9	spindle	spindle	NOUN
dpc-4737	145	10	cells	cell	NOUN
dpc-4737	145	11	,	,	PUNCT
dpc-4737	145	12	extravasated	extravasate	VERB
dpc-4737	145	13	rbcs	rbc	NOUN
dpc-4737	145	14	(	(	PUNCT
dpc-4737	145	15	h&e	h&e	PROPN
dpc-4737	145	16	×100	×100	PROPN
dpc-4737	145	17	)	)	PUNCT
dpc-4737	145	18	.	.	PUNCT
dpc-4737	146	1	figure	figure	NOUN
dpc-4737	146	2	2	2	NUM
dpc-4737	146	3	.	.	PUNCT
dpc-4737	146	4	immunohistochemical	immunohistochemical	ADJ
dpc-4737	146	5	staining	staining	NOUN
dpc-4737	146	6	:	:	PUNCT
dpc-4737	146	7	(	(	PUNCT
dpc-4737	146	8	a	a	X
dpc-4737	146	9	)	)	PUNCT
dpc-4737	146	10	diffuse	diffuse	VERB
dpc-4737	146	11	positive	positive	ADJ
dpc-4737	146	12	staining	staining	NOUN
dpc-4737	146	13	of	of	ADP
dpc-4737	146	14	both	both	DET
dpc-4737	146	15	spindle	spindle	NOUN
dpc-4737	146	16	cells	cell	NOUN
dpc-4737	146	17	and	and	CCONJ
dpc-4737	146	18	vascular	vascular	ADJ
dpc-4737	146	19	spaces	space	NOUN
dpc-4737	146	20	(	(	PUNCT
dpc-4737	146	21	d2	d2	NOUN
dpc-4737	146	22	-	-	PUNCT
dpc-4737	146	23	40	40	NUM
dpc-4737	146	24	×100	×100	NOUN
dpc-4737	146	25	)	)	PUNCT
dpc-4737	146	26	and	and	CCONJ
dpc-4737	146	27	(	(	PUNCT
dpc-4737	146	28	b	b	NOUN
dpc-4737	146	29	)	)	PUNCT
dpc-4737	146	30	positive	positive	ADJ
dpc-4737	146	31	staining	staining	NOUN
dpc-4737	146	32	of	of	ADP
dpc-4737	146	33	the	the	DET
dpc-4737	146	34	spindle	spindle	NOUN
dpc-4737	146	35	cell	cell	NOUN
dpc-4737	146	36	nuclei	nucleus	NOUN
dpc-4737	146	37	for	for	ADP
dpc-4737	146	38	human	human	ADJ
dpc-4737	146	39	herpes	herpe	NOUN
dpc-4737	146	40	virus	virus	NOUN
dpc-4737	146	41	8	8	NUM
dpc-4737	146	42	(	(	PUNCT
dpc-4737	146	43	hhv8	hhv8	PROPN
dpc-4737	146	44	;	;	PUNCT
dpc-4737	146	45	×400	×400	NOUN
dpc-4737	146	46	)	)	PUNCT
dpc-4737	146	47	.	.	PUNCT
dpc-4737	147	1	signaling	signal	VERB
dpc-4737	147	2	in	in	ADP
dpc-4737	147	3	reactivating	reactivate	VERB
dpc-4737	147	4	latent	latent	PROPN
dpc-4737	147	5	kaposi	kaposi	PROPN
dpc-4737	147	6	sarcoma	sarcoma	NOUN
dpc-4737	147	7	-	-	PUNCT
dpc-4737	147	8	herpes	herpe	NOUN
dpc-4737	147	9	virus	virus	NOUN
dpc-4737	147	10	(	(	PUNCT
dpc-4737	147	11	ks	ks	NOUN
dpc-4737	147	12	-	-	PUNCT
dpc-4737	147	13	hv	hv	NOUN
dpc-4737	147	14	)	)	PUNCT
dpc-4737	147	15	,	,	PUNCT
dpc-4737	147	16	a	a	DET
dpc-4737	147	17	key	key	ADJ
dpc-4737	147	18	player	player	NOUN
dpc-4737	147	19	of	of	ADP
dpc-4737	147	20	ks	ks	PROPN
dpc-4737	147	21	pathogenesis	pathogenesis	NOUN
dpc-4737	147	22	has	have	AUX
dpc-4737	147	23	been	be	AUX
dpc-4737	147	24	suggested	suggest	VERB
dpc-4737	147	25	.	.	PUNCT
dpc-4737	148	1	moreover	moreover	ADV
dpc-4737	148	2	,	,	PUNCT
dpc-4737	148	3	propranolol	propranolol	PROPN
dpc-4737	148	4	was	be	AUX
dpc-4737	148	5	proven	prove	VERB
dpc-4737	148	6	to	to	PART
dpc-4737	148	7	efficiently	efficiently	ADV
dpc-4737	148	8	inhibit	inhibit	VERB
dpc-4737	148	9	reactivation	reactivation	NOUN
dpc-4737	148	10	of	of	ADP
dpc-4737	148	11	ks	ks	PROPN
dpc-4737	148	12	-	-	PUNCT
dpc-4737	148	13	hv	hv	NOUN
dpc-4737	148	14	lytic	lytic	ADJ
dpc-4737	148	15	protein	protein	NOUN
dpc-4737	148	16	and	and	CCONJ
dpc-4737	148	17	mrna	mrna	PROPN
dpc-4737	149	1	[	[	X
dpc-4737	149	2	26	26	NUM
dpc-4737	149	3	]	]	PUNCT
dpc-4737	149	4	.	.	PUNCT
dpc-4737	150	1	it	it	PRON
dpc-4737	150	2	was	be	AUX
dpc-4737	150	3	also	also	ADV
dpc-4737	150	4	hypothesized	hypothesize	VERB
dpc-4737	150	5	that	that	SCONJ
dpc-4737	150	6	propranolol	propranolol	NOUN
dpc-4737	150	7	decreases	decrease	VERB
dpc-4737	150	8	the	the	DET
dpc-4737	150	9	proliferation	proliferation	NOUN
dpc-4737	150	10	of	of	ADP
dpc-4737	150	11	ks	ks	PROPN
dpc-4737	150	12	-	-	PUNCT
dpc-4737	150	13	hv	hv	NOUN
dpc-4737	150	14	-	-	PUNCT
dpc-4737	150	15	infected	infect	VERB
dpc-4737	150	16	endothelial	endothelial	ADJ
dpc-4737	150	17	cells	cell	NOUN
dpc-4737	150	18	and	and	CCONJ
dpc-4737	150	19	induced	induce	VERB
dpc-4737	150	20	ks	ks	NOUN
dpc-4737	150	21	-	-	PUNCT
dpc-4737	150	22	hv	hv	NOUN
dpc-4737	150	23	lytic	lytic	ADJ
dpc-4737	150	24	gene	gene	NOUN
dpc-4737	150	25	expression	expression	NOUN
dpc-4737	150	26	in	in	ADP
dpc-4737	150	27	association	association	NOUN
dpc-4737	150	28	with	with	ADP
dpc-4737	150	29	downregulation	downregulation	NOUN
dpc-4737	150	30	of	of	ADP
dpc-4737	150	31	cyclin	cyclin	PROPN
dpc-4737	150	32	dependent	dependent	PROPN
dpc-4737	150	33	kinase	kinase	PROPN
dpc-4737	150	34	6	6	NUM
dpc-4737	150	35	(	(	PUNCT
dpc-4737	150	36	cdk6	cdk6	PROPN
dpc-4737	150	37	)	)	PUNCT
dpc-4737	151	1	[	[	X
dpc-4737	151	2	27	27	NUM
dpc-4737	151	3	]	]	PUNCT
dpc-4737	151	4	.	.	PUNCT
dpc-4737	152	1	trials	trial	NOUN
dpc-4737	152	2	on	on	ADP
dpc-4737	152	3	oral	oral	ADJ
dpc-4737	152	4	propranolol	propranolol	NOUN
dpc-4737	152	5	6	6	NUM
dpc-4737	152	6	original	original	ADJ
dpc-4737	152	7	article	article	NOUN
dpc-4737	152	8	|	|	ADV
dpc-4737	152	9	dermatol	dermatol	ADJ
dpc-4737	152	10	pract	pract	NOUN
dpc-4737	152	11	concept	concept	NOUN
dpc-4737	152	12	.	.	PUNCT
dpc-4737	153	1	2025;15(1):4737	2025;15(1):4737	NUM
dpc-4737	153	2	figure	figure	NOUN
dpc-4737	153	3	4	4	NUM
dpc-4737	153	4	.	.	PUNCT
dpc-4737	153	5	clinical	clinical	ADJ
dpc-4737	153	6	photo	photo	NOUN
dpc-4737	153	7	for	for	ADP
dpc-4737	153	8	cks	ck	NOUN
dpc-4737	153	9	on	on	ADP
dpc-4737	153	10	the	the	DET
dpc-4737	153	11	right	right	ADJ
dpc-4737	153	12	ankle	ankle	NOUN
dpc-4737	153	13	(	(	PUNCT
dpc-4737	153	14	a	a	NOUN
dpc-4737	153	15	)	)	PUNCT
dpc-4737	153	16	before	before	ADP
dpc-4737	153	17	treatment	treatment	NOUN
dpc-4737	153	18	and	and	CCONJ
dpc-4737	153	19	(	(	PUNCT
dpc-4737	153	20	b	b	NOUN
dpc-4737	153	21	)	)	PUNCT
dpc-4737	153	22	after	after	ADP
dpc-4737	153	23	treatment	treatment	NOUN
dpc-4737	153	24	,	,	PUNCT
dpc-4737	153	25	evident	evident	ADJ
dpc-4737	153	26	reduction	reduction	NOUN
dpc-4737	153	27	in	in	ADP
dpc-4737	153	28	the	the	DET
dpc-4737	153	29	size	size	NOUN
dpc-4737	153	30	of	of	ADP
dpc-4737	153	31	the	the	DET
dpc-4737	153	32	nodules	nodule	NOUN
dpc-4737	153	33	.	.	PUNCT
dpc-4737	154	1	figure	figure	NOUN
dpc-4737	154	2	5	5	NUM
dpc-4737	154	3	.	.	PUNCT
dpc-4737	155	1	clinical	clinical	ADJ
dpc-4737	155	2	photo	photo	NOUN
dpc-4737	155	3	for	for	ADP
dpc-4737	155	4	cks	ck	NOUN
dpc-4737	155	5	on	on	ADP
dpc-4737	155	6	the	the	DET
dpc-4737	155	7	right	right	ADJ
dpc-4737	155	8	leg	leg	NOUN
dpc-4737	155	9	(	(	PUNCT
dpc-4737	155	10	a	a	NOUN
dpc-4737	155	11	)	)	PUNCT
dpc-4737	155	12	before	before	ADP
dpc-4737	155	13	treatment	treatment	NOUN
dpc-4737	155	14	,	,	PUNCT
dpc-4737	155	15	and	and	CCONJ
dpc-4737	155	16	(	(	PUNCT
dpc-4737	155	17	b	b	NOUN
dpc-4737	155	18	)	)	PUNCT
dpc-4737	155	19	after	after	ADP
dpc-4737	155	20	treatment	treatment	NOUN
dpc-4737	155	21	;	;	PUNCT
dpc-4737	155	22	more	more	ADJ
dpc-4737	155	23	than	than	ADP
dpc-4737	155	24	90	90	NUM
dpc-4737	155	25	%	%	NOUN
dpc-4737	155	26	of	of	ADP
dpc-4737	155	27	the	the	DET
dpc-4737	155	28	nodules	nodule	NOUN
dpc-4737	155	29	faded	fade	VERB
dpc-4737	155	30	.	.	PUNCT
dpc-4737	156	1	figure	figure	NOUN
dpc-4737	156	2	3	3	NUM
dpc-4737	156	3	.	.	PUNCT
dpc-4737	157	1	clinical	clinical	ADJ
dpc-4737	157	2	photo	photo	NOUN
dpc-4737	157	3	for	for	ADP
dpc-4737	157	4	a	a	DET
dpc-4737	157	5	classic	classic	ADJ
dpc-4737	157	6	kaposi	kaposi	NOUN
dpc-4737	157	7	sarcoma	sarcoma	NOUN
dpc-4737	157	8	(	(	PUNCT
dpc-4737	157	9	cks	ck	NOUN
dpc-4737	157	10	)	)	PUNCT
dpc-4737	157	11	patient	patient	NOUN
dpc-4737	157	12	(	(	PUNCT
dpc-4737	157	13	a	a	X
dpc-4737	157	14	)	)	PUNCT
dpc-4737	157	15	before	before	ADP
dpc-4737	157	16	treatment	treatment	NOUN
dpc-4737	157	17	and	and	CCONJ
dpc-4737	157	18	(	(	PUNCT
dpc-4737	157	19	b	b	NOUN
dpc-4737	157	20	)	)	PUNCT
dpc-4737	157	21	after	after	ADP
dpc-4737	157	22	treatment	treatment	NOUN
dpc-4737	157	23	;	;	PUNCT
dpc-4737	157	24	more	more	ADJ
dpc-4737	157	25	than	than	ADP
dpc-4737	157	26	50	50	NUM
dpc-4737	157	27	%	%	NOUN
dpc-4737	157	28	of	of	ADP
dpc-4737	157	29	the	the	DET
dpc-4737	157	30	nodules	nodule	NOUN
dpc-4737	157	31	faded	fade	VERB
dpc-4737	157	32	,	,	PUNCT
dpc-4737	157	33	with	with	ADP
dpc-4737	157	34	more	more	ADJ
dpc-4737	157	35	than	than	ADP
dpc-4737	157	36	25	25	NUM
dpc-4737	157	37	%	%	NOUN
dpc-4737	157	38	reduction	reduction	NOUN
dpc-4737	157	39	in	in	ADP
dpc-4737	157	40	the	the	DET
dpc-4737	157	41	size	size	NOUN
dpc-4737	157	42	of	of	ADP
dpc-4737	157	43	the	the	DET
dpc-4737	157	44	exophytic	exophytic	ADJ
dpc-4737	157	45	lesion	lesion	NOUN
dpc-4737	157	46	.	.	PUNCT
dpc-4737	158	1	are	be	AUX
dpc-4737	158	2	further	far	ADV
dpc-4737	158	3	extending	extend	VERB
dpc-4737	158	4	to	to	ADP
dpc-4737	158	5	another	another	DET
dpc-4737	158	6	angio	angio	NOUN
dpc-4737	158	7	-	-	NOUN
dpc-4737	158	8	proliferative	proliferative	ADJ
dpc-4737	158	9	more	more	ADV
dpc-4737	158	10	aggressive	aggressive	ADJ
dpc-4737	158	11	form	form	NOUN
dpc-4737	158	12	of	of	ADP
dpc-4737	158	13	sarcoma	sarcoma	NOUN
dpc-4737	158	14	,	,	PUNCT
dpc-4737	158	15	such	such	ADJ
dpc-4737	158	16	as	as	ADP
dpc-4737	158	17	angiosarcoma	angiosarcoma	NOUN
dpc-4737	158	18	,	,	PUNCT
dpc-4737	158	19	in	in	ADP
dpc-4737	158	20	which	which	PRON
dpc-4737	158	21	oral	oral	ADJ
dpc-4737	158	22	propranolol	propranolol	NOUN
dpc-4737	158	23	was	be	AUX
dpc-4737	158	24	given	give	VERB
dpc-4737	158	25	as	as	ADP
dpc-4737	158	26	a	a	DET
dpc-4737	158	27	monotherapy	monotherapy	NOUN
dpc-4737	158	28	or	or	CCONJ
dpc-4737	158	29	in	in	ADP
dpc-4737	158	30	combination	combination	NOUN
dpc-4737	158	31	with	with	ADP
dpc-4737	158	32	chemotherapy	chemotherapy	NOUN
dpc-4737	158	33	drugs	drug	NOUN
dpc-4737	158	34	with	with	ADP
dpc-4737	158	35	very	very	ADV
dpc-4737	158	36	promising	promising	ADJ
dpc-4737	158	37	results	result	NOUN
dpc-4737	158	38	[	[	X
dpc-4737	158	39	24,28	24,28	X
dpc-4737	158	40	]	]	X
dpc-4737	158	41	in	in	ADP
dpc-4737	158	42	the	the	DET
dpc-4737	158	43	present	present	ADJ
dpc-4737	158	44	study	study	NOUN
dpc-4737	158	45	lymphedema	lymphedema	NOUN
dpc-4737	158	46	was	be	AUX
dpc-4737	158	47	present	present	ADJ
dpc-4737	158	48	in	in	ADP
dpc-4737	158	49	100	100	NUM
dpc-4737	158	50	%	%	NOUN
dpc-4737	158	51	of	of	ADP
dpc-4737	158	52	our	our	PRON
dpc-4737	158	53	patients	patient	NOUN
dpc-4737	158	54	and	and	CCONJ
dpc-4737	158	55	partially	partially	ADV
dpc-4737	158	56	improved	improve	VERB
dpc-4737	158	57	in	in	ADP
dpc-4737	158	58	one	one	NUM
dpc-4737	158	59	of	of	ADP
dpc-4737	158	60	the	the	DET
dpc-4737	158	61	partially	partially	ADV
dpc-4737	158	62	responders	responder	NOUN
dpc-4737	158	63	.	.	PUNCT
dpc-4737	159	1	lymphedema	lymphedema	NOUN
dpc-4737	159	2	is	be	AUX
dpc-4737	159	3	a	a	DET
dpc-4737	159	4	frequent	frequent	ADJ
dpc-4737	159	5	complication	complication	NOUN
dpc-4737	159	6	of	of	ADP
dpc-4737	159	7	ks	ks	PROPN
dpc-4737	159	8	[	[	X
dpc-4737	159	9	2	2	NUM
dpc-4737	159	10	]	]	PUNCT
dpc-4737	159	11	,	,	PUNCT
dpc-4737	159	12	its	its	PRON
dpc-4737	159	13	incidence	incidence	NOUN
dpc-4737	159	14	and	and	CCONJ
dpc-4737	159	15	response	response	NOUN
dpc-4737	159	16	to	to	ADP
dpc-4737	159	17	treatment	treatment	NOUN
dpc-4737	159	18	varied	varied	ADJ
dpc-4737	159	19	between	between	ADP
dpc-4737	159	20	different	different	ADJ
dpc-4737	159	21	studies	study	NOUN
dpc-4737	159	22	.	.	PUNCT
dpc-4737	160	1	the	the	DET
dpc-4737	160	2	exact	exact	ADJ
dpc-4737	160	3	etiology	etiology	NOUN
dpc-4737	160	4	of	of	ADP
dpc-4737	160	5	lymphedema	lymphedema	NOUN
dpc-4737	160	6	in	in	ADP
dpc-4737	160	7	kaposi	kaposi	PROPN
dpc-4737	160	8	sarcoma	sarcoma	NOUN
dpc-4737	160	9	is	be	AUX
dpc-4737	160	10	not	not	PART
dpc-4737	160	11	known	know	VERB
dpc-4737	160	12	.	.	PUNCT
dpc-4737	161	1	leakage	leakage	NOUN
dpc-4737	161	2	from	from	ADP
dpc-4737	161	3	dilated	dilated	ADJ
dpc-4737	161	4	lymphatics	lymphatic	NOUN
dpc-4737	161	5	,	,	PUNCT
dpc-4737	161	6	occlusion	occlusion	NOUN
dpc-4737	161	7	of	of	ADP
dpc-4737	161	8	lymphatic	lymphatic	ADJ
dpc-4737	161	9	lumens	lumen	NOUN
dpc-4737	161	10	by	by	ADP
dpc-4737	161	11	proliferated	proliferated	ADJ
dpc-4737	161	12	endothelial	endothelial	ADJ
dpc-4737	161	13	cells	cell	NOUN
dpc-4737	161	14	and	and	CCONJ
dpc-4737	161	15	lymphatovenous	lymphatovenous	ADJ
dpc-4737	161	16	anastomosis	anastomosis	NOUN
dpc-4737	161	17	have	have	AUX
dpc-4737	161	18	been	be	AUX
dpc-4737	161	19	proposed	propose	VERB
dpc-4737	161	20	as	as	ADP
dpc-4737	161	21	a	a	DET
dpc-4737	161	22	possible	possible	ADJ
dpc-4737	161	23	mechanism	mechanism	NOUN
dpc-4737	161	24	[	[	X
dpc-4737	161	25	29	29	NUM
dpc-4737	161	26	]	]	PUNCT
dpc-4737	161	27	.	.	PUNCT
dpc-4737	162	1	lymphedema	lymphedema	NOUN
dpc-4737	162	2	may	may	AUX
dpc-4737	162	3	precede	precede	VERB
dpc-4737	162	4	the	the	DET
dpc-4737	162	5	appearance	appearance	NOUN
dpc-4737	162	6	of	of	ADP
dpc-4737	162	7	ks	ks	NOUN
dpc-4737	162	8	lesions	lesion	NOUN
dpc-4737	162	9	[	[	X
dpc-4737	162	10	2	2	NUM
dpc-4737	162	11	]	]	PUNCT
dpc-4737	162	12	.	.	PUNCT
dpc-4737	163	1	chronic	chronic	ADJ
dpc-4737	163	2	lymph	lymph	NOUN
dpc-4737	163	3	stasis	stasis	NOUN
dpc-4737	163	4	may	may	AUX
dpc-4737	163	5	stimulate	stimulate	VERB
dpc-4737	163	6	angiogenesis	angiogenesis	NOUN
dpc-4737	163	7	,	,	PUNCT
dpc-4737	163	8	facilitating	facilitate	VERB
dpc-4737	163	9	the	the	DET
dpc-4737	163	10	onset	onset	NOUN
dpc-4737	163	11	of	of	ADP
dpc-4737	163	12	hhv8	hhv8	PROPN
dpc-4737	163	13	associated	associate	VERB
dpc-4737	163	14	vascular	vascular	ADJ
dpc-4737	163	15	proliferation	proliferation	NOUN
dpc-4737	163	16	[	[	X
dpc-4737	163	17	30	30	NUM
dpc-4737	163	18	]	]	PUNCT
dpc-4737	163	19	.	.	PUNCT
dpc-4737	164	1	inadequate	inadequate	ADJ
dpc-4737	164	2	lymphatic	lymphatic	ADJ
dpc-4737	164	3	drainage	drainage	NOUN
dpc-4737	164	4	may	may	AUX
dpc-4737	164	5	alter	alter	VERB
dpc-4737	164	6	the	the	DET
dpc-4737	164	7	cell	cell	NOUN
dpc-4737	164	8	trafficking	trafficking	NOUN
dpc-4737	164	9	of	of	ADP
dpc-4737	164	10	t	t	PROPN
dpc-4737	164	11	lymphocytes	lymphocyte	NOUN
dpc-4737	164	12	,	,	PUNCT
dpc-4737	164	13	macrophages	macrophage	NOUN
dpc-4737	164	14	,	,	PUNCT
dpc-4737	164	15	and	and	CCONJ
dpc-4737	164	16	dendritic	dendritic	ADJ
dpc-4737	164	17	cells	cell	NOUN
dpc-4737	164	18	making	make	VERB
dpc-4737	164	19	the	the	DET
dpc-4737	164	20	lymphedematous	lymphedematous	ADJ
dpc-4737	164	21	region	region	NOUN
dpc-4737	164	22	an	an	DET
dpc-4737	164	23	immunologically	immunologically	ADV
dpc-4737	164	24	vulnerable	vulnerable	ADJ
dpc-4737	164	25	area	area	NOUN
dpc-4737	164	26	facilitating	facilitate	VERB
dpc-4737	164	27	original	original	ADJ
dpc-4737	164	28	article	article	NOUN
dpc-4737	164	29	|	|	ADV
dpc-4737	164	30	dermatol	dermatol	ADJ
dpc-4737	164	31	pract	pract	NOUN
dpc-4737	164	32	concept	concept	NOUN
dpc-4737	164	33	.	.	PUNCT
dpc-4737	165	1	2025;15(1):4737	2025;15(1):4737	NUM
dpc-4737	165	2	7	7	NUM
dpc-4737	165	3	9	9	NUM
dpc-4737	165	4	.	.	PUNCT
dpc-4737	166	1	meseguer	meseguer	NOUN
dpc-4737	166	2	-	-	PUNCT
dpc-4737	166	3	yebra	yebra	NOUN
dpc-4737	166	4	c	c	NOUN
dpc-4737	166	5	,	,	PUNCT
dpc-4737	166	6	cardenoso	cardenoso	PROPN
dpc-4737	166	7	-	-	PUNCT
dpc-4737	166	8	alvarez	alvarez	PROPN
dpc-4737	166	9	me	i	PRON
dpc-4737	166	10	,	,	PUNCT
dpc-4737	166	11	bordel	bordel	PROPN
dpc-4737	166	12	-	-	PROPN
dpc-4737	166	13	gomez	gomez	PROPN
dpc-4737	166	14	mt	mt	PROPN
dpc-4737	166	15	,	,	PUNCT
dpc-4737	166	16	fraile	fraile	PROPN
dpc-4737	166	17	-	-	PUNCT
dpc-4737	166	18	alonso	alonso	PROPN
dpc-4737	166	19	mc	mc	PROPN
dpc-4737	166	20	,	,	PUNCT
dpc-4737	166	21	perez	perez	PROPN
dpc-4737	166	22	-	-	PUNCT
dpc-4737	166	23	losada	losada	PROPN
dpc-4737	166	24	me	me	PROPN
dpc-4737	166	25	,	,	PUNCT
dpc-4737	166	26	sanchez	sanchez	PROPN
dpc-4737	166	27	-	-	PUNCT
dpc-4737	166	28	estella	estella	PROPN
dpc-4737	166	29	j	j	PROPN
dpc-4737	166	30	:	:	PUNCT
dpc-4737	166	31	successful	successful	ADJ
dpc-4737	166	32	treatment	treatment	NOUN
dpc-4737	166	33	of	of	ADP
dpc-4737	166	34	classic	classic	ADJ
dpc-4737	166	35	kaposi	kaposi	PROPN
dpc-4737	166	36	sarcoma	sarcoma	NOUN
dpc-4737	166	37	with	with	ADP
dpc-4737	166	38	topical	topical	ADJ
dpc-4737	166	39	timolol	timolol	NOUN
dpc-4737	166	40	:	:	PUNCT
dpc-4737	166	41	report	report	NOUN
dpc-4737	166	42	of	of	ADP
dpc-4737	166	43	two	two	NUM
dpc-4737	166	44	cases	case	NOUN
dpc-4737	166	45	.	.	PUNCT
dpc-4737	167	1	br	br	PROPN
dpc-4737	167	2	j	j	PROPN
dpc-4737	167	3	dermatol	dermatol	NOUN
dpc-4737	167	4	.	.	PUNCT
dpc-4737	168	1	2015;173	2015;173	NUM
dpc-4737	168	2	(	(	PUNCT
dpc-4737	168	3	3):860	3):860	PROPN
dpc-4737	168	4	-	-	PUNCT
dpc-4737	168	5	862	862	NUM
dpc-4737	168	6	.	.	PUNCT
dpc-4737	169	1	doi	doi	NOUN
dpc-4737	169	2	:	:	PUNCT
dpc-4737	169	3	10.1111	10.1111	NUM
dpc-4737	169	4	/	/	SYM
dpc-4737	169	5	bjd.13746	bjd.13746	SYM
dpc-4737	169	6	10	10	NUM
dpc-4737	169	7	.	.	PUNCT
dpc-4737	170	1	alcantara	alcantara	NOUN
dpc-4737	170	2	-	-	PUNCT
dpc-4737	170	3	reifs	reifs	NOUN
dpc-4737	170	4	cm	cm	NOUN
dpc-4737	170	5	,	,	PUNCT
dpc-4737	170	6	salido	salido	PROPN
dpc-4737	170	7	-	-	PUNCT
dpc-4737	170	8	vallejo	vallejo	PROPN
dpc-4737	170	9	r	r	PROPN
dpc-4737	170	10	,	,	PUNCT
dpc-4737	170	11	garnacho	garnacho	NOUN
dpc-4737	170	12	-	-	PUNCT
dpc-4737	170	13	saucedo	saucedo	PROPN
dpc-4737	170	14	gm	gm	PROPN
dpc-4737	170	15	,	,	PUNCT
dpc-4737	170	16	velez	velez	PROPN
dpc-4737	170	17	garcia	garcia	PROPN
dpc-4737	170	18	-	-	PUNCT
dpc-4737	170	19	nieto	nieto	PROPN
dpc-4737	171	1	a	a	DET
dpc-4737	171	2	:	:	PUNCT
dpc-4737	171	3	classic	classic	ADJ
dpc-4737	171	4	kaposi	kaposi	PROPN
dpc-4737	171	5	’s	’s	PART
dpc-4737	171	6	sarcoma	sarcoma	NOUN
dpc-4737	171	7	treated	treat	VERB
dpc-4737	171	8	with	with	ADP
dpc-4737	171	9	topical	topical	ADJ
dpc-4737	171	10	0.5	0.5	NUM
dpc-4737	171	11	%	%	NOUN
dpc-4737	171	12	timolol	timolol	NOUN
dpc-4737	171	13	gel	gel	NOUN
dpc-4737	171	14	.	.	PUNCT
dpc-4737	172	1	dermatol	dermatol	NOUN
dpc-4737	172	2	ther	ther	ADV
dpc-4737	172	3	.	.	PUNCT
dpc-4737	173	1	2016	2016	NUM
dpc-4737	173	2	;	;	PUNCT
dpc-4737	173	3	29:309	29:309	NUM
dpc-4737	173	4	-	-	SYM
dpc-4737	173	5	311	311	NUM
dpc-4737	173	6	.	.	NOUN
dpc-4737	174	1	11	11	NUM
dpc-4737	174	2	.	.	X
dpc-4737	174	3	cmr	cmr	PROPN
dpc-4737	174	4	g	g	PROPN
dpc-4737	174	5	,	,	PUNCT
dpc-4737	174	6	licata	licata	VERB
dpc-4737	174	7	g	g	NOUN
dpc-4737	174	8	,	,	PUNCT
dpc-4737	174	9	briatico	briatico	NOUN
dpc-4737	174	10	g	g	PROPN
dpc-4737	174	11	,	,	PUNCT
dpc-4737	174	12	et	et	PROPN
dpc-4737	174	13	al	al	PROPN
dpc-4737	174	14	.	.	PROPN
dpc-4737	174	15	comparison	comparison	NOUN
dpc-4737	174	16	between	between	ADP
dpc-4737	174	17	propranolol	propranolol	NOUN
dpc-4737	174	18	2	2	NUM
dpc-4737	174	19	%	%	NOUN
dpc-4737	174	20	cream	cream	NOUN
dpc-4737	174	21	versus	versus	ADP
dpc-4737	174	22	timolol	timolol	X
dpc-4737	174	23	0.5	0.5	NUM
dpc-4737	174	24	%	%	NOUN
dpc-4737	174	25	gel	gel	NOUN
dpc-4737	174	26	for	for	ADP
dpc-4737	174	27	the	the	DET
dpc-4737	174	28	treatment	treatment	NOUN
dpc-4737	174	29	of	of	ADP
dpc-4737	174	30	kaposi	kaposi	PROPN
dpc-4737	174	31	sarcoma	sarcoma	PROPN
dpc-4737	174	32	.	.	PUNCT
dpc-4737	175	1	int	int	NOUN
dpc-4737	175	2	j	j	PROPN
dpc-4737	175	3	dermatol	dermatol	NOUN
dpc-4737	175	4	.	.	PUNCT
dpc-4737	176	1	2021	2021	NUM
dpc-4737	176	2	;	;	PUNCT
dpc-4737	176	3	60	60	NUM
dpc-4737	176	4	:	:	PUNCT
dpc-4737	176	5	631–633	631–633	NUM
dpc-4737	176	6	.	.	PUNCT
dpc-4737	177	1	doi	doi	NOUN
dpc-4737	177	2	:	:	PUNCT
dpc-4737	177	3	10.1111	10.1111	NUM
dpc-4737	177	4	/	/	SYM
dpc-4737	177	5	ijd.15407	ijd.15407	NUM
dpc-4737	177	6	12	12	NUM
dpc-4737	177	7	.	.	PUNCT
dpc-4737	178	1	sharquie	sharquie	PROPN
dpc-4737	178	2	ke	ke	PROPN
dpc-4737	178	3	,	,	PUNCT
dpc-4737	178	4	noaimi	noaimi	PROPN
dpc-4737	178	5	aa	aa	PROPN
dpc-4737	178	6	.	.	PUNCT
dpc-4737	179	1	treatment	treatment	NOUN
dpc-4737	179	2	of	of	ADP
dpc-4737	179	3	kaposi	kaposi	PROPN
dpc-4737	179	4	’s	’s	PART
dpc-4737	179	5	sarcoma	sarcoma	NOUN
dpc-4737	179	6	by	by	ADP
dpc-4737	179	7	combination	combination	NOUN
dpc-4737	179	8	of	of	ADP
dpc-4737	179	9	zinc	zinc	NOUN
dpc-4737	179	10	sulfate	sulfate	NOUN
dpc-4737	179	11	and	and	CCONJ
dpc-4737	179	12	propranolol	propranolol	NOUN
dpc-4737	179	13	.	.	PUNCT
dpc-4737	180	1	journal	journal	NOUN
dpc-4737	180	2	of	of	ADP
dpc-4737	180	3	cosmetics	cosmetic	NOUN
dpc-4737	180	4	,	,	PUNCT
dpc-4737	180	5	dermatological	dermatological	ADJ
dpc-4737	180	6	sciences	science	NOUN
dpc-4737	180	7	and	and	CCONJ
dpc-4737	180	8	applications	application	NOUN
dpc-4737	180	9	.	.	PUNCT
dpc-4737	181	1	2018;8	2018;8	NUM
dpc-4737	181	2	(	(	PUNCT
dpc-4737	181	3	4):249	4):249	NUM
dpc-4737	181	4	-	-	SYM
dpc-4737	181	5	255	255	NUM
dpc-4737	181	6	.	.	PUNCT
dpc-4737	182	1	doi	doi	NOUN
dpc-4737	182	2	:	:	PUNCT
dpc-4737	182	3	 	 	SPACE
dpc-4737	182	4	10.4236	10.4236	NUM
dpc-4737	182	5	/	/	SYM
dpc-4737	182	6	jcdsa.2018.84026	jcdsa.2018.84026	PROPN
dpc-4737	182	7	.	.	PUNCT
dpc-4737	183	1	13	13	NUM
dpc-4737	183	2	.	.	X
dpc-4737	183	3	salido	salido	PROPN
dpc-4737	183	4	-	-	PROPN
dpc-4737	183	5	vallejo	vallejo	PROPN
dpc-4737	183	6	r	r	PROPN
dpc-4737	183	7	,	,	PUNCT
dpc-4737	183	8	gonzález	gonzález	NOUN
dpc-4737	183	9	-	-	PUNCT
dpc-4737	183	10	menchen	menchen	PROPN
dpc-4737	183	11	a	a	PRON
dpc-4737	183	12	,	,	PUNCT
dpc-4737	183	13	alcántara	alcántara	ADJ
dpc-4737	183	14	-	-	PUNCT
dpc-4737	183	15	reifs	reifs	PROPN
dpc-4737	183	16	c	c	NOUN
dpc-4737	183	17	,	,	PUNCT
dpc-4737	183	18	españa	españa	ADJ
dpc-4737	183	19	a.	a.	NOUN
dpc-4737	183	20	treatment	treatment	NOUN
dpc-4737	183	21	with	with	ADP
dpc-4737	183	22	oral	oral	ADJ
dpc-4737	183	23	propranolol	propranolol	NOUN
dpc-4737	183	24	for	for	ADP
dpc-4737	183	25	refractory	refractory	NOUN
dpc-4737	183	26	classic	classic	ADJ
dpc-4737	183	27	cutaneous	cutaneous	ADJ
dpc-4737	183	28	kaposi	kaposi	PROPN
dpc-4737	183	29	sarcoma	sarcoma	PROPN
dpc-4737	183	30	.	.	PUNCT
dpc-4737	184	1	jama	jama	PROPN
dpc-4737	184	2	dermatology	dermatology	PROPN
dpc-4737	184	3	.	.	PUNCT
dpc-4737	185	1	2022;11	2022;11	PROPN
dpc-4737	185	2	(	(	PUNCT
dpc-4737	185	3	7	7	NUM
dpc-4737	185	4	):	):	PUNCT
dpc-4737	185	5	832	832	NUM
dpc-4737	185	6	-	-	SYM
dpc-4737	185	7	834	834	NUM
dpc-4737	185	8	.	.	PUNCT
dpc-4737	186	1	doi:10.1001	doi:10.1001	PROPN
dpc-4737	186	2	/	/	SYM
dpc-4737	186	3	jamadermatol.2022.1278	jamadermatol.2022.1278	PROPN
dpc-4737	186	4	14	14	NUM
dpc-4737	186	5	.	.	PUNCT
dpc-4737	187	1	mine	mine	PROPN
dpc-4737	187	2	t	t	PROPN
dpc-4737	187	3	,	,	PUNCT
dpc-4737	187	4	koike	koike	PROPN
dpc-4737	187	5	y	y	PROPN
dpc-4737	187	6	,	,	PUNCT
dpc-4737	187	7	ehara	ehara	PROPN
dpc-4737	187	8	d	d	X
dpc-4737	187	9	,	,	PUNCT
dpc-4737	187	10	murota	murota	NOUN
dpc-4737	187	11	h.	h.	NOUN
dpc-4737	187	12	a	a	DET
dpc-4737	187	13	case	case	NOUN
dpc-4737	187	14	of	of	ADP
dpc-4737	187	15	bilateral	bilateral	ADJ
dpc-4737	187	16	plantar	plantar	NOUN
dpc-4737	187	17	pseudo	pseudo	NOUN
dpc-4737	187	18	-	-	ADJ
dpc-4737	187	19	kaposi	kaposi	ADJ
dpc-4737	187	20	sarcoma	sarcoma	NOUN
dpc-4737	187	21	successfully	successfully	ADV
dpc-4737	187	22	treated	treat	VERB
dpc-4737	187	23	with	with	ADP
dpc-4737	187	24	propranolol	propranolol	NOUN
dpc-4737	187	25	.	.	PUNCT
dpc-4737	188	1	jaad	jaad	NOUN
dpc-4737	188	2	case	case	NOUN
dpc-4737	188	3	reports	report	VERB
dpc-4737	188	4	.	.	PUNCT
dpc-4737	189	1	2021;18:74	2021;18:74	NUM
dpc-4737	189	2	-	-	SYM
dpc-4737	189	3	78	78	NUM
dpc-4737	189	4	.	.	PUNCT
dpc-4737	190	1	doi	doi	NOUN
dpc-4737	190	2	:	:	PUNCT
dpc-4737	190	3	10.1016	10.1016	NUM
dpc-4737	190	4	/	/	SYM
dpc-4737	190	5	j.jdcr	j.jdcr	NOUN
dpc-4737	190	6	.2021.09.032	.2021.09.032	PUNCT
dpc-4737	191	1	15	15	X
dpc-4737	191	2	.	.	PUNCT
dpc-4737	192	1	horst	horst	PROPN
dpc-4737	192	2	c	c	PROPN
dpc-4737	192	3	,	,	PUNCT
dpc-4737	192	4	kapur	kapur	PROPN
dpc-4737	192	5	n.	n.	PROPN
dpc-4737	192	6	propranolol	propranolol	PROPN
dpc-4737	192	7	:	:	PUNCT
dpc-4737	192	8	a	a	DET
dpc-4737	192	9	novel	novel	ADJ
dpc-4737	192	10	treatment	treatment	NOUN
dpc-4737	192	11	for	for	ADP
dpc-4737	192	12	angiolymphoid	angiolymphoid	ADJ
dpc-4737	192	13	hyperplasia	hyperplasia	NOUN
dpc-4737	192	14	with	with	ADP
dpc-4737	192	15	eosinophilia	eosinophilia	PROPN
dpc-4737	192	16	.	.	PUNCT
dpc-4737	193	1	clin	clin	PROPN
dpc-4737	193	2	exp	exp	NOUN
dpc-4737	193	3	dermatol	dermatol	NOUN
dpc-4737	193	4	.	.	PUNCT
dpc-4737	194	1	2014	2014	NUM
dpc-4737	194	2	;	;	PUNCT
dpc-4737	195	1	39(7	39(7	NUM
dpc-4737	195	2	):	):	PUNCT
dpc-4737	195	3	810	810	NUM
dpc-4737	195	4	-	-	SYM
dpc-4737	195	5	812	812	NUM
dpc-4737	195	6	.	.	PUNCT
dpc-4737	196	1	doi:10.1111	doi:10.1111	ADJ
dpc-4737	196	2	/	/	SYM
dpc-4737	196	3	ced.12412	ced.12412	PROPN
dpc-4737	196	4	16	16	NUM
dpc-4737	196	5	.	.	PUNCT
dpc-4737	197	1	krown	krown	PROPN
dpc-4737	197	2	se	se	PROPN
dpc-4737	197	3	,	,	PUNCT
dpc-4737	197	4	metroka	metroka	PROPN
dpc-4737	197	5	c	c	PROPN
dpc-4737	197	6	,	,	PUNCT
dpc-4737	197	7	wernz	wernz	PROPN
dpc-4737	197	8	jc	jc	PROPN
dpc-4737	197	9	.	.	PUNCT
dpc-4737	198	1	kaposi	kaposi	PROPN
dpc-4737	198	2	sarcoma	sarcoma	PROPN
dpc-4737	198	3	in	in	ADP
dpc-4737	198	4	the	the	DET
dpc-4737	198	5	acquired	acquire	VERB
dpc-4737	198	6	immune	immune	ADJ
dpc-4737	198	7	deficiency	deficiency	NOUN
dpc-4737	198	8	syndrome	syndrome	NOUN
dpc-4737	198	9	:	:	PUNCT
dpc-4737	198	10	a	a	DET
dpc-4737	198	11	proposal	proposal	NOUN
dpc-4737	198	12	for	for	ADP
dpc-4737	198	13	uniform	uniform	ADJ
dpc-4737	198	14	evaluation	evaluation	NOUN
dpc-4737	198	15	,	,	PUNCT
dpc-4737	198	16	response	response	NOUN
dpc-4737	198	17	,	,	PUNCT
dpc-4737	198	18	and	and	CCONJ
dpc-4737	198	19	staging	staging	NOUN
dpc-4737	198	20	criteria	criterion	NOUN
dpc-4737	198	21	.	.	PUNCT
dpc-4737	199	1	aids	aids	PROPN
dpc-4737	199	2	clinical	clinical	ADJ
dpc-4737	199	3	trials	trial	NOUN
dpc-4737	199	4	group	group	NOUN
dpc-4737	199	5	oncology	oncology	NOUN
dpc-4737	199	6	committee	committee	NOUN
dpc-4737	199	7	.	.	PUNCT
dpc-4737	200	1	j	j	PROPN
dpc-4737	200	2	clin	clin	PROPN
dpc-4737	200	3	oncol	oncol	PROPN
dpc-4737	200	4	.	.	PUNCT
dpc-4737	201	1	1989;7(9):1201–1207	1989;7(9):1201–1207	NUM
dpc-4737	201	2	17	17	NUM
dpc-4737	201	3	.	.	PUNCT
dpc-4737	202	1	ramaswami	ramaswami	NOUN
dpc-4737	202	2	r	r	NOUN
dpc-4737	202	3	,	,	PUNCT
dpc-4737	202	4	polizzotto	polizzotto	ADJ
dpc-4737	202	5	mn	mn	PROPN
dpc-4737	202	6	,	,	PUNCT
dpc-4737	202	7	lurain	lurain	VERB
dpc-4737	202	8	k	k	PROPN
dpc-4737	202	9	,	,	PUNCT
dpc-4737	202	10	et	et	PROPN
dpc-4737	202	11	al	al	PROPN
dpc-4737	202	12	.	.	PROPN
dpc-4737	202	13	safety	safety	PROPN
dpc-4737	202	14	,	,	PUNCT
dpc-4737	202	15	activity	activity	NOUN
dpc-4737	202	16	,	,	PUNCT
dpc-4737	202	17	and	and	CCONJ
dpc-4737	202	18	long	long	ADJ
dpc-4737	202	19	-	-	PUNCT
dpc-4737	202	20	term	term	NOUN
dpc-4737	202	21	outcomes	outcome	NOUN
dpc-4737	202	22	of	of	ADP
dpc-4737	202	23	pomalidomide	pomalidomide	NOUN
dpc-4737	202	24	in	in	ADP
dpc-4737	202	25	the	the	DET
dpc-4737	202	26	treatment	treatment	NOUN
dpc-4737	202	27	of	of	ADP
dpc-4737	202	28	kaposi	kaposi	PROPN
dpc-4737	202	29	sarcoma	sarcoma	NOUN
dpc-4737	202	30	among	among	ADP
dpc-4737	202	31	individuals	individual	NOUN
dpc-4737	202	32	with	with	ADP
dpc-4737	202	33	or	or	CCONJ
dpc-4737	202	34	without	without	ADP
dpc-4737	202	35	hiv	hiv	PROPN
dpc-4737	202	36	infection	infection	NOUN
dpc-4737	202	37	.	.	PUNCT
dpc-4737	203	1	clinical	clinical	ADJ
dpc-4737	203	2	cancer	cancer	NOUN
dpc-4737	203	3	research	research	NOUN
dpc-4737	203	4	.	.	PUNCT
dpc-4737	204	1	2022	2022	NUM
dpc-4737	204	2	;	;	PUNCT
dpc-4737	204	3	28(5):840	28(5):840	NUM
dpc-4737	204	4	-	-	SYM
dpc-4737	204	5	850	850	NUM
dpc-4737	204	6	.	.	PUNCT
dpc-4737	205	1	doi	doi	NOUN
dpc-4737	205	2	:	:	PUNCT
dpc-4737	205	3	10.1158	10.1158	NUM
dpc-4737	205	4	/1078	/1078	ADJ
dpc-4737	205	5	-	-	PUNCT
dpc-4737	205	6	0432.ccr-21	0432.ccr-21	NUM
dpc-4737	205	7	-	-	PUNCT
dpc-4737	205	8	3364	3364	NUM
dpc-4737	205	9	18	18	NUM
dpc-4737	205	10	.	.	PUNCT
dpc-4737	206	1	paksoy	paksoy	PROPN
dpc-4737	206	2	n	n	CCONJ
dpc-4737	206	3	,	,	PUNCT
dpc-4737	206	4	khanmammadov	khanmammadov	PROPN
dpc-4737	206	5	n	n	CCONJ
dpc-4737	206	6	,	,	PUNCT
dpc-4737	206	7	doğan	doğan	ADJ
dpc-4737	206	8	i̇	i̇	NOUN
dpc-4737	206	9	,	,	PUNCT
dpc-4737	206	10	et	et	PROPN
dpc-4737	206	11	al	al	PROPN
dpc-4737	206	12	.	.	PROPN
dpc-4737	206	13	weekly	weekly	PROPN
dpc-4737	206	14	paclitaxel	paclitaxel	ADJ
dpc-4737	206	15	treatment	treatment	NOUN
dpc-4737	206	16	in	in	ADP
dpc-4737	206	17	the	the	DET
dpc-4737	206	18	first	first	ADJ
dpc-4737	206	19	-	-	PUNCT
dpc-4737	206	20	line	line	NOUN
dpc-4737	206	21	therapy	therapy	NOUN
dpc-4737	206	22	of	of	ADP
dpc-4737	206	23	classic	classic	ADJ
dpc-4737	206	24	kaposi	kaposi	PROPN
dpc-4737	206	25	sarcoma	sarcoma	PROPN
dpc-4737	206	26	:	:	PUNCT
dpc-4737	206	27	a	a	DET
dpc-4737	206	28	real	real	ADJ
dpc-4737	206	29	-	-	PUNCT
dpc-4737	206	30	life	life	NOUN
dpc-4737	206	31	study	study	NOUN
dpc-4737	206	32	.	.	PUNCT
dpc-4737	207	1	medicine	medicine	NOUN
dpc-4737	207	2	.	.	PUNCT
dpc-4737	208	1	2023	2023	NUM
dpc-4737	208	2	;	;	PUNCT
dpc-4737	208	3	102	102	NUM
dpc-4737	208	4	(	(	PUNCT
dpc-4737	208	5	5):e32866	5):e32866	PROPN
dpc-4737	208	6	.	.	PUNCT
dpc-4737	208	7	 	 	SPACE
dpc-4737	208	8	doi	doi	NOUN
dpc-4737	208	9	:	:	PUNCT
dpc-4737	208	10	 	 	SPACE
dpc-4737	208	11	10.1097	10.1097	NUM
dpc-4737	208	12	/md.0000000000032866	/md.0000000000032866	NUM
dpc-4737	208	13	19	19	NUM
dpc-4737	208	14	.	.	PUNCT
dpc-4737	209	1	brambilla	brambilla	PROPN
dpc-4737	209	2	l	l	PROPN
dpc-4737	209	3	,	,	PUNCT
dpc-4737	209	4	boneschi	boneschi	PROPN
dpc-4737	209	5	v	v	NOUN
dpc-4737	209	6	,	,	PUNCT
dpc-4737	209	7	taglioni	taglioni	PROPN
dpc-4737	209	8	m	m	PROPN
dpc-4737	209	9	,	,	PUNCT
dpc-4737	209	10	ferrucci	ferrucci	PROPN
dpc-4737	209	11	s.	s.	PROPN
dpc-4737	209	12	staging	staging	NOUN
dpc-4737	209	13	of	of	ADP
dpc-4737	209	14	classic	classic	ADJ
dpc-4737	209	15	kaposi	kaposi	PROPN
dpc-4737	209	16	’s	’s	PART
dpc-4737	209	17	sarcoma	sarcoma	NOUN
dpc-4737	209	18	:	:	PUNCT
dpc-4737	209	19	a	a	DET
dpc-4737	209	20	useful	useful	ADJ
dpc-4737	209	21	tool	tool	NOUN
dpc-4737	209	22	for	for	ADP
dpc-4737	209	23	therapeutic	therapeutic	ADJ
dpc-4737	209	24	choices	choice	NOUN
dpc-4737	209	25	.	.	PUNCT
dpc-4737	210	1	euro	euro	NOUN
dpc-4737	210	2	j	j	PROPN
dpc-4737	210	3	dermatol	dermatol	NOUN
dpc-4737	210	4	.	.	PUNCT
dpc-4737	211	1	2003	2003	NUM
dpc-4737	211	2	;	;	PUNCT
dpc-4737	211	3	28	28	NUM
dpc-4737	211	4	(	(	PUNCT
dpc-4737	211	5	1):83	1):83	NUM
dpc-4737	211	6	-	-	SYM
dpc-4737	211	7	86	86	NUM
dpc-4737	211	8	.	.	PUNCT
dpc-4737	212	1	20	20	NUM
dpc-4737	212	2	.	.	PUNCT
dpc-4737	212	3	greene	greene	PROPN
dpc-4737	212	4	ak	ak	PROPN
dpc-4737	212	5	,	,	PUNCT
dpc-4737	212	6	goss	goss	PROPN
dpc-4737	212	7	ja	ja	PROPN
dpc-4737	212	8	.	.	PUNCT
dpc-4737	212	9	diagnosis	diagnosis	NOUN
dpc-4737	212	10	and	and	CCONJ
dpc-4737	212	11	staging	staging	NOUN
dpc-4737	212	12	of	of	ADP
dpc-4737	212	13	lymphedema	lymphedema	NOUN
dpc-4737	212	14	.	.	PUNCT
dpc-4737	213	1	semin	semin	PROPN
dpc-4737	213	2	plast	plast	PROPN
dpc-4737	213	3	surg	surg	PROPN
dpc-4737	213	4	.	.	PUNCT
dpc-4737	214	1	2018;32(1):012	2018;32(1):012	NUM
dpc-4737	214	2	-	-	PUNCT
dpc-4737	214	3	016	016	NUM
dpc-4737	214	4	.	.	PUNCT
dpc-4737	215	1	doi	doi	NOUN
dpc-4737	215	2	:	:	PUNCT
dpc-4737	215	3	 	 	SPACE
dpc-4737	215	4	10.1055	10.1055	NUM
dpc-4737	215	5	/	/	SYM
dpc-4737	215	6	s-0038	s-0038	PROPN
dpc-4737	215	7	-	-	PUNCT
dpc-4737	215	8	1635117	1635117	NUM
dpc-4737	215	9	21	21	NUM
dpc-4737	215	10	.	.	PUNCT
dpc-4737	216	1	benajiba	benajiba	PROPN
dpc-4737	216	2	l	l	PROPN
dpc-4737	216	3	,	,	PUNCT
dpc-4737	216	4	lambert	lambert	PROPN
dpc-4737	216	5	j	j	PROPN
dpc-4737	216	6	,	,	PUNCT
dpc-4737	216	7	la	la	PROPN
dpc-4737	216	8	selva	selva	PROPN
dpc-4737	216	9	r	r	PROPN
dpc-4737	216	10	,	,	PUNCT
dpc-4737	216	11	et	et	PROPN
dpc-4737	216	12	al	al	PROPN
dpc-4737	216	13	.	.	PUNCT
dpc-4737	217	1	systemic	systemic	ADJ
dpc-4737	217	2	treatment	treatment	NOUN
dpc-4737	217	3	initiation	initiation	NOUN
dpc-4737	217	4	in	in	ADP
dpc-4737	217	5	classical	classical	ADJ
dpc-4737	217	6	and	and	CCONJ
dpc-4737	217	7	endemic	endemic	ADJ
dpc-4737	217	8	kaposi	kaposi	PROPN
dpc-4737	217	9	’s	’s	PART
dpc-4737	217	10	sarcoma	sarcoma	NOUN
dpc-4737	217	11	:	:	PUNCT
dpc-4737	217	12	risk	risk	NOUN
dpc-4737	217	13	factors	factor	NOUN
dpc-4737	217	14	and	and	CCONJ
dpc-4737	217	15	global	global	ADJ
dpc-4737	217	16	multi	multi	ADJ
dpc-4737	217	17	-	-	ADJ
dpc-4737	217	18	state	state	ADJ
dpc-4737	217	19	modelling	modelling	NOUN
dpc-4737	217	20	in	in	ADP
dpc-4737	217	21	a	a	DET
dpc-4737	217	22	monocentric	monocentric	ADJ
dpc-4737	217	23	cohort	cohort	NOUN
dpc-4737	217	24	study	study	NOUN
dpc-4737	217	25	.	.	PUNCT
dpc-4737	218	1	cancers	cancer	NOUN
dpc-4737	218	2	.	.	PUNCT
dpc-4737	219	1	2021	2021	NUM
dpc-4737	219	2	;	;	PUNCT
dpc-4737	220	1	13	13	NUM
dpc-4737	220	2	(	(	PUNCT
dpc-4737	220	3	11):2519	11):2519	NUM
dpc-4737	220	4	.	.	PUNCT
dpc-4737	220	5	  	  	SPACE
dpc-4737	220	6	doi	doi	NOUN
dpc-4737	220	7	:	:	PUNCT
dpc-4737	220	8	10.3390	10.3390	NUM
dpc-4737	220	9	/	/	SYM
dpc-4737	220	10	cancers13112519	cancers13112519	PROPN
dpc-4737	220	11	22	22	NUM
dpc-4737	220	12	.	.	PUNCT
dpc-4737	221	1	régnier	régnier	NOUN
dpc-4737	221	2	-	-	PUNCT
dpc-4737	221	3	rosencher	rosencher	PROPN
dpc-4737	221	4	e	e	NOUN
dpc-4737	221	5	,	,	PUNCT
dpc-4737	221	6	guillot	guillot	ADJ
dpc-4737	221	7	b	b	NOUN
dpc-4737	221	8	,	,	PUNCT
dpc-4737	221	9	dupin	dupin	PROPN
dpc-4737	221	10	n.	n.	NOUN
dpc-4737	221	11	treatments	treatment	NOUN
dpc-4737	221	12	for	for	ADP
dpc-4737	221	13	classic	classic	ADJ
dpc-4737	221	14	kaposi	kaposi	PROPN
dpc-4737	221	15	sarcoma	sarcoma	PROPN
dpc-4737	221	16	:	:	PUNCT
dpc-4737	221	17	a	a	DET
dpc-4737	221	18	systematic	systematic	ADJ
dpc-4737	221	19	review	review	NOUN
dpc-4737	221	20	of	of	ADP
dpc-4737	221	21	the	the	DET
dpc-4737	221	22	literature	literature	NOUN
dpc-4737	221	23	.	.	PUNCT
dpc-4737	222	1	j	j	PROPN
dpc-4737	222	2	am	be	AUX
dpc-4737	222	3	acad	acad	ADJ
dpc-4737	222	4	dermatol	dermatol	NOUN
dpc-4737	222	5	.	.	PUNCT
dpc-4737	223	1	2013;68(2):313	2013;68(2):313	PROPN
dpc-4737	223	2	-	-	PUNCT
dpc-4737	223	3	331	331	NUM
dpc-4737	223	4	.	.	PUNCT
dpc-4737	223	5	doi:10.1016	doi:10.1016	PROPN
dpc-4737	223	6	/	/	SYM
dpc-4737	223	7	j.jaad.2012	j.jaad.2012	PROPN
dpc-4737	223	8	.04.018	.04.018	NOUN
dpc-4737	224	1	23	23	NUM
dpc-4737	224	2	.	.	PUNCT
dpc-4737	225	1	lamy	lamy	PROPN
dpc-4737	225	2	s	s	PROPN
dpc-4737	225	3	,	,	PUNCT
dpc-4737	225	4	lachambre	lachambre	PROPN
dpc-4737	225	5	mp	mp	PROPN
dpc-4737	225	6	,	,	PUNCT
dpc-4737	225	7	lord	lord	PROPN
dpc-4737	225	8	-	-	PUNCT
dpc-4737	225	9	dufour	dufour	PROPN
dpc-4737	225	10	s	s	PROPN
dpc-4737	225	11	,	,	PUNCT
dpc-4737	225	12	béliveau	béliveau	PROPN
dpc-4737	225	13	r.	r.	PROPN
dpc-4737	225	14	propranolol	propranolol	PROPN
dpc-4737	225	15	suppresses	suppress	VERB
dpc-4737	225	16	angiogenesis	angiogenesis	NOUN
dpc-4737	225	17	in	in	ADP
dpc-4737	225	18	vitro	vitro	NOUN
dpc-4737	225	19	:	:	PUNCT
dpc-4737	225	20	inhibition	inhibition	NOUN
dpc-4737	225	21	of	of	ADP
dpc-4737	225	22	proliferation	proliferation	NOUN
dpc-4737	225	23	,	,	PUNCT
dpc-4737	225	24	migration	migration	NOUN
dpc-4737	225	25	,	,	PUNCT
dpc-4737	225	26	and	and	CCONJ
dpc-4737	225	27	differentiation	differentiation	NOUN
dpc-4737	225	28	of	of	ADP
dpc-4737	225	29	endothelial	endothelial	ADJ
dpc-4737	225	30	cells	cell	NOUN
dpc-4737	225	31	.	.	PUNCT
dpc-4737	226	1	vascul	vascul	PROPN
dpc-4737	226	2	pharmacol	pharmacol	PROPN
dpc-4737	226	3	.	.	PUNCT
dpc-4737	227	1	2010	2010	NUM
dpc-4737	227	2	;	;	PUNCT
dpc-4737	227	3	53(5	53(5	X
dpc-4737	227	4	-	-	PUNCT
dpc-4737	227	5	6):200	6):200	NUM
dpc-4737	227	6	-	-	PUNCT
dpc-4737	227	7	208	208	NUM
dpc-4737	227	8	.	.	PUNCT
dpc-4737	228	1	doi:10.1016	doi:10.1016	PROPN
dpc-4737	228	2	/	/	SYM
dpc-4737	228	3	j.vph.2010	j.vph.2010	PROPN
dpc-4737	228	4	.08.002	.08.002	NOUN
dpc-4737	228	5	24	24	NUM
dpc-4737	228	6	.	.	PUNCT
dpc-4737	229	1	stiles	stiles	PROPN
dpc-4737	229	2	jm	jm	PROPN
dpc-4737	229	3	,	,	PUNCT
dpc-4737	229	4	amaya	amaya	PROPN
dpc-4737	229	5	c	c	PROPN
dpc-4737	229	6	,	,	PUNCT
dpc-4737	229	7	rains	rain	NOUN
dpc-4737	229	8	s	s	PROPN
dpc-4737	229	9	,	,	PUNCT
dpc-4737	229	10	et	et	PROPN
dpc-4737	229	11	al	al	PROPN
dpc-4737	229	12	.	.	PUNCT
dpc-4737	230	1	targeting	target	VERB
dpc-4737	230	2	of	of	ADP
dpc-4737	230	3	betaadrenergic	betaadrenergic	ADJ
dpc-4737	230	4	receptors	receptor	NOUN
dpc-4737	230	5	results	result	NOUN
dpc-4737	230	6	in	in	ADP
dpc-4737	230	7	therapeutic	therapeutic	ADJ
dpc-4737	230	8	efficacy	efficacy	NOUN
dpc-4737	230	9	against	against	ADP
dpc-4737	230	10	models	model	NOUN
dpc-4737	230	11	of	of	ADP
dpc-4737	230	12	the	the	DET
dpc-4737	230	13	development	development	NOUN
dpc-4737	230	14	of	of	ADP
dpc-4737	230	15	ks	ks	PROPN
dpc-4737	230	16	[	[	X
dpc-4737	230	17	31	31	NUM
dpc-4737	230	18	]	]	PUNCT
dpc-4737	230	19	.	.	PUNCT
dpc-4737	231	1	in	in	ADP
dpc-4737	231	2	this	this	DET
dpc-4737	231	3	context	context	NOUN
dpc-4737	231	4	brambilla	brambilla	NOUN
dpc-4737	231	5	et	et	PROPN
dpc-4737	231	6	al	al	PROPN
dpc-4737	232	1	[	[	X
dpc-4737	232	2	30	30	NUM
dpc-4737	232	3	]	]	PUNCT
dpc-4737	232	4	mentioned	mention	VERB
dpc-4737	232	5	that	that	SCONJ
dpc-4737	232	6	limb	limb	NOUN
dpc-4737	232	7	volume	volume	NOUN
dpc-4737	232	8	reduction	reduction	NOUN
dpc-4737	232	9	could	could	AUX
dpc-4737	232	10	be	be	AUX
dpc-4737	232	11	useful	useful	ADJ
dpc-4737	232	12	to	to	PART
dpc-4737	232	13	improve	improve	VERB
dpc-4737	232	14	the	the	DET
dpc-4737	232	15	prognosis	prognosis	NOUN
dpc-4737	232	16	of	of	ADP
dpc-4737	232	17	cks	ck	NOUN
dpc-4737	232	18	,	,	PUNCT
dpc-4737	232	19	and	and	CCONJ
dpc-4737	232	20	they	they	PRON
dpc-4737	232	21	encouraged	encourage	VERB
dpc-4737	232	22	the	the	DET
dpc-4737	232	23	employment	employment	NOUN
dpc-4737	232	24	of	of	ADP
dpc-4737	232	25	elastic	elastic	ADJ
dpc-4737	232	26	stockings	stocking	NOUN
dpc-4737	232	27	.	.	PUNCT
dpc-4737	233	1	there	there	PRON
dpc-4737	233	2	is	be	VERB
dpc-4737	233	3	no	no	DET
dpc-4737	233	4	agreement	agreement	NOUN
dpc-4737	233	5	on	on	ADP
dpc-4737	233	6	which	which	PRON
dpc-4737	233	7	agent	agent	NOUN
dpc-4737	233	8	should	should	AUX
dpc-4737	233	9	be	be	AUX
dpc-4737	233	10	selected	select	VERB
dpc-4737	233	11	as	as	ADP
dpc-4737	233	12	a	a	DET
dpc-4737	233	13	first	first	ADJ
dpc-4737	233	14	-	-	PUNCT
dpc-4737	233	15	line	line	NOUN
dpc-4737	233	16	systemic	systemic	ADJ
dpc-4737	233	17	treatment	treatment	NOUN
dpc-4737	233	18	of	of	ADP
dpc-4737	233	19	cks	ck	NOUN
dpc-4737	233	20	.	.	PUNCT
dpc-4737	234	1	the	the	DET
dpc-4737	234	2	relatively	relatively	ADV
dpc-4737	234	3	low	low	ADJ
dpc-4737	234	4	incidence	incidence	NOUN
dpc-4737	234	5	of	of	ADP
dpc-4737	234	6	the	the	DET
dpc-4737	234	7	disease	disease	NOUN
dpc-4737	234	8	,	,	PUNCT
dpc-4737	234	9	the	the	DET
dpc-4737	234	10	fact	fact	NOUN
dpc-4737	234	11	that	that	SCONJ
dpc-4737	234	12	it	it	PRON
dpc-4737	234	13	usually	usually	ADV
dpc-4737	234	14	occurs	occur	VERB
dpc-4737	234	15	in	in	ADP
dpc-4737	234	16	old	old	ADJ
dpc-4737	234	17	age	age	NOUN
dpc-4737	234	18	,	,	PUNCT
dpc-4737	234	19	and	and	CCONJ
dpc-4737	234	20	the	the	DET
dpc-4737	234	21	presence	presence	NOUN
dpc-4737	234	22	of	of	ADP
dpc-4737	234	23	comorbidities	comorbiditie	NOUN
dpc-4737	234	24	limit	limit	VERB
dpc-4737	234	25	prospective	prospective	ADJ
dpc-4737	234	26	studies	study	NOUN
dpc-4737	234	27	.	.	PUNCT
dpc-4737	235	1	in	in	ADP
dpc-4737	235	2	this	this	DET
dpc-4737	235	3	study	study	NOUN
dpc-4737	235	4	,	,	PUNCT
dpc-4737	235	5	over	over	ADP
dpc-4737	235	6	50	50	NUM
dpc-4737	235	7	%	%	NOUN
dpc-4737	235	8	of	of	ADP
dpc-4737	235	9	the	the	DET
dpc-4737	235	10	treated	treat	VERB
dpc-4737	235	11	patients	patient	NOUN
dpc-4737	235	12	exhibited	exhibit	VERB
dpc-4737	235	13	a	a	DET
dpc-4737	235	14	partial	partial	ADJ
dpc-4737	235	15	response	response	NOUN
dpc-4737	235	16	,	,	PUNCT
dpc-4737	235	17	with	with	ADP
dpc-4737	235	18	one	one	NUM
dpc-4737	235	19	patient	patient	NOUN
dpc-4737	235	20	achieving	achieve	VERB
dpc-4737	235	21	near	near	ADP
dpc-4737	235	22	-	-	PUNCT
dpc-4737	235	23	clearance	clearance	NOUN
dpc-4737	235	24	of	of	ADP
dpc-4737	235	25	lesions	lesion	NOUN
dpc-4737	235	26	.	.	PUNCT
dpc-4737	236	1	these	these	DET
dpc-4737	236	2	findings	finding	NOUN
dpc-4737	236	3	suggest	suggest	VERB
dpc-4737	236	4	that	that	SCONJ
dpc-4737	236	5	systemic	systemic	ADJ
dpc-4737	236	6	propranolol	propranolol	NOUN
dpc-4737	236	7	represents	represent	VERB
dpc-4737	236	8	a	a	DET
dpc-4737	236	9	safe	safe	ADJ
dpc-4737	236	10	and	and	CCONJ
dpc-4737	236	11	effective	effective	ADJ
dpc-4737	236	12	option	option	NOUN
dpc-4737	236	13	for	for	ADP
dpc-4737	236	14	elderly	elderly	ADJ
dpc-4737	236	15	patients	patient	NOUN
dpc-4737	236	16	with	with	ADP
dpc-4737	236	17	non	non	ADJ
dpc-4737	236	18	-	-	ADJ
dpc-4737	236	19	complicated	complicated	ADJ
dpc-4737	236	20	,	,	PUNCT
dpc-4737	236	21	non	non	ADJ
dpc-4737	236	22	-	-	ADJ
dpc-4737	236	23	aggressive	aggressive	ADJ
dpc-4737	236	24	cks	ck	NOUN
dpc-4737	236	25	.	.	PUNCT
dpc-4737	237	1	however	however	ADV
dpc-4737	237	2	,	,	PUNCT
dpc-4737	237	3	further	further	ADJ
dpc-4737	237	4	studies	study	NOUN
dpc-4737	237	5	are	be	AUX
dpc-4737	237	6	warranted	warrant	VERB
dpc-4737	237	7	to	to	PART
dpc-4737	237	8	determine	determine	VERB
dpc-4737	237	9	the	the	DET
dpc-4737	237	10	optimal	optimal	ADJ
dpc-4737	237	11	dosage	dosage	NOUN
dpc-4737	237	12	and	and	CCONJ
dpc-4737	237	13	duration	duration	NOUN
dpc-4737	237	14	of	of	ADP
dpc-4737	237	15	propranolol	propranolol	NOUN
dpc-4737	237	16	treatment	treatment	NOUN
dpc-4737	237	17	in	in	ADP
dpc-4737	237	18	such	such	ADJ
dpc-4737	237	19	cases	case	NOUN
dpc-4737	237	20	.	.	PUNCT
dpc-4737	238	1	the	the	DET
dpc-4737	238	2	prospective	prospective	ADJ
dpc-4737	238	3	design	design	NOUN
dpc-4737	238	4	of	of	ADP
dpc-4737	238	5	the	the	DET
dpc-4737	238	6	study	study	NOUN
dpc-4737	238	7	and	and	CCONJ
dpc-4737	238	8	the	the	DET
dpc-4737	238	9	use	use	NOUN
dpc-4737	238	10	of	of	ADP
dpc-4737	238	11	propranolol	propranolol	NOUN
dpc-4737	238	12	as	as	ADP
dpc-4737	238	13	a	a	DET
dpc-4737	238	14	monotherapy	monotherapy	NOUN
dpc-4737	238	15	help	help	NOUN
dpc-4737	238	16	minimize	minimize	VERB
dpc-4737	238	17	bias	bias	NOUN
dpc-4737	238	18	regarding	regard	VERB
dpc-4737	238	19	its	its	PRON
dpc-4737	238	20	efficacy	efficacy	NOUN
dpc-4737	238	21	,	,	PUNCT
dpc-4737	238	22	particularly	particularly	ADV
dpc-4737	238	23	when	when	SCONJ
dpc-4737	238	24	used	use	VERB
dpc-4737	238	25	in	in	ADP
dpc-4737	238	26	combination	combination	NOUN
dpc-4737	238	27	with	with	ADP
dpc-4737	238	28	other	other	ADJ
dpc-4737	238	29	drugs	drug	NOUN
dpc-4737	238	30	.	.	PUNCT
dpc-4737	239	1	the	the	DET
dpc-4737	239	2	limitation	limitation	NOUN
dpc-4737	239	3	of	of	ADP
dpc-4737	239	4	the	the	DET
dpc-4737	239	5	present	present	ADJ
dpc-4737	239	6	study	study	NOUN
dpc-4737	239	7	is	be	AUX
dpc-4737	239	8	the	the	DET
dpc-4737	239	9	small	small	ADJ
dpc-4737	239	10	number	number	NOUN
dpc-4737	239	11	of	of	ADP
dpc-4737	239	12	patients	patient	NOUN
dpc-4737	239	13	included	include	VERB
dpc-4737	239	14	,	,	PUNCT
dpc-4737	239	15	which	which	PRON
dpc-4737	239	16	can	can	AUX
dpc-4737	239	17	be	be	AUX
dpc-4737	239	18	attributed	attribute	VERB
dpc-4737	239	19	to	to	ADP
dpc-4737	239	20	the	the	DET
dpc-4737	239	21	rarity	rarity	NOUN
dpc-4737	239	22	of	of	ADP
dpc-4737	239	23	the	the	DET
dpc-4737	239	24	disease	disease	NOUN
dpc-4737	239	25	.	.	PUNCT
dpc-4737	240	1	additionally	additionally	ADV
dpc-4737	240	2	,	,	PUNCT
dpc-4737	240	3	the	the	DET
dpc-4737	240	4	limited	limited	ADJ
dpc-4737	240	5	duration	duration	NOUN
dpc-4737	240	6	of	of	ADP
dpc-4737	240	7	the	the	DET
dpc-4737	240	8	study	study	NOUN
dpc-4737	240	9	may	may	AUX
dpc-4737	240	10	have	have	AUX
dpc-4737	240	11	restricted	restrict	VERB
dpc-4737	240	12	the	the	DET
dpc-4737	240	13	ability	ability	NOUN
dpc-4737	240	14	to	to	PART
dpc-4737	240	15	observe	observe	VERB
dpc-4737	240	16	long	long	ADJ
dpc-4737	240	17	-	-	PUNCT
dpc-4737	240	18	term	term	NOUN
dpc-4737	240	19	outcomes	outcome	NOUN
dpc-4737	240	20	and	and	CCONJ
dpc-4737	240	21	fully	fully	ADV
dpc-4737	240	22	assess	assess	VERB
dpc-4737	240	23	the	the	DET
dpc-4737	240	24	efficacy	efficacy	NOUN
dpc-4737	240	25	of	of	ADP
dpc-4737	240	26	the	the	DET
dpc-4737	240	27	treatment	treatment	NOUN
dpc-4737	240	28	.	.	PUNCT
dpc-4737	241	1	references	reference	NOUN
dpc-4737	241	2	1	1	NUM
dpc-4737	241	3	.	.	PUNCT
dpc-4737	241	4	ruocco	ruocco	PROPN
dpc-4737	241	5	e	e	PROPN
dpc-4737	241	6	,	,	PUNCT
dpc-4737	241	7	ruocco	ruocco	PROPN
dpc-4737	241	8	v	v	NOUN
dpc-4737	241	9	,	,	PUNCT
dpc-4737	241	10	tornesello	tornesello	PROPN
dpc-4737	241	11	ml	ml	PROPN
dpc-4737	241	12	,	,	PUNCT
dpc-4737	241	13	gambardella	gambardella	VERB
dpc-4737	241	14	a	a	PRON
dpc-4737	241	15	,	,	PUNCT
dpc-4737	241	16	wolf	wolf	PROPN
dpc-4737	241	17	r	r	PROPN
dpc-4737	241	18	,	,	PUNCT
dpc-4737	241	19	buonaguro	buonaguro	PROPN
dpc-4737	241	20	fm	fm	PROPN
dpc-4737	241	21	.	.	PUNCT
dpc-4737	242	1	kaposi	kaposi	PROPN
dpc-4737	242	2	’s	’s	PART
dpc-4737	242	3	sarcoma	sarcoma	NOUN
dpc-4737	242	4	:	:	PUNCT
dpc-4737	242	5	etiology	etiology	NOUN
dpc-4737	242	6	and	and	CCONJ
dpc-4737	242	7	pathogenesis	pathogenesis	NOUN
dpc-4737	242	8	,	,	PUNCT
dpc-4737	242	9	inducing	induce	VERB
dpc-4737	242	10	factors	factor	NOUN
dpc-4737	242	11	,	,	PUNCT
dpc-4737	242	12	causal	causal	ADJ
dpc-4737	242	13	associations	association	NOUN
dpc-4737	242	14	,	,	PUNCT
dpc-4737	242	15	and	and	CCONJ
dpc-4737	242	16	treatments	treatment	NOUN
dpc-4737	242	17	:	:	PUNCT
dpc-4737	242	18	facts	fact	NOUN
dpc-4737	242	19	and	and	CCONJ
dpc-4737	242	20	controversies	controversy	NOUN
dpc-4737	242	21	.	.	PUNCT
dpc-4737	243	1	clin	clin	PROPN
dpc-4737	243	2	dermatol	dermatol	NOUN
dpc-4737	243	3	.	.	PUNCT
dpc-4737	244	1	2013;31(4):413	2013;31(4):413	NUM
dpc-4737	244	2	-	-	PUNCT
dpc-4737	244	3	422	422	NUM
dpc-4737	244	4	.	.	PUNCT
dpc-4737	245	1	doi	doi	NOUN
dpc-4737	245	2	:	:	PUNCT
dpc-4737	245	3	10.1016	10.1016	NUM
dpc-4737	245	4	/j.clindermatol.2013.01.008	/j.clindermatol.2013.01.008	PUNCT
dpc-4737	245	5	.	.	PUNCT
dpc-4737	246	1	pmid	pmid	NOUN
dpc-4737	246	2	:	:	PUNCT
dpc-4737	246	3	23806158	23806158	NUM
dpc-4737	246	4	.	.	PUNCT
dpc-4737	247	1	pmcid	pmcid	NOUN
dpc-4737	247	2	:	:	PUNCT
dpc-4737	247	3	pmc717	pmc717	PROPN
dpc-4737	247	4	3141	3141	NUM
dpc-4737	247	5	.	.	PUNCT
dpc-4737	248	1	2	2	X
dpc-4737	248	2	.	.	X
dpc-4737	248	3	schwartz	schwartz	PROPN
dpc-4737	248	4	ra	ra	PROPN
dpc-4737	248	5	,	,	PUNCT
dpc-4737	248	6	micali	micali	NOUN
dpc-4737	248	7	g	g	PROPN
dpc-4737	248	8	,	,	PUNCT
dpc-4737	248	9	nasca	nasca	PROPN
dpc-4737	249	1	mr	mr	PROPN
dpc-4737	249	2	,	,	PUNCT
dpc-4737	249	3	scuderi	scuderi	PROPN
dpc-4737	249	4	l.	l.	PROPN
dpc-4737	249	5	kaposi	kaposi	PROPN
dpc-4737	249	6	sarcoma	sarcoma	PROPN
dpc-4737	249	7	:	:	PUNCT
dpc-4737	249	8	a	a	DET
dpc-4737	249	9	continuing	continue	VERB
dpc-4737	249	10	conundrum	conundrum	NOUN
dpc-4737	249	11	.	.	PUNCT
dpc-4737	250	1	j	j	PROPN
dpc-4737	250	2	am	be	AUX
dpc-4737	250	3	acad	acad	ADJ
dpc-4737	250	4	dermatol	dermatol	NOUN
dpc-4737	250	5	.	.	PUNCT
dpc-4737	251	1	2008;59(2	2008;59(2	NUM
dpc-4737	251	2	):	):	PUNCT
dpc-4737	251	3	179	179	NUM
dpc-4737	251	4	-	-	SYM
dpc-4737	251	5	206	206	NUM
dpc-4737	251	6	.	.	PUNCT
dpc-4737	252	1	doi:10.1016	doi:10.1016	PROPN
dpc-4737	252	2	/	/	SYM
dpc-4737	252	3	j.jaad.2008.05.001	j.jaad.2008.05.001	PROPN
dpc-4737	252	4	.	.	PUNCT
dpc-4737	253	1	pmid	pmid	NOUN
dpc-4737	253	2	:	:	PUNCT
dpc-4737	253	3	18638627	18638627	NUM
dpc-4737	253	4	.	.	PUNCT
dpc-4737	254	1	3	3	X
dpc-4737	254	2	.	.	X
dpc-4737	254	3	liu	liu	PROPN
dpc-4737	254	4	z	z	PROPN
dpc-4737	254	5	,	,	PUNCT
dpc-4737	254	6	fang	fang	PROPN
dpc-4737	254	7	q	q	PROPN
dpc-4737	254	8	,	,	PUNCT
dpc-4737	254	9	zuo	zuo	PROPN
dpc-4737	254	10	j	j	PROPN
dpc-4737	254	11	,	,	PUNCT
dpc-4737	254	12	minhas	minhas	PROPN
dpc-4737	254	13	v	v	NOUN
dpc-4737	254	14	,	,	PUNCT
dpc-4737	254	15	wood	wood	NOUN
dpc-4737	254	16	c	c	NOUN
dpc-4737	254	17	,	,	PUNCT
dpc-4737	254	18	zhang	zhang	PROPN
dpc-4737	254	19	t.	t.	PROPN
dpc-4737	254	20	the	the	DET
dpc-4737	254	21	worldwide	worldwide	ADJ
dpc-4737	254	22	incidence	incidence	NOUN
dpc-4737	254	23	of	of	ADP
dpc-4737	254	24	kaposi	kaposi	PROPN
dpc-4737	254	25	’s	’s	PART
dpc-4737	254	26	sarcoma	sarcoma	NOUN
dpc-4737	254	27	in	in	ADP
dpc-4737	254	28	the	the	DET
dpc-4737	254	29	hiv	hiv	PROPN
dpc-4737	254	30	/	/	SYM
dpc-4737	254	31	aids	aids	PROPN
dpc-4737	254	32	era	era	NOUN
dpc-4737	254	33	.	.	PUNCT
dpc-4737	255	1	hiv	hiv	PROPN
dpc-4737	255	2	medicine	medicine	NOUN
dpc-4737	255	3	.	.	PUNCT
dpc-4737	256	1	2018	2018	NUM
dpc-4737	256	2	may;19(5):355	may;19(5):355	PROPN
dpc-4737	256	3	-	-	PUNCT
dpc-4737	256	4	364	364	NUM
dpc-4737	256	5	.	.	PUNCT
dpc-4737	257	1	doi	doi	NOUN
dpc-4737	257	2	:	:	PUNCT
dpc-4737	257	3	10.1111	10.1111	NUM
dpc-4737	257	4	/	/	SYM
dpc-4737	257	5	hiv.12584	hiv.12584	NUM
dpc-4737	257	6	4	4	NUM
dpc-4737	257	7	.	.	PUNCT
dpc-4737	258	1	püttgen	püttgen	PROPN
dpc-4737	258	2	k	k	PROPN
dpc-4737	258	3	,	,	PUNCT
dpc-4737	258	4	lucky	lucky	ADJ
dpc-4737	258	5	a	a	PRON
dpc-4737	258	6	,	,	PUNCT
dpc-4737	258	7	adams	adams	PROPN
dpc-4737	258	8	d	d	PROPN
dpc-4737	258	9	,	,	PUNCT
dpc-4737	258	10	et	et	PROPN
dpc-4737	258	11	al	al	PROPN
dpc-4737	258	12	.	.	PUNCT
dpc-4737	258	13	topical	topical	ADJ
dpc-4737	258	14	timolol	timolol	NOUN
dpc-4737	258	15	maleate	maleate	NOUN
dpc-4737	258	16	treatment	treatment	NOUN
dpc-4737	258	17	of	of	ADP
dpc-4737	258	18	infantile	infantile	ADJ
dpc-4737	258	19	hemangiomas	hemangioma	NOUN
dpc-4737	258	20	.	.	PUNCT
dpc-4737	259	1	pediatrics	pediatric	NOUN
dpc-4737	259	2	.	.	PUNCT
dpc-4737	259	3	2016	2016	NUM
dpc-4737	259	4	;	;	PUNCT
dpc-4737	259	5	138(3	138(3	NUM
dpc-4737	259	6	):	):	PUNCT
dpc-4737	259	7	e20160355	e20160355	X
dpc-4737	259	8	doi	doi	NOUN
dpc-4737	259	9	:	:	PUNCT
dpc-4737	259	10	10.1542	10.1542	NUM
dpc-4737	259	11	/	/	SYM
dpc-4737	259	12	peds.2016	peds.2016	PROPN
dpc-4737	259	13	-	-	PUNCT
dpc-4737	259	14	0355	0355	NUM
dpc-4737	259	15	5	5	NUM
dpc-4737	259	16	.	.	PUNCT
dpc-4737	259	17	léauté	léauté	NOUN
dpc-4737	259	18	-	-	PUNCT
dpc-4737	259	19	labrèze	labrèze	PROPN
dpc-4737	259	20	c	c	NOUN
dpc-4737	259	21	,	,	PUNCT
dpc-4737	259	22	hoeger	hoeger	NOUN
dpc-4737	259	23	p	p	NOUN
dpc-4737	259	24	,	,	PUNCT
dpc-4737	259	25	mazereeuw	mazereeuw	ADJ
dpc-4737	259	26	-	-	PUNCT
dpc-4737	259	27	hautier	hautier	NOUN
dpc-4737	259	28	j	j	PROPN
dpc-4737	259	29	,	,	PUNCT
dpc-4737	259	30	et	et	PROPN
dpc-4737	259	31	al	al	PROPN
dpc-4737	259	32	.	.	PUNCT
dpc-4737	260	1	a	a	DET
dpc-4737	260	2	randomized	randomized	ADJ
dpc-4737	260	3	,	,	PUNCT
dpc-4737	260	4	controlled	control	VERB
dpc-4737	260	5	trial	trial	NOUN
dpc-4737	260	6	of	of	ADP
dpc-4737	260	7	oral	oral	ADJ
dpc-4737	260	8	propranolol	propranolol	NOUN
dpc-4737	260	9	in	in	ADP
dpc-4737	260	10	infantile	infantile	ADJ
dpc-4737	260	11	hemangioma	hemangioma	NOUN
dpc-4737	260	12	.	.	PUNCT
dpc-4737	261	1	n	n	PROPN
dpc-4737	261	2	engl	engl	PROPN
dpc-4737	261	3	j	j	PROPN
dpc-4737	261	4	med	med	PROPN
dpc-4737	261	5	.	.	PROPN
dpc-4737	261	6	2015	2015	NUM
dpc-4737	261	7	;	;	PUNCT
dpc-4737	261	8	372(8):735	372(8):735	NUM
dpc-4737	261	9	-	-	SYM
dpc-4737	261	10	746	746	NUM
dpc-4737	261	11	doi	doi	NOUN
dpc-4737	261	12	:	:	PUNCT
dpc-4737	261	13	10.1056	10.1056	NUM
dpc-4737	261	14	/nejmoa1404710	/nejmoa1404710	SYM
dpc-4737	262	1	6	6	NUM
dpc-4737	262	2	.	.	PUNCT
dpc-4737	262	3	storch	storch	PROPN
dpc-4737	262	4	ch	ch	PROPN
dpc-4737	262	5	,	,	PUNCT
dpc-4737	262	6	hoeger	hoeger	X
dpc-4737	262	7	ph	ph	PROPN
dpc-4737	262	8	.	.	PROPN
dpc-4737	262	9	propranolol	propranolol	PROPN
dpc-4737	262	10	for	for	ADP
dpc-4737	262	11	infantile	infantile	ADJ
dpc-4737	262	12	haemangiomas	haemangioma	NOUN
dpc-4737	262	13	:	:	PUNCT
dpc-4737	262	14	insights	insight	NOUN
dpc-4737	262	15	into	into	ADP
dpc-4737	262	16	the	the	DET
dpc-4737	262	17	molecular	molecular	ADJ
dpc-4737	262	18	mechanisms	mechanism	NOUN
dpc-4737	262	19	of	of	ADP
dpc-4737	262	20	action	action	NOUN
dpc-4737	262	21	.	.	PUNCT
dpc-4737	263	1	br	br	PROPN
dpc-4737	263	2	j	j	PROPN
dpc-4737	263	3	dermatol	dermatol	NOUN
dpc-4737	263	4	.	.	PUNCT
dpc-4737	264	1	2010	2010	NUM
dpc-4737	264	2	;	;	PUNCT
dpc-4737	264	3	163(2	163(2	NUM
dpc-4737	264	4	):	):	PUNCT
dpc-4737	264	5	269–274	269–274	NUM
dpc-4737	264	6	doi	doi	NOUN
dpc-4737	264	7	:	:	PUNCT
dpc-4737	264	8	10.1111	10.1111	NUM
dpc-4737	264	9	/	/	SYM
dpc-4737	264	10	j.1365	j.1365	NOUN
dpc-4737	264	11	-	-	PUNCT
dpc-4737	264	12	2133.2010.09848	2133.2010.09848	NUM
dpc-4737	264	13	.	.	PUNCT
dpc-4737	265	1	7	7	X
dpc-4737	265	2	.	.	X
dpc-4737	265	3	cuesta	cuesta	PROPN
dpc-4737	265	4	am	be	AUX
dpc-4737	265	5	,	,	PUNCT
dpc-4737	265	6	gallardo	gallardo	PROPN
dpc-4737	265	7	-	-	PUNCT
dpc-4737	265	8	vara	vara	PROPN
dpc-4737	265	9	e	e	NOUN
dpc-4737	265	10	,	,	PUNCT
dpc-4737	265	11	casado	casado	PROPN
dpc-4737	265	12	-	-	PUNCT
dpc-4737	265	13	vela	vela	PROPN
dpc-4737	265	14	j	j	PROPN
dpc-4737	265	15	,	,	PUNCT
dpc-4737	265	16	recio	recio	PROPN
dpc-4737	265	17	-	-	PUNCT
dpc-4737	265	18	poveda	poveda	PROPN
dpc-4737	265	19	l	l	NOUN
dpc-4737	265	20	,	,	PUNCT
dpc-4737	265	21	botella	botella	PROPN
dpc-4737	265	22	lm	lm	PROPN
dpc-4737	265	23	,	,	PUNCT
dpc-4737	265	24	albiñana	albiñana	PROPN
dpc-4737	265	25	v.	v.	ADP
dpc-4737	265	26	the	the	DET
dpc-4737	265	27	role	role	NOUN
dpc-4737	265	28	of	of	ADP
dpc-4737	265	29	propranolol	propranolol	NOUN
dpc-4737	265	30	as	as	ADP
dpc-4737	265	31	a	a	DET
dpc-4737	265	32	repurposed	repurpose	VERB
dpc-4737	265	33	drug	drug	NOUN
dpc-4737	265	34	in	in	ADP
dpc-4737	265	35	rare	rare	ADJ
dpc-4737	265	36	vascular	vascular	ADJ
dpc-4737	265	37	diseases	disease	NOUN
dpc-4737	265	38	.	.	PUNCT
dpc-4737	266	1	int	int	PROPN
dpc-4737	266	2	j	j	PROPN
dpc-4737	266	3	mol	mol	ADP
dpc-4737	266	4	sci	sci	PROPN
dpc-4737	266	5	.	.	PUNCT
dpc-4737	267	1	2022;23(8	2022;23(8	NUM
dpc-4737	267	2	):	):	PUNCT
dpc-4737	267	3	4217	4217	NUM
dpc-4737	267	4	.	.	PUNCT
dpc-4737	267	5	 	 	SPACE
dpc-4737	268	1	doi	doi	NOUN
dpc-4737	268	2	:	:	PUNCT
dpc-4737	268	3	10.3390	10.3390	NUM
dpc-4737	268	4	/	/	SYM
dpc-4737	268	5	ijms23084217	ijms23084217	PROPN
dpc-4737	268	6	8	8	NUM
dpc-4737	268	7	.	.	PUNCT
dpc-4737	269	1	chisholm	chisholm	PROPN
dpc-4737	269	2	km	km	PROPN
dpc-4737	269	3	,	,	PUNCT
dpc-4737	269	4	chang	chang	PROPN
dpc-4737	269	5	kw	kw	PROPN
dpc-4737	269	6	,	,	PUNCT
dpc-4737	269	7	truong	truong	PROPN
dpc-4737	269	8	mt	mt	PROPN
dpc-4737	269	9	,	,	PUNCT
dpc-4737	269	10	kwok	kwok	PROPN
dpc-4737	269	11	s	s	PROPN
dpc-4737	269	12	,	,	PUNCT
dpc-4737	269	13	west	west	NOUN
dpc-4737	269	14	rb	rb	PROPN
dpc-4737	269	15	,	,	PUNCT
dpc-4737	269	16	heerema	heerema	NOUN
dpc-4737	269	17	-	-	PUNCT
dpc-4737	269	18	mckenney	mckenney	PROPN
dpc-4737	269	19	ae	ae	PROPN
dpc-4737	269	20	.	.	PUNCT
dpc-4737	270	1	β	β	X
dpc-4737	270	2	-	-	ADJ
dpc-4737	270	3	adrenergic	adrenergic	ADJ
dpc-4737	270	4	receptor	receptor	NOUN
dpc-4737	270	5	expression	expression	NOUN
dpc-4737	270	6	in	in	ADP
dpc-4737	270	7	vascular	vascular	ADJ
dpc-4737	270	8	tumors	tumor	NOUN
dpc-4737	270	9	.	.	PUNCT
dpc-4737	271	1	mod	mod	PROPN
dpc-4737	271	2	pathol	pathol	PROPN
dpc-4737	271	3	.	.	PUNCT
dpc-4737	272	1	2012;25	2012;25	NUM
dpc-4737	272	2	(	(	PUNCT
dpc-4737	272	3	11):1446	11):1446	NUM
dpc-4737	272	4	-	-	SYM
dpc-4737	272	5	1451	1451	NUM
dpc-4737	272	6	.	.	PUNCT
dpc-4737	273	1	doi:10.1038	doi:10.1038	NOUN
dpc-4737	273	2	/modpathol.2012.108	/modpathol.2012.108	PUNCT
dpc-4737	273	3	8	8	NUM
dpc-4737	273	4	original	original	ADJ
dpc-4737	273	5	article	article	NOUN
dpc-4737	273	6	|	|	ADV
dpc-4737	273	7	dermatol	dermatol	ADJ
dpc-4737	273	8	pract	pract	NOUN
dpc-4737	273	9	concept	concept	NOUN
dpc-4737	273	10	.	.	PUNCT
dpc-4737	274	1	2025;15(1):4737	2025;15(1):4737	NUM
dpc-4737	274	2	28	28	NUM
dpc-4737	274	3	.	.	PUNCT
dpc-4737	275	1	amaya	amaya	PROPN
dpc-4737	275	2	cn	cn	PROPN
dpc-4737	275	3	,	,	PUNCT
dpc-4737	275	4	perkins	perkins	PROPN
dpc-4737	275	5	m	m	PROPN
dpc-4737	275	6	,	,	PUNCT
dpc-4737	275	7	belmont	belmont	PROPN
dpc-4737	275	8	a	a	X
dpc-4737	275	9	,	,	PUNCT
dpc-4737	275	10	et	et	PROPN
dpc-4737	275	11	al	al	PROPN
dpc-4737	275	12	.	.	PUNCT
dpc-4737	276	1	non	non	ADJ
dpc-4737	276	2	-	-	ADJ
dpc-4737	276	3	selective	selective	ADJ
dpc-4737	276	4	beta	beta	NOUN
dpc-4737	276	5	blockers	blocker	NOUN
dpc-4737	276	6	inhibit	inhibit	VERB
dpc-4737	276	7	angiosarcoma	angiosarcoma	NOUN
dpc-4737	276	8	cell	cell	NOUN
dpc-4737	276	9	viability	viability	NOUN
dpc-4737	276	10	and	and	CCONJ
dpc-4737	276	11	increase	increase	VERB
dpc-4737	276	12	progression	progression	NOUN
dpc-4737	276	13	free	free	ADJ
dpc-4737	276	14	-	-	PUNCT
dpc-4737	276	15	and	and	CCONJ
dpc-4737	276	16	overall	overall	ADJ
dpc-4737	276	17	-	-	NOUN
dpc-4737	276	18	survival	survival	NOUN
dpc-4737	276	19	in	in	ADP
dpc-4737	276	20	patients	patient	NOUN
dpc-4737	276	21	diagnosed	diagnose	VERB
dpc-4737	276	22	with	with	ADP
dpc-4737	276	23	metastatic	metastatic	ADJ
dpc-4737	276	24	angiosarcoma	angiosarcoma	NOUN
dpc-4737	276	25	.	.	PUNCT
dpc-4737	277	1	oncoscience	oncoscience	PROPN
dpc-4737	277	2	.	.	PUNCT
dpc-4737	278	1	2018	2018	NUM
dpc-4737	278	2	;	;	PUNCT
dpc-4737	278	3	5	5	NUM
dpc-4737	278	4	(	(	PUNCT
dpc-4737	278	5	3	3	NUM
dpc-4737	278	6	-	-	NUM
dpc-4737	278	7	4):109	4):109	NUM
dpc-4737	278	8	-	-	PUNCT
dpc-4737	278	9	119	119	NUM
dpc-4737	278	10	.	.	PUNCT
dpc-4737	279	1	doi	doi	NOUN
dpc-4737	279	2	:	:	PUNCT
dpc-4737	279	3	 	 	SPACE
dpc-4737	279	4	10.18632	10.18632	NUM
dpc-4737	279	5	/	/	SYM
dpc-4737	279	6	oncoscience.413	oncoscience.413	PROPN
dpc-4737	279	7	29	29	NUM
dpc-4737	279	8	.	.	PUNCT
dpc-4737	280	1	santos	santos	PROPN
dpc-4737	280	2	m	m	PROPN
dpc-4737	280	3	,	,	PUNCT
dpc-4737	280	4	vilasboas	vilasboas	ADV
dpc-4737	280	5	v	v	ADP
dpc-4737	280	6	,	,	PUNCT
dpc-4737	280	7	mendes	mende	NOUN
dpc-4737	280	8	l	l	NOUN
dpc-4737	280	9	,	,	PUNCT
dpc-4737	280	10	talhari	talhari	ADJ
dpc-4737	280	11	c	c	NOUN
dpc-4737	280	12	,	,	PUNCT
dpc-4737	280	13	talhari	talhari	ADJ
dpc-4737	280	14	s.	s.	PROPN
dpc-4737	280	15	lymphangiectatic	lymphangiectatic	PROPN
dpc-4737	280	16	kaposi	kaposi	PROPN
dpc-4737	280	17	’s	’s	PART
dpc-4737	280	18	sarcoma	sarcoma	NOUN
dpc-4737	280	19	in	in	ADP
dpc-4737	280	20	a	a	DET
dpc-4737	280	21	patient	patient	NOUN
dpc-4737	280	22	with	with	ADP
dpc-4737	280	23	aids	aids	PROPN
dpc-4737	280	24	.	.	PUNCT
dpc-4737	281	1	an	an	DET
dpc-4737	281	2	bras	bras	NOUN
dpc-4737	281	3	dermatol	dermatol	NOUN
dpc-4737	281	4	.	.	PUNCT
dpc-4737	282	1	2013	2013	NUM
dpc-4737	282	2	;	;	PUNCT
dpc-4737	282	3	88(2):276	88(2):276	PROPN
dpc-4737	282	4	-	-	PUNCT
dpc-4737	282	5	278	278	NUM
dpc-4737	282	6	.	.	PUNCT
dpc-4737	282	7	 	 	SPACE
dpc-4737	283	1	doi	doi	X
dpc-4737	283	2	10.1590	10.1590	NUM
dpc-4737	283	3	/	/	SYM
dpc-4737	283	4	s0365	s0365	NOUN
dpc-4737	283	5	-	-	PUNCT
dpc-4737	283	6	05962013000200019	05962013000200019	NUM
dpc-4737	283	7	  	  	SPACE
dpc-4737	283	8	30	30	NUM
dpc-4737	283	9	.	.	PUNCT
dpc-4737	284	1	brambilla	brambilla	PROPN
dpc-4737	284	2	l	l	PROPN
dpc-4737	284	3	,	,	PUNCT
dpc-4737	284	4	tourlaki	tourlaki	ADV
dpc-4737	284	5	a	a	PRON
dpc-4737	284	6	,	,	PUNCT
dpc-4737	284	7	ferrucci	ferrucci	NOUN
dpc-4737	284	8	s	s	PROPN
dpc-4737	284	9	,	,	PUNCT
dpc-4737	284	10	brambati	brambati	PROPN
dpc-4737	284	11	m	m	PROPN
dpc-4737	284	12	,	,	PUNCT
dpc-4737	284	13	boneschi	boneschi	PROPN
dpc-4737	284	14	v.	v.	ADP
dpc-4737	284	15	treatment	treatment	NOUN
dpc-4737	284	16	of	of	ADP
dpc-4737	284	17	classic	classic	ADJ
dpc-4737	284	18	kaposi	kaposi	PROPN
dpc-4737	284	19	’s	’s	PART
dpc-4737	284	20	sarcoma	sarcoma	NOUN
dpc-4737	284	21	-	-	PUNCT
dpc-4737	284	22	associated	associate	VERB
dpc-4737	284	23	lymphedema	lymphedema	NOUN
dpc-4737	284	24	with	with	ADP
dpc-4737	284	25	elastic	elastic	ADJ
dpc-4737	284	26	stockings	stocking	NOUN
dpc-4737	284	27	.	.	PUNCT
dpc-4737	285	1	j	j	PROPN
dpc-4737	285	2	dermatol	dermatol	NOUN
dpc-4737	285	3	.	.	PUNCT
dpc-4737	286	1	2006	2006	NUM
dpc-4737	286	2	;	;	PUNCT
dpc-4737	286	3	33(7):451	33(7):451	PROPN
dpc-4737	286	4	-	-	PUNCT
dpc-4737	286	5	456	456	PROPN
dpc-4737	286	6	.	.	PUNCT
dpc-4737	287	1	doi	doi	NOUN
dpc-4737	287	2	:	:	PUNCT
dpc-4737	287	3	10.1111	10.1111	NUM
dpc-4737	287	4	/	/	SYM
dpc-4737	287	5	j.1346	j.1346	VERB
dpc-4737	287	6	-	-	PUNCT
dpc-4737	287	7	8138.2006.00108.x	8138.2006.00108.x	NUM
dpc-4737	287	8	31	31	NUM
dpc-4737	287	9	.	.	PUNCT
dpc-4737	288	1	montero	montero	PROPN
dpc-4737	288	2	pérez	pérez	PROPN
dpc-4737	288	3	i	i	PRON
dpc-4737	288	4	,	,	PUNCT
dpc-4737	288	5	rodríguez	rodríguez	NOUN
dpc-4737	288	6	-	-	PUNCT
dpc-4737	288	7	pazos	pazos	PROPN
dpc-4737	288	8	l	l	NOUN
dpc-4737	288	9	,	,	PUNCT
dpc-4737	288	10	álvarez	álvarez	NOUN
dpc-4737	288	11	-	-	PUNCT
dpc-4737	288	12	pérez	pérez	NOUN
dpc-4737	288	13	a	a	PRON
dpc-4737	288	14	,	,	PUNCT
dpc-4737	288	15	et	et	PROPN
dpc-4737	288	16	al	al	PROPN
dpc-4737	288	17	.	.	PUNCT
dpc-4737	289	1	kaposi	kaposi	PROPN
dpc-4737	289	2	sarcoma	sarcoma	PROPN
dpc-4737	289	3	following	follow	VERB
dpc-4737	289	4	postmastectomy	postmastectomy	NOUN
dpc-4737	289	5	lymphedema	lymphedema	NOUN
dpc-4737	289	6	.	.	PUNCT
dpc-4737	290	1	j	j	PROPN
dpc-4737	290	2	cut	cut	PROPN
dpc-4737	290	3	pathol	pathol	NOUN
dpc-4737	290	4	.	.	PUNCT
dpc-4737	291	1	2015	2015	NUM
dpc-4737	291	2	;	;	PUNCT
dpc-4737	291	3	42(11):889	42(11):889	NUM
dpc-4737	291	4	-	-	SYM
dpc-4737	291	5	893	893	NUM
dpc-4737	291	6	.	.	PUNCT
dpc-4737	292	1	doi	doi	NOUN
dpc-4737	292	2	:	:	PUNCT
dpc-4737	292	3	10.1111	10.1111	NUM
dpc-4737	292	4	/	/	SYM
dpc-4737	292	5	cup	cup	NOUN
dpc-4737	292	6	.	.	PUNCT
dpc-4737	293	1	12573	12573	NUM
dpc-4737	293	2	hemangioendothelioma	hemangioendothelioma	ADJ
dpc-4737	293	3	and	and	CCONJ
dpc-4737	293	4	angiosarcoma	angiosarcoma	NOUN
dpc-4737	293	5	.	.	PUNCT
dpc-4737	294	1	plos	plos	PROPN
dpc-4737	294	2	one	one	NUM
dpc-4737	294	3	.	.	PUNCT
dpc-4737	295	1	2013;8	2013;8	NUM
dpc-4737	295	2	(	(	PUNCT
dpc-4737	295	3	3	3	NUM
dpc-4737	295	4	):	):	PUNCT
dpc-4737	295	5	e60021	e60021	NOUN
dpc-4737	295	6	.	.	PUNCT
dpc-4737	296	1	doi	doi	NOUN
dpc-4737	296	2	:	:	PUNCT
dpc-4737	296	3	10.1371	10.1371	NUM
dpc-4737	296	4	/	/	SYM
dpc-4737	296	5	journal.pone.0060021	journal.pone.0060021	PROPN
dpc-4737	296	6	25	25	NUM
dpc-4737	296	7	.	.	PUNCT
dpc-4737	297	1	gramolelli	gramolelli	PROPN
dpc-4737	297	2	s	s	PROPN
dpc-4737	297	3	,	,	PUNCT
dpc-4737	297	4	schulz	schulz	PROPN
dpc-4737	297	5	tf	tf	PROPN
dpc-4737	297	6	.	.	PUNCT
dpc-4737	298	1	the	the	DET
dpc-4737	298	2	role	role	NOUN
dpc-4737	298	3	of	of	ADP
dpc-4737	298	4	kaposi	kaposi	PROPN
dpc-4737	298	5	sarcoma	sarcoma	NOUN
dpc-4737	298	6	-	-	PUNCT
dpc-4737	298	7	associated	associate	VERB
dpc-4737	298	8	herpesvirus	herpesvirus	NOUN
dpc-4737	298	9	in	in	ADP
dpc-4737	298	10	the	the	DET
dpc-4737	298	11	pathogenesis	pathogenesis	NOUN
dpc-4737	298	12	of	of	ADP
dpc-4737	298	13	kaposi	kaposi	PROPN
dpc-4737	298	14	sarcoma	sarcoma	PROPN
dpc-4737	298	15	.	.	PUNCT
dpc-4737	299	1	j	j	PROPN
dpc-4737	299	2	pathol	pathol	NOUN
dpc-4737	299	3	.	.	PUNCT
dpc-4737	300	1	2015	2015	NUM
dpc-4737	300	2	;	;	PUNCT
dpc-4737	300	3	235	235	NUM
dpc-4737	300	4	(	(	PUNCT
dpc-4737	300	5	2):368	2):368	NUM
dpc-4737	300	6	-	-	SYM
dpc-4737	300	7	380	380	NUM
dpc-4737	300	8	.	.	PUNCT
dpc-4737	301	1	doi	doi	NOUN
dpc-4737	301	2	:	:	PUNCT
dpc-4737	301	3	10.1002	10.1002	NUM
dpc-4737	301	4	/	/	SYM
dpc-4737	301	5	path.4441	path.4441	PROPN
dpc-4737	301	6	26	26	NUM
dpc-4737	301	7	.	.	PUNCT
dpc-4737	302	1	chang	chang	PROPN
dpc-4737	302	2	m	m	PROPN
dpc-4737	302	3	,	,	PUNCT
dpc-4737	302	4	brown	brown	PROPN
dpc-4737	302	5	hj	hj	PROPN
dpc-4737	302	6	,	,	PUNCT
dpc-4737	302	7	collado	collado	PROPN
dpc-4737	302	8	-	-	PUNCT
dpc-4737	302	9	hidalgo	hidalgo	PROPN
dpc-4737	302	10	a	a	PROPN
dpc-4737	302	11	,	,	PUNCT
dpc-4737	302	12	et	et	PROPN
dpc-4737	302	13	al	al	PROPN
dpc-4737	302	14	.	.	PUNCT
dpc-4737	303	1	βadrenoreceptors	βadrenoreceptor	NOUN
dpc-4737	303	2	reactivate	reactivate	VERB
dpc-4737	303	3	kaposi	kaposi	PROPN
dpc-4737	303	4	’s	’s	PART
dpc-4737	303	5	sarcoma	sarcoma	NOUN
dpc-4737	303	6	-	-	PUNCT
dpc-4737	303	7	associated	associate	VERB
dpc-4737	303	8	herpesvirus	herpesvirus	NOUN
dpc-4737	303	9	lytic	lytic	ADJ
dpc-4737	303	10	replication	replication	NOUN
dpc-4737	303	11	via	via	ADP
dpc-4737	303	12	pka	pka	NOUN
dpc-4737	303	13	-	-	PUNCT
dpc-4737	303	14	dependent	dependent	ADJ
dpc-4737	303	15	control	control	NOUN
dpc-4737	303	16	of	of	ADP
dpc-4737	303	17	viral	viral	ADJ
dpc-4737	303	18	rta	rta	PROPN
dpc-4737	303	19	.	.	PUNCT
dpc-4737	304	1	j	j	PROPN
dpc-4737	304	2	virol	virol	PROPN
dpc-4737	304	3	.	.	PUNCT
dpc-4737	305	1	2005	2005	NUM
dpc-4737	305	2	;	;	PUNCT
dpc-4737	305	3	79(21):13538	79(21):13538	NUM
dpc-4737	305	4	-	-	SYM
dpc-4737	305	5	13547	13547	NUM
dpc-4737	305	6	.	.	PUNCT
dpc-4737	306	1	doi:10.1128	doi:10.1128	NOUN
dpc-4737	306	2	/	/	SYM
dpc-4737	306	3	jvi.79.21.13538–13547	jvi.79.21.13538–13547	PROPN
dpc-4737	306	4	.2005	.2005	PROPN
dpc-4737	307	1	27	27	NUM
dpc-4737	307	2	.	.	PUNCT
dpc-4737	308	1	mcallister	mcallister	PROPN
dpc-4737	308	2	sc	sc	PROPN
dpc-4737	308	3	,	,	PUNCT
dpc-4737	308	4	hanson	hanson	PROPN
dpc-4737	308	5	rs	rs	PROPN
dpc-4737	308	6	,	,	PUNCT
dpc-4737	308	7	manion	manion	PROPN
dpc-4737	308	8	rd	rd	PROPN
dpc-4737	308	9	.	.	PUNCT
dpc-4737	308	10	propranolol	propranolol	PROPN
dpc-4737	308	11	decreases	decrease	VERB
dpc-4737	308	12	proliferation	proliferation	NOUN
dpc-4737	308	13	of	of	ADP
dpc-4737	308	14	endothelial	endothelial	ADJ
dpc-4737	308	15	cells	cell	NOUN
dpc-4737	308	16	transformed	transform	VERB
dpc-4737	308	17	by	by	ADP
dpc-4737	308	18	kaposi	kaposi	PROPN
dpc-4737	308	19	’s	’s	PART
dpc-4737	308	20	sarcoma	sarcoma	NOUN
dpc-4737	308	21	-	-	PUNCT
dpc-4737	308	22	associated	associate	VERB
dpc-4737	308	23	herpesvirus	herpesvirus	NOUN
dpc-4737	308	24	and	and	CCONJ
dpc-4737	308	25	induces	induce	VERB
dpc-4737	308	26	lytic	lytic	ADJ
dpc-4737	308	27	viral	viral	ADJ
dpc-4737	308	28	gene	gene	NOUN
dpc-4737	308	29	expression	expression	NOUN
dpc-4737	308	30	.	.	PUNCT
dpc-4737	309	1	j	j	PROPN
dpc-4737	309	2	virol	virol	NOUN
dpc-4737	309	3	.	.	PUNCT
dpc-4737	310	1	2015;89(21):11144	2015;89(21):11144	NUM
dpc-4737	310	2	-	-	SYM
dpc-4737	310	3	11149	11149	NUM
dpc-4737	310	4	.	.	PUNCT
dpc-4737	311	1	doi	doi	NOUN
dpc-4737	311	2	:	:	PUNCT
dpc-4737	311	3	  	  	SPACE
dpc-4737	311	4	10.1128	10.1128	NUM
dpc-4737	311	5	/jvi.01569	/jvi.01569	NOUN
dpc-4737	311	6	-	-	PUNCT
dpc-4737	311	7	15	15	NUM